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The Dukat laboratory developed 2-amino-6-chloro-3,4-dihydroquinazoline 
(A6CDQ) as a 5-HT3 receptor ligand. A6CDQ and one of its positional isomers, the 7-chloro 
analog A7CDQ, produced antidepressant-like effects in the mouse tail suspension test 
(TST). Activities at the 5-HT3 receptors or the serotonin transporter (SERT) were considered 
as potential mechanisms for the antidepressant-like effect. However, we investigated and 
systematically ruled out a solely 5-HT3 receptor or hSERT mediated mechanism of 
antidepressant-like effect for both A6CDQ and A7CDQ. 
  xxxvii 
The role of organic cation transporter 3 (OCT3) in the regulation of neurotransmitters 
including serotonin (5-HT) provides an alternative mechanism of reuptake (uptake-2) and 
the therapeutic potential of targeting hOCT3 to achieve antidepressant effects has been 
established. By virtue of possessing protonatable nitrogen atoms, 2-
aminodihyroquinazolines could potentially exhibit activity at OCT3.  A major goal of our 
present study was to explore the non-serotonergic mechanism of antidepressant-like effects 
and to study the as yet unexplored structure-activity-relationships (SARs) at OCT3. We 
examined the role of  i) the chloro group, ii) the methylene bridge and iii) 
electronic/lipophilic effects at the 6-position. Only the presence and not the position of the 
chloro group was deemed important. Removal of the methylene bridge did not affect hOCT 
inhibitory activity. We determined the lipophilic properties of the substituent at the 
quinazoline 5-, 6- and 7-position to be potentially more important than their electronic 
properties.  
We developed the first 3-D homology models of both the human and mouse 
orthologs of OCT3, conducted docking studies and HINT analysis, and identified critical 
amino acid residues interacting with 2-aminodihydroquinazoline analogs at hOCT3 and 
mOCT3. Contrary to OCT inhibitory activity, the presence of both the chloro group and the 
methylene bridge was deemed important for retention of antidepressant-like activity in the 
mouse TST. Potential locomotor stimulant effects for TST-active doses were thoroughly 
investigated and eliminated.     
We have successfully investigated initial SAR of 2-aminodihydroquinazolines at 
hOCT3 and generated the first 3-D homology models of hOCT3 and mOCT3. Highly potent 
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and selective compounds could potentially be developed as radioligands to probe the binding 
site of OCT3 and as a mechanistically novel class of antidepressants. 
 
  
 I. Introduction 
 
 Depression is a serious central nervous system (CNS) disorder. Most clinically 
employed antidepressants target one or both of two neurotransmitter systems (i.e., serotonin 
and norepinephrine) by acting as, for example, reuptake inhibitors at the serotonin 
transporter (SERT) or norepinephrine transporter (NET). Unfortunately, a large proportion 
of depressed individuals are refractory to these agents. 
SERT, NET and dopamine transporters (DAT) are capable of transporting all three 
monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine (DA).1-
13 This complicates matters, as we possess an overly simplistic view of reuptake of 
neurotransmitters and depression. The transporters could be compensating for each other 
and this might explain the lag that is observed during treatment with selective serotonin 
reuptake inhibitors (SSRIs). In 1998, another mechanism of uptake of monoamine 
neurotransmitters, called uptake-2 was identified to consist of organic cation transporter 3 
(OCT3).14 Over the next two decades uptake-2 was characterized to be low-affinity, high-
capacity uniporters and OCTs were shown to be capable of participating in the clearance of 
5-HT and NE.15-18 OCT1-3 are expressed throughout the body, with OCT219,20 and OCT3 
being primarily expressed in the brain whereas OCT1 was found primarily in the periphery.21 
Moreover, OCT3 is expressed in areas of the brain which are believed to be involved in 
depression.14,22,23 OCTs are expressed both on neurons and glial cells,16,24 and increasingly 
OCT3 is thought to be involved in the reuptake of 5-HT and other monoamines.25-28 A 
number of known antidepressants such as, desipramine, imipramine, amitriptyline, sertraline 
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and fluoxetine (FLX) were shown to inhibit OCT3 with desipramine and sertraline doing so 
noncompetitively.29 Also, the antidepressant-like effect of fluvoxamine was shown to be 
enhanced in the presence of decynium-22, a known inhibitor of OCTs17,21,30,31 in wild-type 
mice in the mouse tail suspension test (TST), a rodent model used for the evaluation of novel 
antidepressants.32 This effect was shown to be decreased in OCT3 knockout mice.33 
Therefore, OCT3 presents an attractive target for a mechanistically novel class of 
antidepressant agents and detailed structure-activity relationship (SAR) studies at OCT3 
have not been reported.  
 The phenylguanidine, m-chlorophenylguanidine (mCPG; MD-354; Ki = 35 nM),34 a 
5-HT3 receptor agonist, resulted from investigations of 1-phenylbiguanide, the first selective 
5-HT3 agonist.34 Ring closure of phenylguanidines by way of introducing a methylene bridge 
between the terminal nitrogen atom of the guanidine moiety and the phenyl ring gives rise 
to 2-amino-3,4-dihydroquinazoline (ADQ). 2-Amino-6-chloro-3,4-dihydroquinazoline 
(A6CDQ) was identified to be a 5-HT3 receptor competitive antagonist with high affinity 
and high potency (Ki = 80 nM, IC50 = 0.26 µM).35 There exists literature precedence for 5-
HT3 receptor antagonists such as odansetron and bemesetron to produce an antidepressant-
like effect in the mouse tail suspension test (TST).36,37 A6CDQ (ED50 = 0.23 mg/kg)35 was 
20-times more potent than fluoxetine (20 mg/kg) in the mouse TST. Thus, we hypothesized 
that the antidepressant-like activity of A6CDQ might be mediated via 5-HT3 receptor 
antagonism. A positional isomer of A6CDQ, the 7-chloro substituted 2-amino-3,4-
dihydroquinazoline (A7CDQ), was also shown to be active in the mouse TST at comparable 
doses to A6CDQ. However, A7CDQ (Ki = 1,975 ± 168 nM) was found to bind at 5-HT3 
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receptors with a 25-fold lower affinity than A6CDQ. One aim of the current study was to 
determine the functional activity of A7CDQ at 5-HT3 receptors. The large difference in 
binding affinities of A6CDQ and A7CDQ at 5-HT3 receptors, but comparable efficacy in 
mouse TST suggested that the antidepressant-like effect observed might not be mediated via 
5-HT3 receptors alone. 
Fluoxetine (FLX), also known as prozac, is one of the most widely prescribed 
antidepressants and belongs to the SSRI class of antidepressants.38 FLX inhibits SERT 
potently (IC50 = 0.076 µM) and with high affinity (Ki = 1 nM).38 FLX lacks affinity for the 
orthosteric site of the 5-HT3 receptor but behaves as a functional 5-HT3 receptor antagonist.39 
The question arose: might quinazolines, A6CDQ and A7CDQ, be functionally active at 
hSERT? To determine this, we examined A6CDQ and A7CDQ at hSERT using radioligand 
binding, electrophysiological, molecular modeling and Hydropathic INTeractions (HINT) 
studies. 
 Activities at 5-HT3 receptors and hSERT (releaser or reuptake inhibitor) provide an 
insufficient explanation for the antidepressant-like effects observed. Since the quinazolines 
have protonatable nitrogen atoms capable of existing as a positively charged moiety at 
physiological pH, we explored phenylguanidines and quinazolines as potential OCT ligands. 
Based on preliminary data, we studied the structure-activity relationships (SARs) of 
quinazolines at OCTs by synthesizing analogs with varying substituents. To better 
understand the molecular interactions between quinazolines and the transporter, we built the 
first 3-dimensional homology models of the human and mouse orthologs of OCT3 (hOCT3 
and mOCT3, respectively) based on the inorganic phosphate transporter (PiPT) as a 
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template. Docking of compounds followed by HINT analysis helped us score and rank the 
favorable interactions observed in the ligand-transporter complexes. 
 II. Background 
 
1. Depression: Theories and molecular targets 
 
According to the World Health Organization (WHO), depression is a central nervous 
system (CNS) disorder that affects ~350 million people worldwide and is characterized by 
debilitating melancholia and anhedonia. Furthermore, it is recognized as the leading cause 
of illness-induced disability.40 In the United States alone, 9% of the population suffers from 
depression.41 Traditionally, depression has been associated with low levels of the 
neurotransmitters serotonin (5-HT) (1) and/or norepinephrine (NE) (2) in the synapses 
(Figure 1). One of the most widely prescribed antidepressants, fluoxetine38 (prozac) (FLX; 
3) (Figure 1) targets the serotonin transporter (SERT) and blocks it, thereby preventing the 
reuptake of 5-HT (1) into the presynaptic neuron and increasing the concentration of 5-HT 
(1) in the synapse. The class of drugs which target SERT are known as selective serotonin 
reuptake inhibitors (SSRIs) and continue to be widely used even today. SERT and 
norepinephrine transporters (NET) are recognized as uptake-1. Uptake-1 transporters are 
high-affinity, low-capacity transporters.42 Other classes of antidepressants include, but are 
not limited to, serotonin and norepinephrine reuptake inhibitior (SNRIs), selective 
norepinephrine reuptake inhibtiors (NRIs), tricyclic antidepressants (TCAs) and monoamine 
oxidase inhibitors (MAOIs). Unfortunately, a large portion of the population suffering from 
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depression show either partial response or no response to the current treatment options 
available.43 So there is a pressing need for agents that act via a novel mechanism.  
 
 
Depression is a mental disorder that is comprised of a number of debilitating 
symptoms that are observed for greater than two weeks in an individual.44 The symptoms 
include irritability, anhedonia (loss of interest in pleasurable activities), loss of appetite 
and/or sleep, feeling of helplessness, worthlessness, guilt, low self esteem among others.44 
Broadly, depression is categorized into two major classes – major depressive disorder 
(MDD) and dysthymia.44 MDD, also known as clinical or unipolar depression, is further 
classified into five subtypes – melancholic depression, atypical depression, catatonic 
depression, post partum depression and seasonal affective disorder.44 Dysthymia, also 
known as persistent depressive disorder (PDD), is a milder form of depression which tends 
to last longer.44  
Figure 1. Structures of the neurotransmitters serotonin (5-HT; 1) and norepinephrine 
(NE; 2) traditionally believed to be important in depression. Fluoxetine (FLX; 3) 
(prozac), one of the most well known and widely prescribed antidepressants. 
N
H
HO
NH2
Serotonin (1)
HO
NH2HO
OH
Norepinephrine (2)
F3C
O
H
N CH3
Fluoxetine (3)
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Following are some of the theories concerning the etiology of depression that have been 
proposed:  
a. Monoamine hypothesis: 
One of the earliest theories regarding depression (1950’s) is the monoamine 
hypothesis. The monoamine neurotransmitters consist of 5-HT (1) and the catecholamines – 
dopamine (DA) (4) and norepinephrine (NE) (2). The biosynthesis and metabolism of the 
catecholamine neurotransmitters are shown in Figures 2 and 3, respectively, while that of 5-
HT is shown in Figure 4. The amino acid precursor L-tyrosine (5), via a series of steps, is 
converted to DA (4) and NE (2) (Figure 2).45 The amino acid precursor for 5-HT (1) is L-
tryptophan (13) (Figure 4).46 The enzyme monoamine oxidase (MAO) is involved in the 
metabolism of both the catecholamine, NE45 (2) and 5-HT46 (1) and converts the amine to 
an aldehyde (Figures 3 and 4, respectively).    
 
 
 
 
 
 
HO
COOH
NH2
HO
L-amino
acid
decarboxylase
Aromatic
L-Dopa (6)
Figure 2. Biosynthesis of catecholamines – dopamine (DA; 4) and norepinephrine (NE; 2) from 
the amino acid precursor L-tyrosine (5). Adapted from Griffith et al.45  
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NH2H3CO
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Normetanephrine (8)
MAO
COMT 
 
Figure 3. Metabolism of norepinephrine (NE; 2) by the enzymes monoamine oxidase (MAO), catechol 
O-methyl transferase (COMT), aldehyde reductase (AR) and aldehyde dehydrogenase (AD). Adapted 
from Griffith et al.45  
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Figure 4. Biosynthesis and metabolism of 5-HT (1) from the amino acid precursor L-tryptophan 
(14). Adapted from Glennon and Dukat.46  
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The two major contributors to formulation of the monoamine hypothesis were studies 
related to reserpine and iproniazid (21) (Figure 5). Reserpine is an alkaloid isolated from 
dried root of Rauwolfia serpentina and was found to induce depression in hypertensive 
patients.47-51 Isoniazid (22) and iproniazid (21) (Figure 5) were developed as antitubercular 
agents and were found to cause elevation of mood in tuberculosis patients. They were later 
determined to be monoamine oxidase inhibitors (MAOIs).52 In 1958, Everett and Toman53 
proposed a rudimentary version of the monoamine hypothesis which stated that a deficiency 
of monoamine in the central nervous system is responsible for depression. Jacobsen in 1964 
stated that insufficient catecholamines results in depression.54 
 
 
 
All of this eventually culminated in the catecholamine hypothesis for which Joseph 
Jacob Schildkraut is credited. The hypothesis states that, “some depressions, if not all, are 
associated with an absolute or relative deficit of catecholamines, particularly noradrenaline 
(norepinephrine), in important adrenergic receptors in the brain. Contrariwise, elation may 
Figure 5. Structures of iproniazid (21), isoniazid (22), imipramine (23) and tyramine 
(24). 
N
O NH
N CH3H3C
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be associated with an excess of such amines.”55 Around the same time, there was a growing 
interest in determining the role played by 5-HT (1) in depression. Administration of 
tryptophan (14), an amino acid precursor of 5-HT (1) (see Figure 4), along with an MAOI 
resulted in greater improvement in depressed individuals than administration of a MAOI 
alone.56,57 And so the 5-HT hypothesis was borne from the work of Coppen and states that a 
deficiency in 5-HT leads to depression.58 
Imipramine (23) (Figure 5), a tricyclic antidepressant (TCA), was found by Kuhn to 
be effective in the treatment of depression.59 Eventually in 1964, imipramine (23) was shown 
to block the reuptake of both NE (2) and 5-HT (1),60 lending further credibility to the 
monoamine hypothesis of depression. Both, the MAOIs and TCAs are considered to be the 
first generation antidepressants and are fraught with several side effects. The MAOIs reacted 
dangerously with tyramine (24) (Figure 5) in foods such as cheese and certain wines 
resulting in hypertensive crises61 while the TCAs have a number of unpleasant side effects 
resulting from their action at muscarinic receptors such as blurred vision, dry mouth and 
urinary retention.62,63 In 1961, iproniazid (21) (Figure 5) was withdrawn from the market due 
to side effects related to the kidney.64 
The second generation of antidepressants are comprised of selective serotonin 
reuptake inhibitors (SSRIs) such as FLX (3;65 Figure 1), serotonin and norephinephrine 
reuptake inhibitors (SNRIs) such as venlafaxine (25;66,67 Figure 6), and selective 
norepinephrine reuptake inhibitors (NRIs) such as reboxetine (26;68 Figure 6) among others. 
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All of these drugs work on the principle of increasing the concentration of the monamine 
neurotransmitters, 5-HT (1) and/or NE (2), in the synapse keeping in line with the 
monoamine hypothesis. In the past few years, there has been a shift towards drugs that act 
at multiple targets as opposed to drugs that act selectively at one target (e.g. SSRIs, SNRIs). 
These include agents that act at monoaminergic targets such as SERT, NET along with other 
targets such as serotonin receptors (5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7)69-75 and GABA 
receptors.76,77    
 
Of the seven families of the 5-HT receptors, 5-HT1-7, only 5-HT3 receptors are ligand 
gated-ion channel (LGIC) receptors.46 All of the other six families are G-protein coupled 
receptors (GPCRs) and are either negatively or positively coupled to adenylyl cyclase (AC) 
or phospholipase.46 5-HT3 receptors are most abundant in the chemoreceptor triggering zone 
(CTZ)78 and it is for this reason that 5-HT3 receptor antagonists, such as ondansetron (27; 
Figure 7), tropisteron (28; Figure 7) and others have been successfully used as antiemetics 
Figure 6.  Structures of venlafaxine (25), a serotonin and norepinephrine reuptake inhibitor 
(SNRI), and reboxetine (26), a norepinephrine reuptake inhibitor (NRI). 
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O CH3
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for chemotherapy-induced emesis.79,80  Besides the CTZ, 5-HT3 receptors have also been 
identified in the hippocampus, amygdala, nucleus accumbens (NAc), and caudate 
nucleus.78,81,82 5-HT3 receptors are located both pre as well as postsynaptically and are 
involved in both control of 5-HT (1) release as well as neurotransmission.78 Because 5-HT3 
receptors are LGIC receptors, they allow passage of Na+/K+ ions through the channel in 
response to binding of an agonist.46 The potential role of 5-HT3 receptors in depression has 
been studied and, in the past, 5-HT3 receptor antagonists such as ondansetron (27; Figure 7) 
and bemesetron (29; Figure 7) have been shown to possess antidepressant-like activity in the 
mouse TST.36,37 Moreover, the antidepressant-like effect of bemesetron (29; Figure 7) was 
shown to be augmented by ketamine, a nonselective NMDA receptor antagonist.37 
Tropisetron (28; Figure 7), another 5-HT3 receptor antagonist, was also shown to produce 
antidepressant-like effects in the mouse and rat forced swim test (FST).83,84 m-
Chlorophenylbiguanidine (mCPBG) (30; Figure 8), a known 5-HT3 receptor agonist, 
successfully attenuated this effect of tropisetron (28; Figure 7) and other antidepressants 
such as imipramine (23; Figure 5) and desipramine (31; Figure 8).83 This antidepressant-like 
effect exerted by 5-HT3 receptor antagonists could be attributed to antagonism of the 
postsynaptic receptors36 thereby allowing 5-HT (1) to interact with other postsynaptic 5-HT 
receptors (such as 5-HT1A/B/C and 5-HT2A/2C receptors).78 Antidepressants belonging to the 
distinct classes such as TCAs, SSRIs, NRIs have been shown to be functional antagonists of 
5-HT3 receptors.39 This includes FLX (3), one of the most well known SSRIs.39 A number 
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of groups have suggested that this 5-HT3 receptor antagonism might contribute partially to 
the antidepressant effects of FLX (3).39,85-87 This is further bolstered by the fact that a 
combination of 5-HT3 receptor antagonists with SSRIs leads to increased antidepressant-like 
effects.36,87,88 For example, ondansetron (27; Figure 7) was shown to increase the 
antidepressant-like effects of FLX (3) (SSRI) and venlafaxine (25; Figure 6) (SNRI) in 
mice.36 Another point of interest is that treatment with ondansetron (27; Figure 7) was shown 
to induce serotonin syndrome.89 This syndrome occurs when the levels of 5-HT (1) in the 
synapse increases both in the central (CNS) and peripheral nervous (PNS) system.  All of 
this suggests that antagonism of 5-HT3 receptors could lead to an increase in 5-HT (1) and 
holds therapeutic potential in depression.  
 
 
 
 
 
 
N
CH3
O N
N
H3C
Ondansetron (27) Tropisetron (28)
N
H
O O
N
CH3
H
H
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Cl
ClO
O
NH3C
Figure 7. Structures of 5-HT3 receptor antagonists, ondansetron (27), tropisetron (28) and 
bemesetron (29). 
  15 
 
 
 
 
 
 
b. Glutamate/Neuronal plasticity hypothesis:  
An idea that has been gaining momentum since the 1990's is the glutamate hypothesis 
of depression. Glutamate (32; Figure 9) is considered to be an excitatory neurotransmitter, 
with glutamate synapses accounting for the vast majority of the neocortex followed by 
GABAergic synapses.90 Initially, it was thought that glutamate (32; Figure 9) binds to and 
acts via the ionotropic glutamate receptors (iGluRs).91,92 Later on it was discovered that 
glutamate (32) also exerts its action via another class of receptors called metabotropic 
glutamate receptors (mGluRs).93,94 The iGluRs consist of three ligand-gated ion channel 
(LGIC) receptors that modulate the flow of K+ and Na+ ions,91,92 while the mGluRs consist 
of eight large G-protein coupled receptors (GPCRs) that exert their effect through second 
messengers.93,94 The three iGluRs are α-amino-3-hydroxy-5-methylisoxazolepropionic acid 
(AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors.91,92 The eight mGluRs are 
Desipramine (31)
N
HN
CH3
Figure 8. Structures of the 5-HT3 receptor agonist m-chlorophenylbiguanide (mCPBG; 30) 
and the antidepressant desipramine (31).  
N N
Cl
NH2
NH2
NH2
m-Chlorophenylbiguanide 
(mCPBG; 30)
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further subdivided into three groups – group I consisting of mGlu1 and mGlu5, group II 
consisting of mGluR2 and mGluR3 and group III consisting of mGluR4, mGluR6, mGluR7 
and mGluR8.95 NMDA receptor antagonists were discovered to possess antidepressant-like 
effect in a number of studies.96-100 This was confirmed via clinical studies in patients 
suffering from MDD who were intravenously administered ketamine (33; Figure 9), a 
nonselective NMDA receptor antagonist and showed rapid (within 2-4 hours of 
administration) and sustained (up to 3-7 days after administration) antidepressive 
effect.101,102  In subsequent years, this antidepressant effect of ketamine (33) has been linked 
to its effect on neuronal plasticity, i.e., increasing the number and function of synapses in 
the prefrontal cortex,103 increased signaling via mammalian target of rapamycin complex 1 
(mTORC1)103 and increased levels of brain-derived neurotrophic factor (BDNF)104,105 
(Figure 10). Other agents acting at NMDA receptors,106,107 as well as mGluR2/mGluR3 
antagonists108-110 and agents that potentiate the activity of AMPA receptor111 have also 
shown antidepressant-like effect in behavioral models (Figure 10). 
  
Figure 9. Structures of the neurotransmitter, glutamate (32) and selective NMDA receptor 
antagonist, ketamine (33). 
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c. GABA hypothesis:  
ɣ-Aminobutyric acid (GABA) (34; Figure 11) is an inhibitory neurotransmitter that 
functions in tandem with the glutamate system and signals via GABAA and GABAB 
receptors.113 The concentration of GABA (34) was found to be reduced in the cerebrospinal 
fluid (CSF) of patients suffering from MDD.114 The areas of the brain that have been 
explored with respect to GABAergic neurotransmission are the occipital cortex (OCC), 
anterior cingulate cortex and prefrontal cortex (PFC).  
Two major types of studies have been undertaken so far to determine the role of 
GABA (34) in depression. The first, magnetic resonance imaging (MRI), suggests a decrease 
in concentrations of GABA (34) in OCC,115-118 anterior cingulate cortex,116 and PFC119 and 
supports involvement of GABA (34) in depression. The second study involved the enzyme 
glutamic acid dehydrogenase (GAD) and its level in various regions of the brain. GAD 
converts glutamate (32) to GABA (34; Figure 12) and exists as two different isoforms – 
GAD65 and GAD67.120 However, GAD67 expression studies have proven to be unreliable 
since they show both a correlation121,122 and an utter lack of it123-125 in healthy and MDD-
suffering individuals.  
 The synthesis and metabolism of GABA (34) and glutamate (32) are interconnected 
(Figure 12). Reuptake of glutamate (32) by excitatory amino acid transporter (EAAT 1/2) 
expressed on glial cells,120 its subsequent conversion to glutamine by glutamate 
synthetase,126 followed by reconversion to glutamate (32) by glutaminase, and finally 
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conversion of glutamate (32) to GABA (34) by glutamic acid dehydrogenase (Figure 12) 
being the major steps. This serves as a major source for production of GABA (34).127 
Reduction in number and function of glial cells and EAAT1/2 has been observed in MDD.128-
130 The idea that this reduction of glial efficiency could account for the reduction in levels 
of GABA (34) observed in MDD has unfortunately not been substantiated.131 A number of 
agents – agonists, antagonists and positive allosteric modulators (PAMs) – have been tested 
at GABAA and GABAB to investigate their involvement in MDD. Some of these studies 
have shown promising results, i.e., reduction of MDD scores by coadministration of 
alprazolam (35;132 Figure 11), a PAM at GABAA, and effective combination of eszopiclone 
(36; Figure 11), another PAM at GABAA with a SSRI.133,134 Other studies have shown no 
significant advantage of targeting GABAA.135   
 
Figure 11. Structures of the inhibitory neurotransmitter ɣ-aminobutyric acid (GABA) (34), 
and PAMs at GABAA, alprazolam (35) and eszopiclone (36). 
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d. Cholinergic/Adrenergic imbalance hypothesis: 
 Janowsky et al.136 (1970’s) proposed the cholinergic-adrenergic imbalance 
hypothesis and Dagyte et al.137 further defined it “depression was proposed to be a disease 
of cholinergic dominance”. The evidence for this hypothesis resulted from studies involving 
administration of acetylcholinesterase inhibitors (AChEIs), muscarinic acetylcholine 
receptor (mAChR) antagonists, nicotinic acetylcholine receptor (nAChR) agonists and 
antagonists. Diisopropylfluorophosphonate (DFP, 37), an irreversible AChEI (Figure 13), 
was shown to produce depressive symptoms in normal individuals. Moreover, it was shown 
to reduce mania in manic individuals.138 Other AChEIs, such as EA-1701139 (irreversible 
AChEI) and physostigmine140-142 (38) (reversible AChEI, Figure 13) also produced similar 
effects as DFP (37).  
 
Acteylcholinesterase (AChE) is an enzyme that is responsible for terminating the 
signaling of the neurotransmitter acetycholine (ACh) (39; Figure 14) by converting it to 
choline (41) and acetate (42; Figure 15).143 AChEIs inhibit this enzyme and cause an increase 
Figure 13. Structures of diisopropylfluorophosphonate (DFP, 37), an irreversible AChEI, 
and physostigmine (38), a reversible AChEI.    
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in the amount of ACh in the synapse which binds to and activates mAChRs and/or 
nAChRs.143 The tendency of AChEIs to produce depressive symptoms in normal individuals 
coupled with the finding of increased choline concentrations in the brain of depressed 
individuals144,145 further cemented the involvement of the cholinergic system in depression. 
Administration of agents acting at mAChRs and nAChRs have shown potential to alleviate 
some cognitive symptoms of depression. Scopolamine (43; Figure 14), a nonselective 
muscarinic receptor antagonist was shown to produce antidepressant effects in patients 
suffering from MDD.146 The mechanism by which scopolamine exerts this effect has not 
been elucidated yet.146 With respect to nAChRs, the evidence is more divided. Both nAChR 
agonists and antagonists have shown antidepressant-like effects.147-149 The regions of the 
brain which have been repeatedly implicated in depression – hippocampus,150-153 PFC154 and 
amygdala154,155-157 – all have cholinergic innervations. Thus, an imbalance of the cholinergic 
system may be contributing to the dysfunction of these regions of the brain, ultimately 
playing a role in depression. Despite being in existence since the time of the monoamine 
hypothesis, the cholinergic/adrenergic imbalance hypothesis is still in development.     
 
 
 
Figure 14. Structures of acetylcholine (ACh, 39) and scopolamine (43), a non selective 
muscarinic receptor antagonist. 
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e.  Anhedonia/Opioid hypothesis: 
κ Opioid receptors (KOR) and the neuropeptide neurotransmitter dynorphins are 
expressed in areas of brain that are implicated in depression – e.g. hippocampus, PFC, 
amygdala, ventral tegmental area (VTA), and nucleus accumbens (NAc).158-162 κ Opioid 
receptors are GPCRs that signal via Gαi.163 µ and δ Opioid receptors (MOR and DOR, 
respectively) and nociceptin receptors (NOR) constitute the remaining members of the 
opioid receptor family.163,164 It is believed that activation of a KOR causes dysregulation of 
the dopaminergic system in the NAc and VTA, producing anhedonia (inability to feel 
pleasure),165,166 a major symptom of depression. This has been further supported by 
administration of a KOR agonist that produces prodepressive effects such as anhedonia and 
aversive effects in rodents167-169 and dysphoria in humans,170,171 and KOR antagonists that 
block these effects.172,173 The activation of KOR has also been linked to anxiety via its 
actions in the amygdala,174,175 though this has been countered.176,177 Since KOR are GPCRs 
that signal via Gαi, their activation causes inhibition of cAMP.163 Activation of KOR also 
activates the MAPK pathway consisting of three kinases – extracellular regulated kinase 
(ERK1/2), p38 stress kinase (p38), and c-Jun N-terminal kinase (JNK).178,179 MAPK cause 
phosphorylation and activation of a number of cellular proteins like cAMP response 
element-binding protein (CREB) and other transcription factors as well as AMPA receptors 
and impact their trafficking.180 
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f. Stress/Hypothalamus-pituitary-adrenal (HPA) axis hypothesis: 
 Increased levels of cortisol (44; Figure 16), a glucocorticoid, has been observed in 
patients suffering from depression.181 Cortisol (44) is involved in a number of important 
processes such as metabolism and regulation of the immune system, as well as behavior.182 
Glucocorticoids such as cortisol (44) exert their effect via various steroid receptors, among 
them mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs),183 which are a 
part of a much broader family of nuclear receptors and are involved in regulation of gene 
expression via transcription factors such as CREB among others.184  
The production and release of cortisol (44) is affected by the 
levels of adrenocorticotrophic hormone (ACTH) which is 
released from the pituitary gland. ACTH levels are increased 
when the levels of corticotrophin release hormone (CRH) 
released from the paraventricular nucleus (PVN) of the 
hypothalamus are increased185 (Figure 17). Glucocorticoids 
have a negative feedback loop wherein released 
glucocorticoids bind and activate MRs and GRs expressed in the CNS (hippocampus) 
leading to a decrease in the levels of CRH and ACTH and subsequently glucocorticoids186 
Figure 16. Structure of the 
glucocorticoid cortisol 
(44). 
Cortisol (44)
HO
H3C H
H3C OH
H
O
H
O OH
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(Figure 17). Thus, hippocampal atrophy 
observed in MDD187 might disrupt the 
negative control on the HPA axis and 
increases the levels of cortisol (44). In the 
event of exposure to chronic stress this 
negative feedback loop is affected and the 
HPA axis is hyperactivated,181,188 a 
phenomenon observed in 50% of depressed 
patients.183,189-191 Elevated levels of cortisol 
(44) contribute to the atrophy of neurons of 
the hippocampus. This further diminishes the 
negative control of the hippocampus on the 
HPA axis. This self-sustained hyperactivity of the HPA axis is thought to retard neurogenesis 
and contribute to symptoms observed in depression.193,194 The involvement of GR in reduced 
neurogenesis has been shown by administration of a GR antagonist (reverses neurogenesis 
brought about by HPA hyperactivity)195-197 and GR+/- knockout mice (decreased 
neurogenesis and depressed phenotype).198 However, it is still not clear whether HPA 
hyperactivity is a cause or effect of depression.182,185  
 
 
Figure 17. The HPA axis and negative 
feedback loop mediated via glucocorticoid 
receptors (GRs) and cortisol (44) that helps 
to regulate it. Adapted from Pariante et al.192 
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g. Stress/Neuroplasticity hypothesis: 
The hypothesis states, “impaired mechanisms of neuroplasticity are a core 
pathophysiological feature of MDD, that chronic stress is an important causal factor in the 
development of this impairment, and that antidepressant treatments act, at least in part, 
through mitigation of impaired mechanisms of plasticity”.199 Stress has been shown to affect 
different regions of the brain in distinctly different manners.199 The hippocampus and PFC 
are shown to atrophy as a result of chronic stress187,200-202 and this mirrors what has been 
observed in depressed patients.128,203,204 The amygdala, on the other hand, shows signs of 
increased activity by virtue of an increase in the number of synapses205 as observed in 
MDD.206-208 The hippocampus is involved in a number of processes such as memory and 
concentration209 that are impaired in patients suffering from MDD. Moreover, the 
hippocampus positively modulates the dopaminergic neurons in the VTA and NAc and a 
reduction in hippocampal activity leads to a decrease in dopaminergic activity in the VTA. 
This is thought to contribute to the feeling of anhedonia observed in MDD.210 The increased 
activity of the amygdala as a result of chronic stress leads to an increase in fear-induced 
learning211 as well as anxiety in animal models.212 These changes in the morphology of the 
brain are brought about by various mechanisms that regulate and participate in long-term 
potentiation (LTP) and long-term depression (LTD). An increase in the concentration of 
calcium ions and cyclic adenosine monophosphate (cAMP), a second messenger, causes 
LTP via calcium-calmodulin kinase II and IV (CAMKII, CAMKIV).213 CAMKII increases 
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the number of AMPA receptors and their function in synapses by phosphorylation.199 
CAMKIV on the other hand activates CREB, a transcription factor,214 that along with other 
neurotrophic factors such as BDNF, stabilize newly formed synapses.215,216 Chronic stress 
impacts the levels of both CREB217,218 and BDNF219-224 and interferes with neurogenesis 
leading to atrophy. Antidepressants, when administered chronically, have been shown to 
reverse some of these effects of stress related to atrophy and neurogenesis.225,226   
 
h. Neuroinflammation hypothesis: 
“The cytokine hypothesis of depression posits that depression is caused by action of 
cyotkines”.227 Cytokines are small molecular weight proteins that activate the immune 
system in response to an infection. Interferons (IFNα, IFNβ, IFNɣ), a type of cytokines, have 
been administered in the treatment of diseases such as cancer, multiple sclerosis and hepatits 
C.228 Patients receiving IFNα developed depressive symptoms such as anhedonia, irritability 
and fatigue.229-231 Around this time there was an increased interest in determining the 
possible role of inflammation in depression. Smith (1991) put forth the theory that 
“depression was associated with increased secretion of cytokines (especially IL-1) by 
macrophages” and termed it the macrophage hypothesis of depression.232 Over the next few 
years, efforts were made to correlate levels of cytokines233 and other inflammatory 
markers234 to depression. Particular attention has been bestowed on cytokines such as 
interleukins (IL-1β, IL-6) and IFNs. Unfortunately, contrary evidence exists for the 
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involvement of IL-1β235-237 and IL-6.238,239 IFNs on the other hand have been shown to be 
increased in individuals suffering from depression.240-242  
Among the various molecular mechanisms by which cytokines are believed to 
contribute to depression, activation of the HPA axis and action on the serotonergic system 
have been studied extensively. Cytokines activate the hippocampus, which in turn causes 
activation of the HPA axis. This leads to increased production of CRH, ACTH and 
glucocorticoids. IL-1, IL-6 and tumor necrosis factor α (TNFα) are all believed to be capable 
of this hippocampal activation.243 Increased levels of glucocorticoids eventually leads to 
neuronal atrophy and dysregulation of the negative feedback on the hippocampus and results 
in hyperactivation of the HPA axis similar to what is observed in response to stress. In terms 
of actions on the serotonergic system, IFNα, IFNɣ, and IL-2 induce the enzyme indoleamine 
2,3-dioxygenase.244 This enzyme is responsible for conversion of L-tryptophan (14) to 
kynurenine (45) and quinolic acid (48) or kynurenic acid (47) as shown in Figure 18. This 
indoleamine 2,3-dioxygenase-catalyzed metabolism leads to a depletion of L-tryptophan 
(14), a precursor of 5-HT (1). The resultant depletion of L-tryptophan (14) could account for 
the depressive symptoms observed.245,246 Moreover, the metabolites produced from L-
tryptophan (14), 3-hydroxykynurenin (46) and quinolic acid (48), and kynurenic acid (47), 
are NMDA receptor antagonist and agonists,247 respectively (Figure 18). Ketamine (33; 
Figure 9), an NMDA receptor antagonist, has been shown to have a rapid antidepressant 
effect102,106 and kynurenic acid (47) potentially possesses similar properties. On the other 
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hand, NMDA receptor agonists can potentially cause depressive symptoms by virtue of 
being neurotoxic.248-250    
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Figure 18. Metabolism of L-tryptophan (14), a precursor of 5-HT (1), to form the metabolite 
kynurenine (45) catalyzed by indoleamine 2,3-dioxygenase which is induced by IFNα, IFNɣ, IL-
2. Kynurenine (45) is further converted to 3-hydroxykynurenine (46) and quinolic acid (48), both 
of which act as NMDA receptor antagonists and possess neurotoxic properties. Kynurenic acid 
(47), on the other hand, is a NMDA receptor agonist and possesses neuroprotective properties. 
Adapted from Loftis and Hauser228 and Zunszain et al.247   
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2. Organic Cation Transporters (OCTs): Novel target for antidepressants 
a. Classification: 
Organic cation transporters (OCTs) belong to the SLC22 family of transporters.251 
The solute carriers (SLCs) consist of 53 families of transporters (SLC1-53; Figure 19) 
classified on the basis of their amino acid sequences.251,252 Besides the OCTs, the SLC22 
family also consists of organic anion transporters (OATs), carnitine/cation transporters 
(OCTNs) and urate transporters (URAT) (Figure 19).251,252 Transport by OCTs is 
characterized as being polyspecific, independent of Na+, bidirectional253 and electrogenic.14 
They are considered polyspecific and bidirectional since they are capable of transporting 
substances varying widely in their sizes254 in either direction. They do not require Na+ to 
drive the transport of substrates,253 unlike monoamine transporters such as SERT, NET and 
DAT.255 Also, they are electrogenic, i.e., they generate an inward current as a result of 
transport.14 OCTs are capable of interacting with a wide variety of substrates as well as 
inhibitors254 – from endogenous substrates (e.g., DA,16,17 5-HT,16,17 NE,16,17,256 (4, 1, and 2 
respectively in Figures 1 and 2); epinephrine (49), histamine (50) (Figure 20)16,17,256) to drugs 
and xenobiotics (e.g., cimetidine (51), metformin (52) (Figure 20)257-262) and model cations 
such as 1-methyl-4-phenylpyridinium (MPP+) (53;19,263-267 Figure 20), tetraethylammonium 
(TEA+) (54;19,268-271 Figure 20). The substrates can either be positively charged species (e.g. 
furamidine (55;272 Figure 20)) or uncharged species (e.g. cimetidine (51;257,258 Figure 20) 
They are further subdivided into 3 types – OCT1, OCT2, and OCT3 (Figure 19).251  
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b. Expression: 
The expression patterns of the three subtypes of OCTs are overlapping to some extent 
and have been identified in various species including rodents such as rats and mice and other 
mammals such as rabbits, pigs and humans. The first OCT that was discovered was cloned 
from the kidney cells of rats and was named rOCT1.273 Subsequently, the corresponding 
Figure 20. Structures of the neurotransmitters epinephrine (49) and histamine (50), antiulcer 
drug cimetidine (51), hypoglycemic drug metformin (52), the model substrates 1-methyl-4-
phenylpyridinium (MPP+) (53) and tetraethylammonium (TEA+) (54), and antiprotozoal and 
antifungal drug furamidine (55).  
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orthologs were cloned from other species such as humans,19,263 rabbits274 and mice.275 OCT2 
was also first isolated from rats,276 followed by humans,19 pigs,20 rabbits277 and mice.278 
OCT3 was discovered by cloning and expression in the carcinoma cell line of human kidney 
cells called Caki-1.256 Subsequently, OCT3 were also isolated and identified from rats14,281 
and mice.280  
In humans, the mRNA of hOCT1 is primarily detected in the liver19,262,281,282 while 
that of hOCT2 is primarily expressed in the kidneys.19,281,282 Additionally, hOCT2 mRNA is 
also detected in small intestine, lung, brain and inner ear.16,19,283-285 hOCT3 mRNA, on the 
other hand, has a wider expression profile262,280 that includes the heart, liver, kidney, lung, 
intestine, adrenal gland, placenta and brain.21 Specifically, hOCT1 is expressed in the 
following regions of the human body – in hepatocytes on the sinusoidal (basolateral) 
membrane,286 in the intestine on the lateral membrane of epithelial cells,287 in the lung on 
the luminal (apical) membrane of the ciliated epithelial cells,283 and in the kidney on the 
luminal (apical) membrane of tubule epithelial cells.288 The hOCT2 protein is detected in the 
epithelial cells of the proximal tubule of the kidney on the basolateral membrane.286,289 It has 
also been detected in the lung on ciliated epithelial cells, specifically the luminal 
membrane283 and in the hippocampal region of the brain in pyramidal cells.16 In the brain, 
hOCT3 is expressed on glial cells24 including the plasma membrane of astrocytes in 
humans.290  Besides this, hOCT3 is also expressed in placenta on the basolateral membrane 
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vesicles,266 in the lungs287 and intestine283 on the luminal membranes of epithelial cells and 
in the liver on the sinusoidal membrane.262  
 
c. Structure: 
OCTs are comprised of ~543-547 amino acids arranged in the form of 12 α-helical 
transmembrane domains (TMDs, Figure 21).21,291 The TMDs are connected to each other by 
a series of intracellular loops (ICLs) and extracellular loops (ECLs). The N- and C-termini 
of OCTs are located intracellularly.21,291 The ECL1 between TMD1 and TMD2 is large and 
consists of a number of sites for glycosylation. This is believed to help in localization and 
proper functioning of transporter. The ICL3 between TMD6 and TMD7 is also large and 
consists of sites that are potentially phosphorylated by protein kinases A, C and G or tyrosine 
kinase.21,291 This is a mechanism of regulation of the transporters.21,291 The OCTs share a 
high degree of amino acid identity with each other – 70% between OCT1 and OCT2 and 
~50% with OCT3.254  
 Unfortunately, the crystal structures of OCTs have not yet been solved. However, 
homology modeling studies of rOCT1 based on the Escherichia coli lactose permease 
transporter (PDB ID: 1PV6, 3.5 Å	 resolution)292 have revealed several amino acids that 
might be important in the interactions with substrates and/or inhibitors.293-297 These amino 
acids are located in TMDs 4, 10 and 11 and are all located at the same depth creating a 
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binding region that is accessible from either the intracellular or the extracellular side.293-297 
Mutagenesis studies have subsequently confirmed the importance of these amino acids.295  
 
 
 
 
 
 
 
d. Identification of OCT3 as uptake-2: 
Extraneuronal monoamine trasnporters (EMT) also known as uptake-2, were thought 
to be low-affinity/high-capacity Na+-independent transporters unlike uptake-1 which are 
characterized as high-affinity/low-capacity Na+/Cl--dependent transporters. In 1998, Wu et 
al.14 established OCT3 as the EMT/uptake-2 using techniques such as Northern blot analysis, 
RT-PCR and in situ hybridization. One of the defining features of the EMT is “sensitivity to 
Figure 21. Schematic representation of OCTs. The 12 transmembrane domains are colored 
blue to red from the amino (N) to the carboxyl (C) termini. A large ECL1 contains multiple 
potential sites for glycosylation, while a large ICL3 contains multiple potential sites for 
phosphorylation.  
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steroids.”14 rOCT3 was shown to possess this trait by Wu et al.14 specifically with respect to 
very similar inhibitory potencies of β-estradiol (56) (Figure 22) at EMT and rOCT3 (IC50 = 
1.8 µM and 1.1 µM, respectively). 
 
e. Knockout (KO) mice models: 
The three subtypes of OCTs have successfully been knocked out to generate viable 
mouse models. These knockout (KO) mouse models have successfully implicated OCTs in 
the excretion of drugs. A lack of OCTs in the KO mouse models affected the levels of drugs, 
such as m-iodobenzylguanidine (57; Figure 23) and metformin (52; Figure 20), in several 
organs including the liver of mice. The levels of model substrates such as TEA+ (54; Figure 
20)298 and MPP+ (53; Figure 20),298 drugs such as m-iodobenzylguanidine (57; Figure 23)298 
(anticancer) and metformin (52; Figure 20)299,300 (hypoglycemic) in the liver were found to 
be lower in OCT1 KO mice as compared to wildtype (WT) mice. Unlike in OCT1 KO mice, 
the levels of TEA+ (54) were unaffected in OCT2 KO mice when compared to OCT2 WT 
mice.301 This was thought to occur because of compensation by OCT1 expressed in the 
Figure 22. Structure of β-estradiol (56), having inhibitory potencies of 1.8 µM and 1.1 µM 
at EMT and rOCT3,14 respectively. 
β-etsradiol (56)
H3C OH
H
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kidney of mice.254 In order to better understand this phenomenon, OCT1/OCT2 double KO 
mice were generated.301 These displayed a considerably higher level of TEA+ (54; Figure 
20)301 and the drug cisplatin (58; Figure 23)302,285 (anticancer) as compared to WT mice 
indicating that OCT1 and OCT2 might be involved in the excretion of MPP+ (53) and 
cisplatin (58). The levels of MPP+ (53) were observed to be greatly reduced in the hearts of 
OCT3 KO mice as well as in fetuses born of OCT3 KO mice.303 Moreover, OCT3 has also 
been implicated in salt-intake regulation304 as well as regulation of behavioral responses to 
fear and anxiety.  
  
 
 
 
f. Polymorphisms: 
Single nucleotide polymorphisms (SNPs) have been identified in all three human 
OCTs. Kerb et al.305 identified five SNPs resulting in changes in amino acid residues - R61C, 
C88R, F160L, G401S, M420del. Out of these five, three of them – R61C, C88R, and G401S 
– resulted in a decrease in uptake of MPP+ (53) indicating that these residues are potentially 
important for both affinity and selectivity of substrates.305 The mutant M420del did not show 
reduced uptake for the model substrate MPP+ (53) but did for metformin (52) 
Figure 23. Structures of anticancer drugs m-iodobenzylguanidine (57) and cisplatin (58).  
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(hypoglycemic) and might be involved in variability observed among patients.300 Unlike for 
hOCT1, hOCT2 was studied in a larger and ethnically much more diverse population 
showing 27 potential sites for variations  in the gene.306 Some SNPs resulting in single amino 
acid mutations were specific for certain groups of populations such as African-American, 
and Mexican-American population group.306 It was postulated that because of its role in 
excretion of xenobiotics from the kidney, “there is selection against changes in amino acid 
sequence of hOCT2”.306 Six SNPs were detected for hOCT3 in a Caucasian population 
group.307 However, none of these SNPs resulted in amino acid mutations indicating the 
importance of this transporter in the human body.307  
 
g. Updating the monoamine hypothesis:  
An increasing number of studies have displayed the therapeutic potential of targeting 
OCT3 for antidepressant effect. Administration of corticosterone (59; Figure 24) showed a 
greater antidepressant-like effect in the FST when compared to a TCA.308 Corticosterone 
(59) is a known blocker of OCTs.308 In 2008, Baganz et al.25 demonstrated an increase both 
in mRNA levels as well as protein expression of OCT3 in the hippocampal region of the 
mouse brain in SERT+/- (heterozygous) and SERT-/- (knockout) as compared to SERT+/+ 
(homozygous) mice. Despite this increase in levels of OCT3, no change was observed in 
distribution patterns with OCT3 being expressed within the same areas of the hippocampus 
as SERT.25 Decynium-22 (60;309 Figure 24), an OCT3 inhibitor (IC50 = 0.9 µM),29 was 
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shown to inhibit uptake of histamine (50) by OCT3 to a significantly large extent in SERT-
/- mice as compared to SERT+/- and SERT+/+ mice.25 Histamine (50) was utilized since it is a 
substrate for OCT3 but not SERT and other monoamine transporters.18,310 A similar trend 
was observed in the mouse TST, wherein decynium-22 (60) (1.0 µg/kg) was seen to possess 
antidepressant-like activity in SERT-/- and SERT+/- mice but not in SERT+/+ mice.25 This 
further cemented the idea that OCT3 might act as a compensatory mechanism of reuptake 
of 5-HT (1) from the synapse which might “kick-in” in the absence of SERT (uptake-1) or 
upon inhibition of uptake-1 by SSRIs and contribute to unresponsiveness to SSRIs. 
 
In another study, decynium-22 (60; Figure 24) was shown to increase concentrations 
of  5-HT (1) in the medial hypothalamus in rats by 200% and ~400% above the baseline in 
the absence and presence of mild restraint.303 This indicated a role for OCT3 in the clearance 
of 5-HT (1) in the medial hypothalamus.303 Further, Feng et al.311 showed a similar increase 
in basal 5-HT (1) levels by 200-650% upon administration of decynium-22 (60) (10, 30 and 
Figure 24. Structures of corticosterone (59), a known blocker of OCTs308 and decynium-22 
(60), a known OCT3 inhibitor (IC50 = 0.9 µM).29  
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100 µM) by microdialysis in the medial hypothalamus of rats. Activation of the HPA axis 
leading to an increase in corticosterone (59), a glucocorticoid, was shown to cause down 
regulation of OCT3 as a result of chronic inhibition and decreased 5-HT (1) clearance in 
mouse hippocampus leading to an antidepressant-like effect.312  
 Clinically available antidepressants belonging to the TCA and SSRI class of 
antidepressants, such as desipramine (31) (TCA) (Figure 8), amitriptyline (61) (TCA) 
(Figure 25), imipramine (23) (TCA) (Figure 5), sertraline (62) (SSRI) (Figure 25), 
paroxetine (63) (SSRI) (Figure 25), and FLX (3) (SSRI) (Figure 1), have also been shown 
to inhibit hOCT3 using 4-(4-diethylaminostyryl)-1-methylpyridinium (4-Di-1-ASP) (64; 
Figure 25) as the substrate.29 The IC50 value (2.3 µM) for sertraline (62) indicated that the 
concentration which would be required to inhibit hOCT3 is much higher than what could be 
achieved clinically.29 On the other hand, desipramine (31) was shown to have an IC50 value 
(0.7 µM) within the range of concentrations attained following clinically used doses.29  
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Figure 25. Structures of antidepressants amitriptyline (61), sertraline (62) and paroxetine 
(63) and hOCT3 substrate 4-(4-diethylaminostyryl)-1-methylpyridium (4-Di-1-Asp) (64).  
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III. Specific aims and rationale 
 
2-Amino-6-chloro-3,4-dihydroquinazoline (A6CDQ) (65; Figure 26) was 
synthesized and developed by the Dukat laboratory as part of SAR studies for ligands acting 
at 5-HT3 receptors. A6CDQ (65) was identified to be a potent high-affinity 5-HT3 receptor 
antagonist (Ki = 80 nM, IC50 = 0.26 µM).35 5-HT3 receptor antagonists such as ondansetron 
(27) and bemesetron (29) had been shown to possess antidepressant-like activity in the 
mouse TST.36,37 Thus, A6CDQ (65) was examined in the mouse TST and was shown to 
possess antidepressant-like activity (ED50 = 0.23 mg/kg,35 Figure 27). When examined at 40 
proteins (including GPCRs, LGICs and transporters) A6CDQ (65) was shown to lack 
affinity (Ki > 10,000 nM). Therefore, we hypothesized that the antidepressant-like activity 
of A6CDQ (65) might be mediated via 5-HT3 receptor antagonism.  
A positional isomer of A6CDQ (65), 2-amino-7-chloro-3,4-dihydroquinazoline 
(A7CDQ; 66, Figure 26), was determined to possess 25-fold lower affinity at 5-HT3 
receptors (Ki = 1,975  nM) as compared to A6CDQ (65).35 In the mouse TST, A7CDQ (66) 
was seen to possess equipotent antidepressant-like activity in comparison to A6CDQ (65) 
(Figure 27).313 Both A6CDQ (65) and A7CDQ (66) were 20 times more potent than FLX 
(3) (20 mg/kg) (Figure 27). One of the present goals was to determine the functional activity 
of A7CDQ (66) at 5-HT3 receptors.  
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FLX (3) belongs to one of the most widely prescribed class of antidepressants - the 
SSRIs.38 FLX (3) binds with high affinity (Ki = 1 nM)38 to, and potently inhibits, SERT (IC50 
= 0.076 µM)38 to prevent the reuptake of 5-HT (1) from the synapse. This leads to an 
enhanced concentration of 5-HT (1) in the synapse resulting in antidepressant effects. 
Besides its action at SERT, FLX (3) is also functionally active at 5-HT3 receptors i.e., it is a 
Figure 26. Structures of positional isomers 2-amino-6-chloro-3,4-dihydroquinazoline 
(A6CDQ) (65) and 2-amino-7-chloro-3,4-dihydroquinazoline (A7CDQ) (66).  
A6CDQ (65)
NHN
NH2
Cl
A7CDQ (66)
NHN
NH2
Cl
Figure 27. A6CDQ (65) and A7CDQ (66) are ~20-fold more potent than the commercially 
available antidepressants, FLX (3), imipramine (23) and desipramine (31) in the mouse 
TST.35,313   
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functional 5-HT3 receptor antagonist.39 This implies that FLX (3) has no affinity for the 
orthosteric site at 5-HT3 receptors but mediates its antagonism via an allosteric site. We 
explored the possibility that the 2-aminodihydroquinazolines, A6CDQ (65) and A7CDQ 
(66), might be functionally active at hSERT by conducting radioligand binding, 
electrophysiological, molecular modeling and Hydropathic INTeractions (HINT) studies at 
hSERT.  
The guanidine moiety of 2-aminodihydroquinazolines can exist as protonated species 
at physiological pH. Thus, we explored the possibility that our compounds, the 2-
aminodihydroquinazolines, might possess activity at the OCTs. 
 
The specific aims of the current project are:  
1. To determine the functional activity of A7CDQ (66) at 5-HT3 receptors. 
Approach: 
- Conduct electrophysiological studies of A7CDQ (66) at m5-HT3A receptors 
expressed in Xenopus laevis oocytes. 
2. To elucidate the non 5-HT3 serotonergic mechanism of antidepressant-like 
activity exerted by A6CDQ (65) and A7CDQ (66) in the mouse TST. 
Approach: 
- Obtain binding affinities of A6CDQ (65) and A7CDQ (66) at hSERT. 
  46 
- Determine functional activities of A6CDQ (65) and A7CDQ (66) at hSERT by 
performing electrophysiological studies. 
- Conduct molecular modeling studies 
• Generate hSERT models. 
• Dock A6CDQ (65) and A7CDQ (66) at hSERT and study their interactions 
to determine their modes of binding. 
• Quantify the observed interactions using Hydropathic INTeraction (HINT) 
analysis at chosen hSERT-ligand complexes.  
3. To elucidate the non-serotonergic mechanism of antidepressant-like activity of 
the 2-aminodihydroquinazoline A6CDQ (65) at uptake-2 (OCT3) 
Approach: 
- Determine functional activity of the 2-aminodihydroquinazoline A6CDQ (65) at 
OCTs (human and mouse) by measuring uptake of [3H]MPP+ (53). 
4. To develop structure-activity relationships (SARs) at uptake-2 (OCT3) that are 
currently lacking. 
Approach: 
- Synthesize 2-aminodihydroquinazoline and their ring-opened (phenylguanidine) 
analogs and to test the activity and selectivity of resulting analogs at OCTs (human 
and mouse) by measuring uptake of [3H]MPP+ (53). 
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5. To identify binding sites and modes of interactions of 2-
aminodihydroquinazoline and phenylguanidine analogs at hOCT3 and mOCT3 
using molecular modeling. 
Approach: 
- Build 3-dimensional homology models of the human and mouse orthologs of OCT3 
(hOCT3 and mOCT3) based on the inorganic phosphate transporter (PiPT) as the 
template. 
- Study interactions of 2-aminodihydroquinazoline and their ring-opened 
phenylguanidine analogs at hOCT3 and mOCT3 by performing docking studies. 
- Quantify interactions observed using HINT analysis for selected hOCT3-ligand 
complexes. 
6. To determine if 2-aminodihydroquinazoline and phenylguanidine analogs 
retain antidepressant-like effect.  
Approach: 
- Examine selected examples of 2-aminodihydroquinazoline analogs in the mouse tail 
suspension test (TST) at different doses (generate dose-response curves). 
- Examine active doses identified in TST in the locomotor activity assay to assess 
potential locomotor stimulant effect.  
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An overarching goal of this work is to synthesize compounds necessary to evaluate the 
hypotheses that have been developed. The syntheses of all target compounds will be 
discussed at the beginning of each section.   
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IV. Results and discussion 
 
GOAL 1: To determine the functional activity of A7CDQ (66) at 5-HT3 receptors. 
 
A7CDQ (66) was available from previous studies.313 
 
We examined the activity of A7CDQ (66), the positional isomer of A6CDQ (65), at 
m5-HT3A receptors expressed in Xenopus laevis oocytes. Similar to A6CDQ (65),35 A7CDQ 
(66) was also found to inhibit 5-HT (1)-induced responses at m5-HT3A receptors (IC50 = 
5.77 ± 1.13 µM) albeit with a 22-fold lower potency compared to A6CDQ (65). This, 
coupled with the 25-fold lower affinity of A7CDQ (66) (Ki = 1,975 nM)35 at 5-HT3 receptors, 
suggested that antagonism at 5-HT3 receptors alone is an insufficient explanation for the 
equipotent antidepressant-like effect observed for A6CDQ (65) and A7CDQ (66) in the 
animal model of depression.    
 
 
GOAL 2: To elucidate the non 5-HT3 serotonergic mechanism of antidepressant-like 
activity exerted by A6CDQ (65) and A7CDQ (66) in the mouse TST. 
 
The compounds, A6CDQ (65) and A7CDQ (66), were available from previous studies.313 
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1. Binding studies at hSERT: 
Radioligand binding studies conducted at hSERT using [3H]citalopram indicated that 
both A6CDQ (65)313 and A7CDQ (66)313 bind poorly with affinities of 5,852 nM and 
>10,000 nM, respectively. FLX (3), besides being a classical SSRI, is also a functional 5-
HT3 receptor antagonist.39 Functional antagonism implies that FLX (3) does not bind to the 
orthosteric binding site but achieves the effect (antagonism) via an alternate site (allosteric 
site). Hence, despite their poor binding affinities at the orthosteric binding site of hSERT, 
we examined if the 2-aminodihydroquinazolines, A6CDQ (65) and A7CDQ (66), would 
behave as allosteric modulators at hSERT using electrophysiological studies. In terms of 
receptor chemistry, allosteric modulators are defined as binding to a site distinct from the 
orthosteric site and could either be negative, positive or silent allosteric modulators.314,315 
All three types of allosteric modulators – negative (NAM), positive (PAM) and silent (SAM) 
allosteric modulators, lack intrinsic activity.314,315 NAMs and PAMs cause a decrease and an 
increase, respectively, in the responses elicited in the presence of an agonist.314,315 Silent 
allosteric modulators on the other hand, do not cause any change in the response.314,315 The 
phenomenon of allosterism has been reported for transporters such as for DAT by Schmitt 
et al.316 in 2013.  
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2. Electrophysiological studies at hSERT: 
A6CDQ (65) and A7CDQ (66) were found to possess distinct and unique 
electrophysiological signatures at hSERT. A6CDQ (65) (10 µM) produced inward hSERT-
mediated currents similar to the endogenous ligand 5-HT (1) (5 µM) at comparable potencies 
(Km = 2.80 µM and Km = 0.94 µM, respectively) (Figures 28 A and 28 D, respectively). 
A7CDQ (66) (100 µM), on the other hand, behaved similar to FLX (3) (1 µM) and produced 
an outward hSERT-mediated current albeit with a 600-fold lower potency (Km = 43.6 µM 
and 0.076 µM, respectively) (Figures 28 B, 28 C and 28 D).  
  
 
In order to confirm that A7CDQ (66) is a reuptake inhibitor, we tested A7CDQ (66) 
in combination with the transport releasers 5-HT (1) and A6CDQ (65). A7CDQ (66) (50 
Figure 28. A. A6CDQ (65) (10 µM) induced an inward hSERT-mediated current similar to 
5-HT (1) (5 µM). B. A7CDQ (66) (100 µM) induced an outward hSERT-mediated current 
similar to C. FLX (3) (1 µM). D. A6CDQ (65) similar to 5-HT (1) behaves as a releaser and 
A7CDQ (66) similar to FLX (3) behaves as a reuptake inhibitor.    
NHN
NH2
Cl
NHN
NH2
Cl
NHN
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µM) successfully blocked (i.e., decreased the amplitude of the inward hSERT-mediated 
currents by 5-HT (1) (2 µM) (Figure 29 A) and abolished the inward hSERT-mediated 
currents by A6CDQ (65) (10 µM) (Figure 29 B)). FLX (3), on the other hand, besides 
abolishing the inward hSERT-mediated current by A6CDQ (65), produced a hyperpolarizing 
outward hSERT-mediated current (Figure 29 C). Therefore, A7CDQ (66) successfully 
antagonized A6CDQ (65) and appeared to behave as a reuptake inhibitor at hSERT, whereas 
A6CDQ (65) behaved as a releaser.  
 
 
To determine the mechanism of inhibition exerted by A7CDQ (66) at hSERT, kinetic 
studies were performed in the absence and presence of varying concentrations of A7CDQ 
Figure 29. A. A7CDQ (66) (50 µM) blocked the inward hSERT-mediated currents by 5-HT 
(1) (2 µM) at hSERT and B. completely abolished inward hSERT-mediated currents by 
A6CDQ (65) (10 µM). C. FLX (3) (2 µM) abolished hSERT-mediated currents by A6CDQ 
(65) (10 µM) and lead to an outward hSERT-mediated current.   
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(66) (20, 50 and 100 µM, representative recording at 50 µM of A7CDQ (66) shown in Figure 
30 B). 5-HT (1) induced inward hSERT-mediated currents in the absence of A7CDQ (66) 
(Figure 30 A) generated a Km = 1.3 ± 0.2 µM (Figure 30 C). 5-HT (1) induced inward 
hSERT-mediated currents in the presence of 20, 50 and 100 µM of A7CDQ (66)  gave the 
following Km = 2.1 ± 0.3 (Vmax = 112.3 ± 2.8); Km = 2.3 ± 0.3 (Vmax = 106.7 ± 3.3) and Km 
= 2.8 ± 0.3 (Vmax = 102.3 ± 2.2), respectively (Figure 30 C). Statistically significant 
differences in Km values and no difference in Vmax values were observed leading to the 
conclusion that the mode of inhibition by A7CDQ (66) is competitive in nature.     
The low binding affinity of A7CDQ (66) (Ki > 10,000 nM) poses a conundrum in 
light of its competitive nature. [3H]Citalopram was the radioligand employed to measure the 
binding affinities of both A6CDQ (65) and A7CDQ (66). The low binding affinity of 
A7CDQ (66) could potentially be explained by its very poor activity at hSERT, i.e., 600-
fold lower inhibitory potency of A7CDQ (66) as compared to FLX (3) (Ki = 1 nM) at hSERT. 
In the radioligand binding assay, the maximum concentration of A7CDQ (66) tested was 10 
µM. There exists a possibility that, had A7CDQ (66) been tested at a higher concentration 
(i.e., approaching its IC50), we might have obtained a value for the binding affinity.  Thus, 
A7CDQ (66) appears to be a competitive reuptake inhibitor of extremely low affinity and 
potency.  
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3. hSERT homology modeling studies: 
Having determined that A6CDQ (65) and A7CDQ (66) possess activity at hSERT, 
we wished to study their interactions at a molecular level. Switching the position of the 
chloro group from the 6- to the 7-position changed the activity from a releaser to a reuptake 
inhibitor at hSERT. We conducted molecular modeling studies to determine if there exist 
differences in the interactions of the chloro group at the two positions. SERT, along with 
DAT and NET, belong to the SLC6 family of transporters. At the time, the crystal structure 
Figure 30. A. Electrical recordings of 5-HT (1) induced hSERT-mediated inward currents 
at different concentrations of 5-HT (1) (0.1-30 µM) in the absence of A7CDQ (66). B. 
Representative electrical recording of 5-HT (1) (0.1-100 µM) induced hSERT-mediated 
inward currents in the presence of A7CDQ (66) (50 µM). Similar recordings were also 
obtained in the presence of two other concentrations of A7CDQ (66) (20, 100 µM) not shown 
here. C. Concentration-response curves of 5-HT (1) in the absence and presence of A7CDQ 
(66) (20, 50 and 100 µM). Km = 1.3 ± 0.2 µM for 5-HT (1) in the absence of A7CDQ (66). 
Km = 2.1 ± 0.3 µM (Vmax = 112.3 ± 2.8); Km = 2.3 ± 0.3 µM (Vmax = 106.7 ± 3.3); Km = 2.8 
± 0.3 µM (Vmax = 102.3 ± 2.2) for 5-HT (1) when concentration of A7CDQ (66) is 20, 50 
and 100 µM, respectively.  
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of hSERT was unavailable; thus, we utilized the crystal structure of the Drosophila 
melanogaster dopamine transporter (dDAT) co-crystallized with nortriptyline (TCA) (PDB 
ID: 4M48).317 Subsequently, in April 2016, the crystal structure of hSERT (PDB ID: 5I6X, 
3.15- Å resolution) was solved by Coleman et al.318 in complex with the antidepressants 
paroxetine (63) and (S)-citalopram. We compared our homology models with the crystal 
structure of hSERT using Sybyl X-2.1 and determined that they differed by a root mean 
square deviation (RMSD) of 2.8 Å (Figure 31 A). For large molecules, such as proteins, a 
RMSD of <4.0 Å indicates a high degree of similarity.319 The amino acid residues are 
numbered differently in the crystal structure and our homology models (discussed in 
‘construction and validation of models’). A majority of the residues contributing to the 
binding site seem to be oriented in an overlapping manner (Figure 31 B) except for Phe341 
(Phe333 in our model) and Ser439 (Ser430 in our model) indicating that our model was 
strikingly similar to the crystal structure. The phenyl side chain of Phe341 was seen to be 
interacting with the cyanophthalane and fluorophenyl moieties of (S)-citalopram and 
paroxetine (63), respectively.318 This interaction might be responsible for the conformation 
of the phenyl side chain observed in the crystal structure of hSERT. Ser439 in the crystal 
structure, along with other hydrophobic residues create a pocket or cavity which is primarily 
hydrophobic in nature.318 This pocket or cavity accommodates the fluoro and dioxol ring 
groups of (S)-citalopram and paroxetine (63), respectively.318 In contrast, Ser430 (equivalent 
to Ser439 in the crystal structure) in our modeling studies is involved in polar interactions 
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with the nitrogen atoms of both A6CDQ (65) and A7CDQ (66). This difference in the nature 
of interaction of the Ser residue might pose a problem.     
 
 
 
 
 
a. Construction and validation of models: 
One hundred 3-dimensional homology models of hSERT were constructed on the 
basis of alignment by Sakloth et al.320 The amino acid residues from both the C- and N-
termini (13 and 76 residues, respectively) were truncated as well as those from extracellular 
Ser336 
(Ser328) 
Phe335 
(Phe327) 
Phe341 
(Phe333) 
Ala169 
Ile172 
Tyr176 
Tyr95 
Asp98 
Ala173 
Ser439 
(Ser430) 
Figure 31. A. Crystal structure of hSERT (PDB ID: 5I6X, 3.15-Å resolution) overlapped 
with homology models of hSERT displayed as wheat and pale cyan colored ribbons, 
respectively. B. The binding site residues of the crystal structure (wheat colored capped 
sticks) overlap well with the residues of the homology models (pale cyan-capped sticks) 
except for Phe341 and Ser430. The numbering for amino acid residues of our homology 
model are shown in parenthesis for those residues whose numbering differs from the crystal 
structure.  
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loop 2 (7 residues). Since SERT is dependent on Na+ and Cl- ions for transport of 5-HT (1), 
we extracted two Na+ and one Cl- ions from the crystal structure of dDAT and merged it 
with each of the 100 homology models prior to docking of ligands.     
To validate the models, we docked the substrate 5-HT (1) and the known competitive 
inhibitor FLX (3) at the central substrate (S1) site. We used the residues – Asp98 and Ile172 
–  to define a binding site since mutagenesis data implicated their importance for binding of 
5-HT (1).321 The binding mode for 5-HT (1) identified by our modeling studies was in 
agreement to previously conducted studies.322 The protonated amine of 5-HT (1) is involved 
in an ionic salt-bridge interaction with the carbonyl oxygen of Asp98 (Figure 32 and 34). 
The phenyl ring of 5-HT (1) is involved in a number of interactions, such as hydrophobic 
interactions with Ile172, Ala173, Gly434 and an edge-to-face cation-π interaction with 
Tyr176 (Figure 32 and 34). Additionally, the 5-OH group of 5-HT (1) is involved in an H-
bonding interaction with the backbone carbonyl of Thr431 (Figure 32 and 34). For FLX (3), 
the binding mode identified by us was similar to that reported for LeuBAT.323 The protonated 
amine of FLX (3), in addition to being involved in an ionic salt-bridge interaction with 
carbonyl oxygens of Asp98, is also involved in H-bond interactions with the backbone 
carbonyls of Tyr95 and Ala96 (Figure 33). The aromatic rings of FLX (3) – an unsubstituted 
phenyl ring and a CF3-substituted phenyl ring – are involved in hydrophobic interactions 
with Ile172 and Thr489 and with Ile172, Thr431 and Gly434, respectively (Figure 33).  
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Figure 32. Structure of 5-HT (1) docked at hSERT. The ligand and amino acid 
residues are shown as green and pale-cyan capped sticks, respectively. Chloride 
(lime green) and sodium (marine blue) ions are represented as spheres. The 
dashed red line indicates an ionic salt-bridge interaction between the protonated 
N-atom of the ligand and the O-atom of the carboxylate group of Asp98.  
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Figure 33. Structure of FLX (3) docked at hSERT. The ligand and amino acid residues 
are shown as cyan and pale cyan-capped sticks, respectively. Chloride (lime green) and 
sodium (marine blue) ions are represented as spheres. The dashed red lines indicate a 
bidentate ionic salt-bridge interaction between the protonated N-atom of the ligand and 
the O-atoms of the carboxylate group of Asp98.  
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b. Docking studies and Hydropathic INTeraction (HINT) analysis: 
The electrophysiological and mechanistic studies indicated that A7CDQ (66) acts 
similar to the known reuptake inhibitor FLX (3) and inhibits 5-HT (1) in a competitive 
manner at hSERT. A6CDQ (65), by virtue of being a releaser similar to 5-HT (1), and being 
inhibited by both A7CDQ (66) and FLX (3), might interact at the same site as 5-HT (1). 
Thus, both A7CDQ (66), an inhibitor, and A6CDQ (65), a releaser, interact at the same site. 
These findings are supported by literature evidence for DAT where both releasers320,324 and 
reuptake inhibitors325 interact at the same site and utilize similar amino acid residues. 
Therefore, we performed modeling studies by docking the 2-aminodihydroquinazolines, 
A6CDQ (65) and A7CDQ (66), at the 5-HT (1) central substrate (S1) binding site using the 
two amino acid residues - Asp98 and Ile172 - to define the site. 
A6CDQ (65) and A7CDQ (66), docked in a highly similar and overlapping manner 
with respect to each other (Figure 34 and 35). The N-atoms of the guanidinium moiety of 
the 2-aminodihydroquinazolines were involved in a bidentate salt-bridge ionic interaction 
with the carboxylate O-atom of Asp98 at hSERT (Figure 34 and 35). The phenyl rings of 
A6CDQ (65) and A7CDQ (66) are involved in hydrophobic interactions with Ile172 and an 
edge-to-face cation-π interaction with the phenyl ring of Tyr176 (Figure 34 and 35). The 
chloro group of both A6CDQ (65) and A7CDQ (66) are surrounded by a subset of common 
and additional distinct hydrophobic amino acid residues. The common hydrophobic amino 
acid residues include – Ile172, Ala173, Gly434 and Leu435 (Figure 35). A6CDQ (65), in 
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addition is also involved in hydrophobic interactions with Ala169; while A7CDQ (66) is 
additionally involved with Tyr176 and Thr431 (Figure 35).  
 
 
  
Figure 34. Superimposed structures of 2-aminodihydroquinazolines A6CDQ (65) (orange) 
and A7CDQ (66) (magenta) as well as 5-HT (1) (green) and FLX (3) (cyan) docked at 
hSERT. The ligands and amino acid residues are shown as capped sticks and pale cyan- 
capped sticks, respectively. Chloride (lime green) and sodium (marine blue) ions are 
represented as spheres. The dashed red lines indicate ionic salt-bridge interactions between 
the protonated N-atoms of the ligands and the O-atoms of the carboxylate group of Asp98.  
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To quantify the interactions observed in our modeling studies we conducted a 
Hydropathic INTeraction (HINT) analysis.326 HINT is defined as the sum of electrostatic 
and hydrophobic interactions between any two molecules,326 in our case, the transporter, 
hSERT and our compounds, A6CDQ (65) and A7CDQ (66). HINT takes into account both 
Figure 35. Structures of the 2-aminodihydroquinazolines A6CDQ (65) (orange) and A7CDQ 
(66) (magenta) superimposed at the central substrate (S1) binding site of hSERT. The ligands 
and amino acid residues are displayed as capped sticks and pale cyan-capped sticks, 
respectively. Chloride (lime green) and sodium (marine blue) ions are represented as spheres. 
The dashed red lines indicate a bidentate ionic salt-bridge interaction between the N-atoms 
of the guanidinium moiety and the O-atom of the carboxylate group of Asp98.  
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favorable and unfavorable interactions and a higher HINT score implies favorable 
interactions between the two molecules.326  
Of the four molecules – 5-HT (1), FLX (3), A6CDQ (65) and A7CDQ (66) - the 
known releaser, 5-HT (1) and the reuptake inhibitor, FLX (3) were shown to possess a high 
positive HINT score (913 and 1931, respectively) (Table 1). FLX (3) possessed a ~2-fold 
higher HINT score than 5-HT (1) and had the highest hydrophobic and electrostatic (polar) 
interactions at hSERT (Table 1). The 2-aminodihydroquinazolines A6CDQ (65) and 
A7CDQ (66) have 1.8- and 3.2-fold lower HINT scores than 5-HT (1) and FLX (3), 
respectively (Table 1). Our HINT analysis is in agreement with the electrophysiological data 
obtained and might account for the lower potency and affinity observed for A6CDQ (65) 
and A7CDQ (66) at hSERT.  The much larger molecule, FLX (3), seems to be capable of 
making both greater electrostatic (polar) and hydrophobic interactions at hSERT as 
compared to 5-HT (1), A6CDQ (65) and A7CDQ (66).  Our compounds, the 2-
aminodihydroquinazolines, by virtue of being smaller, lack these extensive electrostatic 
(polar) and hydrophobic interactions.  
The HINT score can be broken down into components consisting of contributions 
from individual atoms.326 Among the four shared hydrophobic amino acid residues – Ile172, 
Ala173, Gly434 and Leu 435 – the chloro group at the 6-position of A6CDQ (65) makes 
higher scoring hydrophobic interactions with these than the chloro group at the 7-position of 
A7CDQ (66) (Table 2). Moreover, the 6-Cl group of A6CDQ (65) is also involved in 
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hydrophobic interactions with Ala169 that is lacking for the 7-Cl group of A7CDQ (66) 
(Table 2). In contrast, the 7-Cl group of A7CDQ (66) is involved with two additional 
hydrophobic amino acid residues Tyr176 and Thr431 (Table 2).  
 
Table 1. Summary of HINT scores of 5-HT (1), A6CDQ (65), FLX (3) and A7CDQ (66) at 
hSERT. The total HINT score and hydrophobic component for FLX (3) are highlighted in 
blue since these are the highest of the four compounds. 
 
Ligand HINT 
score 
Hydrophobic  Total 
Polar 
Polar 
interactions with 
Asp98 
Hydrophobic 
interactions 
with Ile172 
5-HT (1) 913 458 1416 1073 20 
A6CDQ (65) 509 559 465 345 88 
FLX (3) 1931 1018 1794 875 291 
A7CDQ (66) 596 576 596 332 84 
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Table 2. Residue-based break down of HINT scores of A6CDQ (65) and A7CDQ (66) with 
respect to the chloro group. The amino acids highlighted in blue are distinct for A6CDQ (65) 
and A7CDQ (66).  
 
 
Ligands Amino acids involved in 
hydrophobic interactions 
with chloro group of 
ligands 
Hydrophobic 
contributions to HINT 
score 
A6CDQ (65) Ala169 47 
 Ile172 59 
 Ala173 45 
 Gly434 44 
 Leu435 23 
A7CDQ (66) Ile172 26 
 Ala173 40 
 Tyr176 15 
 Thr431 58 
 Gly434 10 
 Leu435 21 
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GOAL 3: To elucidate the non-serotonergic mechanism of antidepressant-like activity 
of the 2-aminodihydroquinazoline A6CDQ (65) at uptake-2 (OCT3). 
 
Since neither 5-HT3 receptor antagonism nor activities at hSERT could explain their 
equipotent antidepressant-like effect in the mouse TST, and because guanidines have been 
shown to interact with OCTs,254 we examined our compounds, the 2-
aminodihydroquinazoines, at OCTs. The functional studies were conducted in HEK293 cells 
expressing human and mouse OCT1-3 by measuring the uptake of [3H]MPP+ (53).  
 
In a preliminary screening, A6CDQ (65) was examined and found to inhibit hOCT3 
(IC50 = 3.9 µM; Table 3). Further examination showed that A6CDQ (65) inhibited all three 
subtypes of hOCT (Table 3). Moreover, A6CDQ (65) was seen to possess ~4-fold selectivity 
for hOCT3 over hOCT2 and was not selective for hOCT3 over hOCT1 (Table 3).  Thus it 
became our lead in the formulation of SAR currently lacking for OCT3.  
 
GOAL 4: To develop structure-activity relationships (SARs) at uptake-2 (OCT3) that 
are currently lacking. 
We wished to determine the role played by the chloro group by exploring both the 
importance of its presence and position.  
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1. Role of the chloro group: 
 
Hypothesis 1: If the presence and position of the chloro substituent contribute to OCT3 
inhibition, its positional isomers should be less active or inactive compared to A6CDQ (65). 
 
We tested this hypothesis by synthesizing and examining the other positional isomers, the 
5-chloro (A5CDQ; 67), 7-chloro (A7CDQ; 66), and the 8-chloro (A8CDQ; 68) as well as 
the des-Cl (ADQ; 69) 2-aminodihydroquinazoline analogs at OCT1-3. ADQ (69)327 was 
resynthesized for the current studies. The synthesis of A8CDQ (68) and ADQ (69) are 
outlined in Scheme 1 and 2, respectively.  
 
The synthesis of 2-amino-8-chloro-3,4-dihydroquinazoline (A8CDQ; 68) involved 
cyclization of 2-amino-3-chlorobenzylamine (71) with cyanogen bromide as shown in 
Scheme 1 using a procedure known for other benzylamines.328 2-Amino-3-
chlorobenzylamine (71) was obtained by reduction of the nitrile group of 2-amino-3-
chlorobenzonitrile (70) using a procedure reported in the literature for other benzonitrile 
scaffolds involving BH3·THF complex.329 
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Scheme 1.a Synthesis of A8CDQ (68). 
aReagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH 
 
ADQ (69) was synthesized in two steps according to a reported procedure327 starting from 
isatoic anhydride (72) to give 2-aminoquinazolin-4(3H)-one (73) and the carbonyl group of 
the amide was reduced using a BH3·THF complex based on a literature procedure for the 
same compound.327 
 
Scheme 2.a Synthesis of ADQ (69). 
  
aReagents and conditions: a. S-methylpseudothiourea sulfate, Na2CO3, 80% aq. MeCN, 
reflux; b. BH3·THF, reflux; c. HCl/EtOH 
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The structures of 2-amino-8-chloro-3,4-dihydroquinazoline hydrochloride (A8CDQ; 68) 
and 2-amino-3,4-dihydroquinazoline hydrochloride (ADQ; 69) were confirmed by IR, 1H 
NMR and elemental analysis for C, H, N. 
 
At all three OCTs, the presence of the chloro group was important for inhibitory 
activities. At hOCT3 specifically, removing the chloro substituent, resulting in ADQ (69) 
(IC50 = 12.2 µM), led to a ~3-fold decrease in potency as compared to the lead, A6CDQ (65). 
Shifting the chloro group to the 5-position in A5CDQ (67) (IC50 = 0.9 µM), led to a ~4.5-
fold improvement in inhibitory potency as compared to the lead, A6CDQ (65). More 
importantly, we observed a ~13-fold increase in potency for A5CDQ (67) as compared to 
ADQ (68) (IC50 = 12.2 µM) (see Table 3). The position of the chloro group is not as critical 
as its presence, since all the chloro-substituted 2-aminodihydroquinazoline positional 
isomers (A5CDQ (67), A6CDQ (65), A7CDQ (66) and A8CDQ (68)) possessed comparable 
inhibitory potencies at hOCT1-3 (Table 3).   
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Table 3. Inhibitory potencies of chloro-substituted 2-aminodihydroquinazoline analogs at 
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R hOCT1 hOCT2 hOCT3 
 
ADQ      (69)    H 14.5 ± 3.5 46.5 ± 1.1 12.2 ± 3.4 
A5CDQ  (67) 5-Cl   2.3 ± 0.8 13.3 ± 6.9   0.9 ± 0.2 
A6CDQ  (65) 6-Cl   3.0 ± 0.8 16.4 ± 4.7   3.9 ± 2.4 
A7CDQ  (66) 7-Cl   4.8 ± 1.2   9.2 ± 2.8   5.9 ± 3.9 
A8CDQ  (68) 8-Cl   6.1 ± 0.4   26.1 ± 19.7   1.9 ± 0.2 
 
To better understand the role of the chloro substituent, we examined the contribution 
of the lipophilic and electronic properties of the chloro group to the inhibitory potency at 
hOCT1-3. Our preliminary molecular modeling studies suggested that the chloro group on 
the 6-position is involved in hydrophobic interactions at hOCT3 (Figure 36).  
 
NHN
NH2
R
7
6
5
8
Figure 36. Structures of A6CDQ (65) 
(orange) and A6MDQ (74) (cyan) docked 
at the substrate binding region of hOCT3. 
The ligands and amino acid residues are 
displayed as capped sticks and light blue- 
capped sticks, respectively. The dashed 
red lines indicate bidentate ionic salt-
bridge interactions between two N-atoms 
of the guanidinium moiety and an O-atom 
of the carboxylate group of Asp478. The 
Cl and CH3 groups of A6CDQ (65) and 
A6MDQ (74) and the hydrophobic amino 
acid residues – Trp358, Aal362, Tyr365 
and Gln366 are displayed as space-filling 
spheres.  
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We utilized the classical medicinal chemistry approach of Craig’s plot330 to consider 
the 6-methyl analog (A6MDQ; 74). The Craig plot divides substituents into four quadrants 
on the basis of their lipophilic and electronic properties (Figure 37).330 A methyl group 
possesses similar lipophilic (π = 0.71 and 0.56 for chloro and methyl, respectively)331 but 
opposite electronic (σ = 0.23 and -0.17 for chloro and methyl, respectively)331 properties in 
comparison to a chloro group (Figure 37).330 The preliminary molecular modeling and 
docking studies of A6MDQ (74), displayed a high degree of similarity in the poses of 
A6CDQ (65) and A6MDQ (74) at the binding region of hOCT3. Our modeling studies 
predicted that A6MDQ (74) will possess activity at hOCT3.  
Figure 37. The Craig plot consists of substituents divided on the basis of their electronic 
(σ) and lipophilic (π) properties. The chloro and methyl group, encircled in red, possess 
similar lipophilic (π) and opposite electronic (σ) properties. Adapted from Craig.330  
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Hypothesis 2: If the lipophilic (π) property of the chloro substituent of A6CDQ (65) 
contributes to OCT3 inhibition, then the 6-methyl analog (A6MDQ; 74) should be equally 
active or more active compared to A6CDQ (65). 
 
The 6-methyl analog, A6MDQ (74) was synthesized in collaboration with Malaika D. 
Argade, a graduate student in the Dukat laboratory and its synthesis is shown in Scheme 3. 
 
A6MDQ (74) (IC50 = 2.0 µM; Table 4), was observed to possess comparable 
inhibitory potency at hOCT3 as A6CDQ (65) (IC50 = 3.9 µM; Table 3), thereby validating 
our hypothesis and supporting our modeling studies. Therefore, the lipophilic (π) property 
of the substituent at the 6-position appears to be more important than the electronic (σ) 
property. To determine if this holds true for the other positions (5, 7 and 8), we synthesized 
and tested the 5-methyl (A5MDQ; 75), 7-methyl (A7MDQ; 76) and the 8-methyl (A8MDQ; 
77) analogs as outlined in Scheme 4. 
A6MDQ (74) was synthesized in a three-step reaction beginning from oxidation of 
5-methylisatin (78) to give 6-methylisatoic anhydride (79) using freshly-prepared urea-H2O2 
complex332 according to a procedure by Deligeorgiev et al.333 The 6-methylisatoic anhydride 
(79) was converted to 2-amino-6-methylquinazolin-4(3H)-one (80) by reacting it with S-
methylpseudothiourea sulfate using a reported procedure.327 Reduction of the amide group 
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of 80 was carried out using BH3·THF complex as per a literature procedure for compounds 
with quinazoline scaffolds but different substituents334 to give A6MDQ (74).  
 
Scheme 3.a Synthesis of A6MDQ (74). 
  
aReagents and conditions: a. urea-H2O2 complex, HCOOH, H2SO4, sonication; b. S-
methylpsuedothiourea sulfate, Na2CO3, 80% aq. MeCN, reflux; c. BH3·THF, reflux; d. 
HCl/EtOH 
 
The synthesis of 2-amino-5-methyl-3,4-dihydroquinazoline (A5MDQ; 75), 2-amino-7-
methyl-3,4-dihydroquinazoline (A7MDQ; 76) and 2-amino-8-methyl-3,4-
dihydroquinazoline (A8MDQ; 77) involved cyclization of the appropriately substituted 2-
aminobenzylamines (84-86) with cyanogen bromide as shown in Scheme 4 using a 
procedure known for other benzylamines.328 The 2-aminobenzylamine analogs (84-86) were 
obtained by reduction of a nitrile group on appropriately substituted 2-aminobenzonitriles 
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(81-83) using a procedure reported in literature for other benzonitrile scaffolds involving 
BH3·THF complex.329 
Scheme 4.a Synthesis of A5MDQ (75), A7MDQ (76) and A8MDQ (77). 
 
aReagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH 
 
The structures of 2-amino-6-methyl-3,4-dihydroquinazoline hydrochloride (A6MDQ; 74), 
2-amino-5-methyl-3,4-dihydroquinazoline (A5MDQ; 75), 2-amino-7-methyl-3,4-
dihydroquinazoline hydrochloride (A7MDQ; 76) and 2-amino-8-methyl-3,4-
dihydroquinazoline hydrochloride (A8MDQ; 77) were confirmed by IR, 1H NMR, and 
elemental analysis for C, H, N. 
 
Following the synthesis and characterization of the compounds, we tested A5MDQ 
(75), A7MDQ (76) and A8MDQ (77) at hOCT1-3. At the 5- and 7-position too, the lipophilic 
(π) property of the substituent seems to be more important than the electronic (σ) property, 
since both A5MDQ (75) and A7MDQ (76) possess comparable inhibitory potencies at 
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hOCT3 compared to their chloro-substituted counterpart, A5CDQ (67) and A7CDQ (66) 
(Table 4 and 5). Furthermore, in both series, potency decreases in the same rank order: 5 > 
6 > 7 > H. 
Table 4. Inhibitory potencies of methyl-substituted 2-aminodihydroquinazoline analogs at 
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R hOCT1 hOCT2 hOCT3 
 
ADQ      (69) H 14.5 ± 3.5  46.5 ± 1.2 12.2 ± 3.4 
A5MDQ (75) 5-CH3   4.6 ± 0.6     26.4 ± 0.7   0.5 ± 0.0 
A6MDQ (74) 6-CH3   8.2 ± 2.2  12.1 ± 0.3   2.0 ± 0.4 
A7MDQ (76) 7-CH3   6.3 ± 1.3    12.1 ± 3.2    8.4 ± 4.3 
A8MDQ (77) 8-CH3 NDa 
aNote added in proof (see Appendix A) 
Table 5. Comparison of inhibitory potencies of chloro- and methyl-substituted 2-
aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of 
[3H]MPP+ (53). 
   IC50 ± SEM (µM)   
 Ligand R hOCT3 Ligand R hOCT3 
 
ADQ      (69) H 12.2 ± 3.4 ADQ     (69) H 12.2 ± 3.4 
A5MDQ (75) 5-CH3   0.5 ± 0.0   A5CDQ (67) 5-Cl   0.9 ± 0.2  
A6MDQ (74)  6-CH3   2.0 ± 0.4 A6CDQ (65) 6-Cl   3.9 ± 2.4 
A7MDQ (76) 7-CH3   8.4 ± 4.3   A7CDQ (66) 7-Cl   5.9 ± 3.9 
A8MDQ (77) 8-CH3 NDa A8CDQ (68) 8-Cl 1.9 ± 0.2 
aNote added in proof (see Appendix A) 
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2. Probing the 6-position of 2-aminodihydroquinazolines: 
In order to further probe the 6-position with respect to steric properties and bulk, we 
synthesized a series of halo-substituted 2-aminodihydroquinazoline analogs (i.e. 6-F, 6-Br 
and 6-I) and tested them against hOCT1-3 for their activity and selectivity. The synthesis of 
A6FDQ (87) is shown in Scheme 5 and that for A6BrDQ (88) and A6IDQ (89) are shown 
in Scheme 6. 
For A6FDQ (87), the corresponding 6-fluoroisatoic anhydride (91) was synthesized 
by oxidation of 5-fluoroisatin (90) using a freshly prepared urea-H2O2 complex332 in the 
presence of sulphuric acid as a catalyst using a procedure reported in literature for the same 
compound.333 The 6-fluoroisatoic anhydride (91) was converted to 2-amino-6-
fluoroquinazolin-4(3H)-one (92) whose amide group was reduced to give A6FDQ (87). 
Scheme 5.a Synthesis of A6FDQ (87). 
 
aReagents and conditions: a. urea-H2O2 complex, HCOOH, H2SO4, sonication; b. S-
methylpseudothiourea sulfate, Na2CO3, 80% aq. MeCN, reflux; c. BH3·THF, reflux; d. 
HCl/EtOH 
a b c,d
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Similar to the methyl substituted series the synthesis of 2-amino-6-bromo-3,4-
dihydroquinazoline (A6BrDQ; 88) and 2-amino-6-iodo-3,4-dihydroquinazoline (A6IDQ; 
89) was carried out by cyclization of 2-amino-5-bromobenzylamine (95) and 2-amino-5-
iodobenzylamine (96), respectively, with cyanogen bromide as shown in Scheme 6 using a 
procedure known for other benzylamines.328 The reduction of the nitrile group on 2-amino-
5-bromobenzonitrile (93) and 2-amino-5-iodobenzonitrile (94) was conducted following a 
procedure reported in the literature for other benzonitrile scaffolds involving BH3·THF 
complex.329  
 
Scheme 6.a Synthesis of A6BrDQ (88) and A6IDQ (89) 
 
aReagents and conditions: a. BH3·THF, reflux; b. CNBr, toluene, reflux; c. HCl/EtOH 
 
The structures of 2-amino-6-fluoro-3,4-dihydroquinazoline hydrochloride (A6FDQ; 
87) and 2-amino-6-bromo-3,4-dihydroquinazoline hydrobromide (A6BrDQ; 88) were 
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confirmed by IR, 1H NMR and elemental analysis for C, H, N while that of 2-amino-6-iodo-
3,4-dihydroquinazoline (A6IDQ; 89) was confirmed by IR, 1H NMR and MS.  
 
With respect to both volume and lipophilicity (π), the values increase from fluoro to 
iodo, while for the electronic (σ) property the values are comparable between the halogens 
(Table 6).  When tested at hOCT1-3, the 6-fluoro analog (A6FDQ (87); IC50 = 0.5 µM) was 
at least 3-folds more potent than the lead, A6CDQ (65) (Table 7). This contradicts our earlier 
finding, that the lipophilicity (π) of the substituent at the 6-position is more important than 
the electronic (σ) properties as the fluoro group is less lipophilic compared to the chloro 
group (Table 6). However, at this point we do not know if our compounds act as substrates 
for hOCTs. Hence, there might exists differences in SAR for substrates and inhibitors which 
might explain the comparable inhibitor potency of A6FDQ (87) and A6CDQ (65) (Table 7). 
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Table 6. Values for volume,a electronic (σ) and lipophilic (π) properties331 of halogen 
substituents at the 6-position of 2-aminodihydroquinazoline analogs. 
 
 
 
 
 
aCalculated for the entire molecule using SYBYL X-2.1 (Tripos International) 
 
Table 7. Inhibitory potencies of unsubstituted and 6-halo-substituted 2-
aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of 
[3H]MPP+ (53). 
   IC50 ± SEM (µM) 
Ligand R hOCT1 hOCT2 hOCT3 
ADQ       (69)     H 14.5 ± 3.5 46.5 ± 1.1 12.2 ± 3.4 
A6CDQ  (65) 6-Cl   3.0 ± 0.8 16.4 ± 4.7   3.9 ± 2.4 
A6FDQ   (87) 6-F   1.3 ± 0.1 11.9 ± 0.2     0.5 ± 0.0 
A6BrDQ (88) 6-Br NDa 
A6IDQ    (89) 6-I NDa 
aNote added in proof (see Appendix A) 
Volume (Å) 480.3 495.9 530.3 529.0 544.0 
σ 0.00 0.06 0.23 0.23 0.18 
π 0.00 0.14 0.71 0.86 1.12 
F Cl Br I 
A6FDQ (87) A6CDQ (65) A6IDQ (89) A6BrDQ (88) ADQ (69) 
H 
NHN
NH2
R
7
6
5
8
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3. Role of the methylene bridge: 
Our next goal was to determine if the entire quinazoline ring contributes to OCT3 inhibitory 
action. 
 
Hypothesis 3: If the intact quinazoline ring contributes to OCT3 inhibition, ring-opened 
analogs should be less active or inactive compared to their quinazoline counterparts. 
 
The ring-opened analogs lack the methylene bridge linker between the nitrogen atom and 
the phenyl ring. Opening the ring for both A5CDQ (67) and A7CDQ (66) results in the same 
compound, 3-CPG (97) which exists as multiple rotamers due to the rotatable bond between 
the anilinic nitrogen atom and the phenyl ring (Figure 38). The ring-opened analogs of the 
6-chloro (A6CDQ; 65), des-Cl (ADQ; 69) and 6-methyl analogs (A6MDQ; 74) are the 
corresponding phenylguanidines analogs 4-CPG (98), PG (99) and 4-MePG (100), 
respectively (Figure 38). To further explore the 4-position of the phenylguanidines in terms 
of steric properties and bulk, we synthesized and tested the 4-tert-butyl (4-t-BuPG; 101), the 
4-benzyl (4-BnPG; 102), and the 4-halo-substituted phenylguanidine analogs, i.e., 4-FPG 
(103), 4-BrPG (104), 4-IPG (105). The guanidines 97,34 98,34 99,34 100336 and 102336 were 
previously synthesized in our laboratory and were available for the current studies. The 
guanidine 101336 was resynthesized and 103-105 were synthesized for the current studies as 
outlined in Scheme 7. 
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Figure 38. 2-Aminodihydroquinazoline analogs (67, 66, 65, 69 and 74) and their ring opened 
phenylguanidine counterparts (97, 98, 99 and 100) with their inhibitory potencies (IC50) in 
micromolar (µM).   
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Scheme 7.a Synthesis of phenylguanidines 101-105.  
 
aReagents and conditions: a. HCl/Et2O, Et2O; b. NH2CN, EtOH; c. NH4NO3, H2O, EtOH 
 
4-tert-Butylphenylguanidine (4-t-BuPG; 101), 4-fluorophenylguanidine (4-FPG; 
103), 4-bromophenylguanidine (4-BrPG; 104) and 4-iodophenylguanidine (4-IPG; 105) 
were synthesized by reacting cyanogen bromide with the hydrochloride salt of the 
corresponding anilines (110-113) according to a reported procedure336 as shown in Scheme 
7 and then converted to the nitrate salts using ammonium nitrate in excess. The structures of 
4-fluorophenylguanidine nitrate (4-FPG; 103), 4-bromophenylguanidine nitrate (4-BrPG; 
104) and 4-iodophenylguanidine nitrate (4-IPG; 105) were confirmed using IR, 1H NMR 
and elemental analysis for C, H, N. Because 4-tert-butylphenylguanidine nitrate (4-t-BuPG; 
101) is a known compound and was resynthesized, the structure was confirmed using IR, 1H 
NMR and melting point (mp 181-183 °C; lit.34 mp 183-185 °C).  
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Similar to 2-aminodihydroquinazoline analogs, the ring-opened phenylguanidine 
analogs also inhibited the three subtypes of hOCTs (Table 8). The unsubstituted 
phenylguanidine (PG; 99) (IC50 = 99.8 µM) was a very weak inhibitor at hOCT1-3 with a 
~35-fold lower potency at hOCT3 compared to 4-CPG (98) (IC50 = 2.8 µM; Table 8). Also, 
4-BnPG (102) (IC50 = 452.5 µM; Table 8) displayed a ~162-fold decrease in potency at 
hOCT3 when compared to 4-CPG (98) (Table 8). The 4-tert-butyl substituted 
phenylguanidine (4-t-BuPG; 101), in contrast, was one of the most potent inhibitors of the 
phenylguanidine series (IC50 = 2.2 µM; Table 8). Hence, there appears to be a limitation in 
the amount of bulk tolerance at the binding region of hOCT1-3. At the 4-position of the 
phenylguanidines too, the lipophilic (π) properties of the substituents seem to be more 
important than their electronic (σ) properties since the 4-CPG (98) (IC50 = 2.8 µM), 4-MePG 
(100) (IC50 = 4.6 µM) and the 4-t-BuPG (101) (IC50 = 2.2 µM) all possess comparable 
potencies at hOCT3 (Table 8). 
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Table 8. Inhibitory potencies of ring-opened phenylguanidine analogs at hOCT1-3 
determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R hOCT1 hOCT2 hOCT3 
 PG          (99) H     41.1 ± 14.4   89.0 ± 12.2   99.8 ± 2.8 
3-CPG    (97) 3-Cl     13.7 ± 0.8   60.5 ± 4.1     7.6 ± 0.7 
4-CPG    (98) 4-Cl     10.0 ± 0.6   18.9 ± 0.1     2.8 ± 0.7 
4-MePG  (100) 4-CH3     10.0 ± 0.2     9.3 ± 4.8     4.6 ± 1.1 
4-t-BuPG (101) 4-C(CH3)3       0.9 ± 0.2     6.3 ± 3.4     2.2 ± 0.2 
4-BnPG  (102) 4-CH2C6H5   761.4 ± 254.7   96.2 ± 8.0 452.5 ± 87.9 
4-FPG     (103) 4-F  
NDa   4-BrPG   (104) 4-Br 
4-IPG      (105) 4-I 
 
aNote added in proof (see Appendix A) 
 
4. Species differences: 
 
Since our rodent model of depression utilized mice, and because OCT data were 
obtained using hOCTs, we determined the activity of the 2-aminodihydroquinazoline and 
ring-opened phenylguanidine analogs at mOCT1-3. The 2-aminodihydroquinazoline 
analogs possessed inhibitory potencies 17.5- to 1.5-fold lower at mOCT1-3 as compared to 
their human counterparts (Table 9). A similar trend of differences in potency at mOCT3 vs. 
hOCT3 for ligands such as diazepam, ketamine (33) and FLX (3) has been reported in the 
literature.337 The range of inhibitory potencies of the 2-aminodihydroquinazoline analogs at 
mOCT3 was smaller compared to at hOCT3. For instance, the des-Cl analog, ADQ (69) 
NH2N
NH2
R
4
3
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possessed an inhibitory potency that was 1.4-fold lower compared to that of the 5-chloro 
analog, A5CDQ (67) (Table 9). In contrast, the difference in inhibitory potencies at hOCT3 
between ADQ (69) and A5CDQ (67) was ~13-fold.  
 
Table 9. Inhibitory potencies of all the substituted 2-aminodihydroquinazoline analogs at 
mOCT1-3 determined by measuring uptake of [3H]MPP+ (53).  
 
   IC50 ± SEM (µM) 
 Ligand R mOCT1 mOCT2 mOCT3 
 ADQ      (69) H >100  31.8 ± 1.3 18.8 ± 2.3 
A5CDQ (67)  5-Cl 45.2 ± 9.4  16.1 ± 5.5 13.9 ± 1.4 
A6CDQ (65)  6-Cl 38.2 ± 9.3    6.2 ± 0.5 30.3 ± 13.0 
A7CDQ (66)  7-Cl 40.7 ± 13.7  13.0 ± 0.8 15.9 ± 3.1 
A8CDQ (68)  8-Cl 22.0 ± 12.1  18.1 ± 8.5 23.5 ± 2.1 
A5MDQ (75) 5-CH3       ND >100 >100 
A6MDQ (74) 6-CH3   >100  15.0 ± 0.5 12.7 ± 2.4 
A7MDQ (76) 7-CH3  27.3 ± 14.7      7.7 ± 3.3  27.3 ± 14.7 
A8MDQ (77) 8-CH3 ND 
A6FDQ  (87)  6-F ND 19.3 ± 4.3 
A6BrDQ(88)  6-Br ND 
 
 
In the phenylguandinde series, all analogs except 4-t-BuPG (101) were weak 
inhibitors of mOCT3 with inhibitory potencies above 100 µM (Table 10). Interestingly, the 
unsubstituted (PG; 99), chloro-substituted (3-CPG (97) and 4-CPG (98)) as well as the 
methyl-substituted (4-MePG; 100) analogs displayed “stimulatory” activity at mOCT1. 
Additionally, the unsubtituted analog (PG; 99) also displayed a “stimulatory” activity at 
NHN
NH2
R
7
6
5
8
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mOCT2. This stimulatory activity indicates that presence of analogs increases the 
accumulation of [3H]MPP+ (53) in the cells. Stabilization of the transporters (mOCT1 and 
mOCT2) in an open configuration by the analogs might explain the increased accumulation 
of [3H]MPP+ (53) and hence the stimulation observed.  
 
Table 10. Inhibitory potencies of the ring-opened phenylguanidine analogs at mOCT1-3 
determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R mOCT1 mOCT2 mOCT3 
 PG          (99) H    Stimulation Stimulation >100 
3-CPG    (97) 3-Cl    Stimulation >100 >100 
4-CPG    (98) 4-Cl    Stimulation 14.2 ± 0.4 >100 
4-MePG  (100) 4-CH3    Stimulation 22.1 ± 2.4 >100 
4-t-BuPG (101) 4-C(CH3)3   18.3 ± 1.0   5.0 ± 1.0   46.0 ± 2.1 
4-BnPG  (102) 4-CH2C6H5   82.0 ± 0.9 92.5 ± 4.3 491.8 ± 127.6 
4-FPG     (103) 4-F  
ND   4-BrPG   (104) 4-Br 
4-IPG      (105) 4-I 
 
 
GOAL 5: To identify binding sites and modes of interactions of 2-
aminodihydroquinazoline and phenylguanidine analogs at hOCT3 and mOCT3 using 
molecular modeling. 
 
In order to study the interactions between OCT3 and the 2-aminodihydroquinazoline 
and phenyguanidine analogs we conducted molecular modeling studies. The crystal 
NH2N
NH2
R
4
3
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structures of OCTs have not yet been solved and so far no 3-dimensional homology models 
have been reported for hOCT3. Hence, we generated the first 3-dimensional homology 
models of OCT3 based on a suitable template. 
Homology models of rOCT1,295 rOCT2,338 rbOCT2,339 and hOCT2340 have, 
however, been reported in the literature. In 2005, Popp et al.295 and Zhang et al.339 generated 
homology models of rOCT1 and rbOCT2 based on the crystal structures of lactose permease 
transporter (LacY, PDB ID: 1PV6)292 and the glycerol-3-phosphate transporter (GlpT, PDB 
ID: 1PW4),341 respectively. Popp et al.295 focused on amino acids belonging to TMD4 and 
performed mutagenesis studies to determine their role in substrate selectivity, affinity and/or 
turnover rates for rOCT1 for TEA+ (54) and MPP+ (53). The chosen amino acid residues 
(from position 219-229) of TMD4 are conserved within the three subtypes of OCT1-3 but 
are different from those in the closely related family of OATs.295 From their findings, the 
authors successfully identified three amino acid residues from TMD4 – Trp218, Tyr222 and 
Thr226 – that affected the uptake of MPP+ (53) and TEA+ (54) significantly.295 This coupled 
with earlier findings implicating three residues from TMD10 – Ala443, Leu447 and 
Gln448294 – and one key residue from TMD11 Asp475293 gives rise to a fairly large binding 
region consisting of individual, overlapping binding sites.295 
 The primary focus of the mutagenesis and homology modeling studies of rbOCT2 
was to identify amino acid residues that confer selectivity for rbOCT1 over rbOCT2.339 The 
amino acids chosen for this mutagenesis study were Gln353, Arg403 and Glu447.339 Their 
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studies concluded that the Glu447 residue is a “key contributor to binding properties of 
rbOCT2”.339 This is in agreement with an earlier study by Gorboulev et al.294 identifying 
Gln448 in rOCT2 as the residue responsible for the difference in the affinity of 
corticosterone for rOCT1 vs. rOCT2. Importantly, the study by Zhang et al.339 involving 
rbOCT2 confirmed the amino acid residues identified by Popp et al.295 and others line and 
face the central cavity of the transporter.  
 Continuing on their previous work, Schmitt et al.338 modeled rOCT2 in inward open 
and outward open conformations based on LacY (PDB ID: 1 PV6)292 to study the function 
of rOCT2 using a charge-to-substrate ratio. This ratio gives an indication of the number of 
molecules transported in one cycle.338 A ratio of one implies that a single molecule is 
transported while a ratio of greater than one indicates co-transportation of more than one 
molecule.338 Their modeling studies suggested that the central cavity in rOCT2 was lined 
with negatively charged residues in the outward open conformation.338 On the other hand, 
in the inward open conformation, the central cavity of the transporter possessed a neutral 
charge.338 This, coupled with their extensive charge-to-substrate ratio studies, indicated that 
“nonsubstrate inorganic cations are translocated nonspecifically with organic cation 
substrates”.338 The homology models of rOCT2 generated as part of the above study very 
closely resembled the homology models of rOCT1295 because of the very high homology 
between the two and use of the same template.338        
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In 2015, Li et al.340 investigated the role of a number of amino acid residues in rOCT3 
and hOCT3 and generated a homology model of hOCT2 based on GlpT (PDB ID: 1PW4)341 
as the template. They developed rOCT3 and hOCT3 mutants wherein nonconserved residues 
in the substrate binding pocket were mutated to resemble the binding pocket in rOCT1 to 
study the role of these residues in substrate selectivity.340 The nonconserved residues studied 
were Leu161, Phe445 and Glu445 in rOCT3 and Leu166, Phe450 and Glu451 in hOCT3.340 
The role of the conserved Asp residue, previously established for rOCT1295 and rOCT2,338 
was also confirmed to be essential for hOCT3 since mutation of the Asp478 residue resulted 
in abolishing transport of [3H]MPP+ (53).340    
 
1. Template: 
In the early incipient stages of our molecular modeling studies, we generated 
homology models of hOCT3 based on the crystal structure of the Escherichia coli lactose 
permease transporter (LacY, PDB ID: 1PV6, 3.5-Å resolution)292 as our template. At that 
point, the LacY was the most suitable template available according to the basic local 
alignment search tool (BLAST)342 and had been previously utilized to generate homology 
models of rOCT1295 and rOCT2.338 The LacY was co-crystallized with a galactoside, β-D-
galactopyranosyl-1-thio-ß-D-galactopyranoside (TDG), in an inward-facing 
conformation.292 The LacY belongs to the oligosaccharide: H+ symporter family of the MFS 
transporters and consists of 12 TMDs with intracellular N- and C-termini.292 The LacY 
  90 
utilizes energy generated from downhill H+ translocation to drive the uphill transport of the 
substrate (galactoside).292 In early 2013, the crystal structure of an eukaryotic inorganic 
phosphate transporter (PiPT, PDB ID: 4J05, 2.9-Å resolution) was reported.343 PiPT belongs 
to the phosphate: H+ symporter family of MFS transporters and has been suggested to serve 
as a suitable template for transporters belonging to the SLC22 family.343 Hence, we revised 
our modeling studies by generating one hundred 3-dimensional homology models of OCT3 
based on PiPT. The crystal structure of PiPT was solved in complex with its substrate, 
inorganic phosphate, by Pedersen at al.343 at a resolution of 2.9 Å in an inward occluded 
conformation. Similar to the template, PiPT, OCT3 also consists of 12 TMDs with 
intracellular N- and C-termini.343 The 12 TMDs of PiPT are divided into two bundles of 6 
helices each – the N- and C-domain.343 These domains possess different functions making 
the structure of PiPT asymmetric.343 The N-domain of PiPT is primarily involved in 
translocation of H+, while the C-domain is involved in substrate recognition.343 Since the in 
vitro inhibition data was obtained using hOCT3 and the behavioral assays were conducted 
in mice, we built homology models of both hOCT3 and mOCT3 and subsequently conducted 
docking studies on both, hOCT3 and mOCT3. HINT analysis326 was conducted on chosen 
hOCT3-ligand complexes. 
 
 
 
  91 
2. Alignment and generation of models: 
The sequence of the template, PiPT was obtained as a FASTA file from the Protein 
Databank (PDB ID: 4J05),343 while that of hOCT3 and mOCT3 were obtained from the 
Universal Protein Resource (UniProt) database (UniProt accession code: O75751 and 
Q9WTW5), respectively. The two sequences, template and protein of interest (hOCT3 or 
mOCT3), were aligned using Clustal W 2.0344 followed by manual adjustments to the 
sequence (Figure 39). The amino acid residues belonging to the extracellular loop between 
TMDs 1 and 2 and that between 6 and 7, were truncated for several reasons – lack of 
appropriate corresponding residues in the crystal structure of PiPT being the major reason. 
Another reason was the long, floppy, flexible nature of the extracellular loop between TMDs 
6 and 7. Moreover, the loop is far away and seemingly uninvolved in the binding region of 
hOCT3.  
The binding site of the substrate, phosphate, in PiPT is composed of residues from 
TMDs 4, 5, 7, 10 and 11.343 They are Tyr150 in TMD4, Gln177 and Phe174 in TMD5, 
Asp324, Tyr320 and Tyr328 in TMD7, Asn431 in TMD10 and Lys459 in TMD11.343 Of 
these residues, the two tyrosine residues in TMD7, Tyr320 and Tyr328, are conserved in 
OCT1.343 A positively-charged lysine residue, Lys459, in the PiPT influences the affinity of 
the transporter for phosphate.343 OCT3 possesses a negatively charged aspartate residue, 
Asp474, instead of the positively charged lysine residue in PiPT343 (Figure 39). Between the 
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two orthologs – human and mouse OCT3 – all the residues composed of the binding region 
are conserved (Figure 39).        
  
  
Figure 39. Sequence alignments of the template (PiPT) and the proteins of interest (hOCT3 
and mOCT3). The asterisks (*) indicate residues that are fully conserved between the 
sequences (template PiPT and hOCT3 or mOCT3). The colon (:) and period (.) indicate 
residues that are highly conserved and weakly conserved between the sequences, 
respectively. Lack of any of these symbols indicate differences in amino acid residues. The 
amino acid residues highlighted in the red boxes constitute the substrate binding region of 
OCTs.       
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3. Validation: 
To support our modeling studies, we docked the substrate, MPP+ (53), to one hundred 
homology models for each hOCT3 and mOCT3 and studied the observed interactions. We 
utilized the aspartate residue (Asp478 in hOCT3 and Asp473 in mOCT3) to define a 12 Å 
spherical binding pocket in the docking software GOLD suite 5.2.345  
In both hOCT3 and mOCT3, the protonated amine of MPP+ (53) was observed to be 
involved in an ionic salt-bridge interaction with the carboxylate oxygen atom of the key Asp 
residue (Asp478 in hOCT3 and Asp473 in mOCT3) (Figure 40). The pyrdinium ring of 
MPP+ (53) was seen to be involved in a π-π stacking interaction with a Trp residue (Trp223 
in hOCT3 and Trp218 in mOCT3) (Figure 40). Moreover, the phenyl ring of MPP+ (53) was 
involved in a cation-π interaction with the protonated guanidinium moiety of Arg20 (hOCT3 
and mOCT3) (Figure 40).    
Figure 40. Structure of MPP+ (53) 
(cyan in hOCT3 and yellow in 
mOCT3) docked in the substrate 
binding region of hOCT3 and 
mOCT3. The ligands and amino 
acid residues are displayed as 
capped sticks. The dashed red lines 
indicate ionic salt-bridge 
interactions between the protonated 
N-atom of MPP+ (53) and the O-
atom of the carboxylate group of 
Asp478 and Asp473 in hOCT3 and 
mOCT3, respectively. The labels in 
the parenthesis correspond to 
mOCT3. 
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PROCHECK analysis of the selected hOCT3 and mOCT3 models generated 
Ramachandran plots. In the Ramachandran plots,346 amino acids are distributed in four 
regions -  most favored (red), additional allowed region (yellow), generously allowed region 
(light yellow) and disallowed region (white). For hOCT3, 87.9% of amino acids were in the 
most favored region, 9.1% in the additional allowed region and 3.0% in the disallowed 
region (Figure 41). Val36 is the only amino acid residue in the disallowed region and is 
located far away from the binding region of hOCT3 (Figure 41). Similar to hOCT3, for 
mOCT3, 87.9% of amino acid residues were located in the most favored region and 12.1% 
in the additional allowed region (Figure 42). However, in the case of mOCT3, no residues 
were found in the disallowed region (Figure 42).   
 
Figure 41. Ramachandran plot of 
hOCT3. Phi and psi indicate 
backbone conformation angles of 
amino acid residues. Val36 is the 
only amino acid in the disallowed 
region and is located far from the 
binding region of hOCT3. 
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4. Docking studies and HINT analysis:   
To study the interactions of the 2-aminodihydroquinazoline and phenylguanidine 
analogs at the human and mouse orthologs of OCT3, we performed docking studies. The 
interactions observed were quantified using HINT analysis326 on chosen transporter-ligand 
complexes.  
 
a. Docking at the substrate binding region of hOCT3: 
Kinetic studies performed on the lead compound, A6CDQ (65), to determine the 
mechanism of inhibition, revealed a competitive mechanism. This indicates that A6CDQ 
(65) is exerting its inhibitory effect by interacting at the substrate binding region.  The role 
Figure 42. Ramachandran plot of 
mOCT3. Phi and psi indicate 
backbone conformation angles of 
amino acid residues. No amino 
acid residues were found in the 
disallowed region of mOCT3. 
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of the key Asp residue (Asp478339 in hOCT3 and Asp475293 in rOCT1) has been established 
by mutagenesis studies. Hence, we docked the 2-aminodihydroquinazoline analogs and the 
ring-opened phenylguanidine analogs, at the substrate binding region using the Asp residue 
to define a spherical region with a radius of 12 Å.    
All of the 2-aminodihydroquinazoline analogs docked at hOCT3 in a highly 
overlapping manner (Figure 43). Two of the N-atoms of the guanidinium moiety of the 2-
aminodihydroquinazoline analogs were found to be involved in a bidentate ionic salt-bridge 
interaction with one of the O-atoms of the carboxylate group of Asp478 (Figure 43). Besides 
this key interaction, all of the 2-aminodihydroquinazoline analogs were also involved in 
cation-π interactions with the pyrrole ring of Trp223 and the phenyl ring of Phe165 (Figure 
43). The phenyl ring of the 2-aminodihydroquinazoline analogs were additionally involved 
in a T-shaped π-π stacking interaction with the phenyl ring of Trp358 (Figure 43).       
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Role of the chloro group:  
In order to identify the interactions involving the chloro group at hOCT3, we docked 
and studied in greater detail the chloro substituted 2-aminodihydroquinazoline analogs 
(A5CDQ (67), A6CDQ (65), A7CDQ (66), A8CDQ (68)) and the des-Cl analog (ADQ) (69). 
The chloro group of the lead compound, A6CDQ (65), was observed to be involved in 
Figure 43. Structures of all the 2-aminodihydroquinazoline analogs – ADQ (yellow) (69), 
A5CDQ (red) (67), A6CDQ (orange) (65), A7CDQ (magenta) (66), A8CDQ (green) (68), 
A5MDQ (salmon pink) (75), A6MDQ (cyan) (74), A7MDQ (purple) (76), A8MDQ (teal) 
(77), A6FDQ (wheat) (87), A6BrDQ (brown) (88) and A6IDQ (fluorescent green) (89) - 
docked at the substrate binding region of hOCT3. The ligands and amino acid residues are 
displayed as capped sticks and light blue-capped sticks, respectively. The dashed red lines 
indicate a bidentate ionic salt-bridge interaction between the two N-atoms of the guanidinium 
moiety of the ligands and an O-atom of the carboxylate group of Asp478.  
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hydrophobic interactions with Trp358, Ala362, Tyr365 and Gln366 at the substrate binding 
region of hOCT3 (Figure 44). Similarly, if the 6-methyl analog (A6MDQ; 74), as discussed 
in Goal 4 (Figure 36), interacts in a similar manner as A6CDQ (65), it might utilize similar 
hydrophobic interactions as the chloro substitutent, i.e., Trp358, Ala362, Tyr 365 and 
Gln366. The in vitro biological studies showed that A6MDQ (74) (IC50 = 2.0 µM; Table 3) 
possessed a comparable inhibitory potency to A6CDQ (65) (IC50 = 3.9 µM; Table 3) and are 
in agreement with our prediction from the preliminary molecular modeling studies. These 
findings support our model.  
 
 
 
Figure 44. Structures of ADQ 
(yellow) (69) and A6CDQ 
(orange) (65) docked at the 
substrate binding region of 
hOCT3. The chloro group (green) 
of A6CDQ (65) and the 
hydrophobic amino acid residues 
(Trp358, Ala362, Tyr365 and 
Gln366) are displayed as space 
filling spheres. The ligands and 
amino acid residues are displayed 
as capped sticks and light blue- 
capped sticks, respectively. The 
dashed red lines indicate a 
bidentate ionic salt-bridge 
interaction between the two N-
atoms of the guanidinium moiety 
of the ligands and an O-atom of 
the carboxylate group of Asp478. 
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Probing the 6-position of 2-aminodihydroquinazolines: 
The 6-halo-substituted 2-aminodihydroquinazoline analogs (A6FDQ (87), A6CDQ 
(65), A6BrDQ (88) and A6IDQ (89)) possess substituents with increasing steric and 
lipophilic (π) properties (Table 6). Their electronic (σ) properties, however, are comparable 
(Table 6). Our modeling studies suggested that the substrate binding region of hOCT3 was 
capable of accommodating all four 6-halo-substituted 2-aminodihydroquinazoline analogs 
including A6IDQ (89), the analog with the largest substituent (Figure 45 and 46). Similar to 
other 2-aminodihydroquinazoline analogs, the guanidinium moiety of the 6-halo-substituted 
analogs were also involved in a bidentate ionic salt-bridge interaction with Asp478 (Figure 
45).  
 
Figure 45. Structures of 
A6FDQ (87) (wheat), 
A6CDQ (65) (orange), 
A6BrDQ (88) (brown) and 
A6IDQ (89) (fluorescent 
green) docked at the substrate 
binding region of hOCT3. 
The ligands and amino acid 
residues are displayed as 
capped sticks and light blue- 
capped sticks, respectively. 
The dashed red lines indicate 
a bidentate ionic salt-bridge 
interaction between the two 
N-atoms of the guanidnium 
moiety of the ligands and an 
O-atom of the carboxylate 
group of Asp478. 
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Role of the methylene bridge: 
Docking studies of the ring-opened phenylguanidine analogs revealed two possible 
modes of interaction – I and II. The primary difference between the two modes was the 
orientation of 4-BnPG (102). In mode I, 4-BnPG (102) is oriented in a manner similar to all 
the other phenylguanidine analogs and is involved in an ionic salt-bridge interaction with 
Figure 46. Structures of A6FDQ (87) (wheat), A6CDQ (65) (orange), A6BrDQ (88) 
(brown) and A6IDQ (89) (fluorescent green) docked at the substrate binding region of 
hOCT3. The halogen substituents (6-F, 6-Cl, 6-Br and 6-I) and the hydrophobic amino acid 
residues (Trp358, Ala362, Tyr365 and Gln366) are displayed as space filling spheres. The 
ligands and amino acid residues are displayed as capped sticks and light blue-capped sticks, 
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between 
the two N-atoms of the guanidnium moiety of the ligands and an O-atom of the carboxylate 
group of Asp478. 
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Asp478 (Figure 47). In contrast, in mode II, 4-BnPG (102) was flipped over so that the 
guanidinium moiety was now pointed towards Glu451 instead of Asp478 (Figure 48). In 
both modes I and II, the rest of the ring-opened phenylguanidine analogs docked in a similar 
and overlapping manner and were engaged in a bidentate ionic salt-bridge interaction with 
Asp478 (Figure 47 and 48). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Interaction mode I of the ring-opened phenylguanidine analogs at hOCT3. 
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100) 
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG 
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3. 
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks, 
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between 
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate 
group of Asp478. The guanidinium moiety of 4-BnPG (102), similar to other 
phenylguanidine analogs, was pointing towards Asp478. 
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To determine the probability of the two interaction modes – I or II – we performed 
HINT analysis326 and studied in detail the atom-based interactions between the ligands and 
the transporter for both modes (see Table 11).   
 
Figure 48. Interaction mode II of the ring-opened phenylguanidine analogs at hOCT3. 
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100) 
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG 
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3. 
The ligands and amino acid residues are displayed as capped sticks and pale cyan-capped 
sticks, respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction 
between the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the 
carboxylate group of Asp478. The 4-BnPG (102) is flipped over with its guanidinium 
moiety pointing towards Glu451 located on the other end of the binding region.   
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Table 11. HINT scores for both the interaction modes (I and II) of the phenylguanidine 
analogs. 
   Mode I Mode II 
 Ligand R Hint 
scor
e 
Amino acids 
interacting with 
substituent 
Hint 
score 
Amino acids 
interacting with 
substituent 
    PG      (99)     H 96 - 549 - 
3-CPG   (97) 3-Cl 426 Arg19, Arg20, 
Trp223 
338 Arg20, Gln247, 
Trp358 
4-CPG   (98) 4-Cl 250 Arg20, Trp223 547 Trp358, Ser361, 
Ala362, Tyr365 
4-MePG (100) 4-Me 144 Trp223, Phe250 356 Ala362, Tyr365 
4-t-BuPG (101) 4-tBu 143 Phe250, Tyr365, 
Val453, Trp358 
-467 Val453, Ser361, 
Ala362, Tyr365 
4-BnPG (102) 4-Bn -7 Val453 -484 Ala362, Tyr365 
 
 
For interaction mode I, the HINT score was positive for all the phenylguanidine 
analogs except for the 4-BnPG (102) analog (Table 11). When we looked closely at the atom-
based contributions to the total HINT score, we discovered that the benzyl group at the 4-
position of 4-BnPG (102) was clashing with the Glu451 residue in the substrate binding 
region of hOCT3 (Figure 49). This clash is potentially responsible for the overall negative 
HINT score observed and might explain the low potency of 4-BnPG (102) at hOCT3 (IC50 
= 452.5 µM; Table 8). On the other hand, in interaction mode II, both 4-BnPG (102) and 4-
t-BuPG (101) possessed negative HINT scores (Table 11). This seems counterintuitive since 
4-t-BuPG (101) is one of the most potent compound (IC50 = 2.2 µM; Table 8) of the ring-
NH2N
NH2
R
4
3
  104 
opened phenylguanidine series. Thus, HINT analysis indicated that the interaction mode I is 
more probable of the two modes.  
  
  
Figure 49. Interaction mode I of the ring-opened phenylguanidine analogs at hOCT3. 
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100) 
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG 
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of hOCT3. 
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks, 
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between 
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate 
group of Asp478. The benzyl group of 4-BnPG (102) (red-colored meshed surface) was 
clashing with the side chain of Glu451 (tan-colored meshed surface) and might explain the 
very weak inhibitory activity of 4-BnPG (102) at hOCT3. 
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b. Docking at the substrate binding region of mOCT3: 
Docking studies at mOCT3 resulted in poses different to those observed in hOCT3. 
Since the binding region of OCT3 is fairly large, the molecules can potentially orient 
themselves in various different ways. Upon docking the 2-aminodihydroquinazoline analogs 
at mOCT3, we observed the guanidinium moiety interacting in a bidentate ionic salt-bridge 
interaction with the carboxylate oxygen atom of Asp473 (analogous to Asp478 in hOCT3) 
(Figure 50). This interaction was also observed in hOCT3 and might potentially be important 
for the inhibitory activities of our molecules. However, the 2-aminodihydroquinazoline 
analogs are oriented at a 90º angle in mOCT3 (Figure 50) as compared to the poses observed 
in hOCT3 (Figure 43).  
For the phenylguanidine series, similar to hOCT3, we also observed two interaction 
modes – I and II – in mOCT3. In mode I (Figure 51), all the analogs are oriented in an 
overlapping manner with the nitrogen atoms of the guanidinium moiety involved in a 
bidentate ionic-salt bridge interaction with the carboxylate oxygen atom of Asp473. In 
contrast, in mode II (Figure 52), all the phenylguanidine analogs, except for 4-BnPG (102) 
are oriented in a similar and overlapping manner with the guanidinium moieties pointing 
towards Asp473. The 4-BnPG (102) is flipped over and its guanidinium moiety was pointing 
towards Glu446 (analogus to Glu451 in hOCT3) which is located at the opposite end of the 
binding region (Figure 51). The two modes (I and II) mimic those we observed in hOCT3. 
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Unfortunately, our modeling studies are currently unable to explain the species differences 
in the activities that are observed for the phenylguanidine series. 
 
 
 
 
 
 
 
  
Figure 50. Structures of 2-aminodihydroquinazoline analogs - ADQ (yellow) (69), A5CDQ 
(red) (67), A6CDQ (orange) (65), A7CDQ (magenta) (66), A8CDQ (green) (68), A5MDQ 
(salmon pink) (75), A6MDQ (cyan) (74), A7MDQ (purple) (76), A8MDQ (teal) (77), 
A6FDQ (wheat) (87), A6BrDQ (brown) (88) and A6IDQ (fluorescent green) (89) - docked 
at the binding region of mOCT3. The ligands and amino acid residues are displayed as 
capped sticks and pale cyan-capped sticks, respectively. The dashed red lines indicate a 
bidentate ionic salt-bridge interaction between the two N-atoms of the guanidinium moiety 
of the ligands and an O-atom of the carboxylate group of Asp478. 
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Figure 51. Interaction mode I of the ring-opened phenylguanidine analogs at mOCT3. 
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100) 
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG 
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of mOCT3. 
The ligands and amino acid residues are displayed as capped sticks and light blue-capped 
sticks, respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction 
between the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the 
carboxylate group of Asp473.  
  108 
 
  
Figure 52. Interaction mode II of the ring-opened phenylguanidine analogs at mOCT3. 
Structures of PG (99) (yellow), 3-CPG (97) (red), 4-CPG (98) (orange), 4-MePG (100) 
(cyan), 4-t-BuPG (101) (white), 4-BnPG (102) (raspberry), 4-FPG (103) (tan), 4-BrPG 
(104) (brown) and 4-IPG (105) (limon) docked at the substrate binding region of mOCT3. 
The ligands and amino acid residues are displayed as capped sticks and tan capped sticks, 
respectively. The dashed red lines indicate a bidentate ionic salt-bridge interaction between 
the two N-atoms of the guanidinium moiety of the ligands and an O-atom of the carboxylate 
group of Asp473. The 4-BnPG (102) is flipped over with its guanidinium moiety pointing 
towards Glu446 located on the other end of the binding region. 
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GOAL 6: To determine if 2-aminodihydroquinazoline and phenylguanidine analogs 
retain antidepressant-like effect.  
 
1. Mouse tail suspension test (TST): 
In the course of elucidating the initial SAR, we synthesized and tested a number of 
2-aminodihydroquinazoline analogs. We wished to determine if selected analogs retained 
their antidepressant-like activity in the mouse TST. To determine if the chloro group or its 
position is important for antidepressant-like activity, we tested the 5- and 8-chloro 
substituted 2-aminodihydroquinazolines (A5CDQ (67) and A8CDQ (68)) as well as the des-
Cl analog ADQ (69). The Dukat laboratory had already established that both A6CDQ (65)35 
and A7CDQ (66)313 possess antidepressant-like effects. A6MDQ (74), the 6-methyl 
substituted analog, had comparable inhibitory potency at hOCT3 as A6CDQ (65) and we 
tested it to determine if it retained the antidepressant-like activity shown by A6CDQ (65). 
Additionally, we tested A6FDQ (87), that was synthesized as part of determining the role of 
steric properties and bulk at the 6-position of 2-aminodihydroquinazolines. Finally, to check 
the importance of the methylene bridge for antidepressant-like action, we tested the 4-chloro 
and 4-tert-butyl substituted ring-opened phenylguanidine analogs, 4-CPG (98) and 4-t-
BuPG (99), respectively. We also tested the commercially available SSRI, FLX (3) as a 
standard against which to compare the activity of our molecules. FLX (3) is commonly used 
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in the TST at a dose of 20 mg/kg.347 We examined five doses of FLX (3) and showed that it 
was inactive at a dose of <20 mg/kg (Figure 53).  
 
Similar to A6CDQ (65)35 and A7CDQ (66),313 A5CDQ (67) was shown to produce 
an antidepressant-like effect at 1.0 mg/kg (Figure 54). The efficacy of A5CDQ (67) (effect 
(± SEM) = 22.6 ± 8.9 s) was comparable to FLX (3) (effect (± SEM) = 22.4 ± 8.0 s) at a 
dose that was 20-times lower and the effective dose (ED50) was determined to be 0.57 mg/kg 
(Figure 55). A8CDQ (68) and ADQ (69), on the other hand, showed a lack of antidepressant-
like activity in the mouse TST (Figures 56 and 57, respectively). This coupled with the 
comparable inhibitory potencies of the chloro-substituted 2-aminodihydroquinazoline 
analogs (A5CDQ (67), A6CDQ (65), A7CDQ (66) and A8CDQ (68)) at mOCT3 suggests 
that the SAR for OCT3 inhibitory activity and mouse TST might be different. Our molecular 
modeling studies at mOCT3 indicates no potential clashes that A8CDQ (68) might be 
Figure 53. Effect (± SEM) of FLX (3) on 
duration of immobility in the mouse TST. 
FLX (3) significantly reduced the duration 
of immobility at a dose of 20 mg/kg 
compared to saline according to one-way 
analysis of variance (ANOVA). For FLX 
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s 
post-hoc test (** p < 0.01).     
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involved in at the binding region. So far, we can conclude that not only the presence, but 
also the position, of the chloro group of 2-aminodihydroquinazolines is important for TST 
activity in mouse, whereas only the presence of the chloro group is sufficient for inhibitory 
activity at OCT3.  
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A5CDQ (67) Figure 54. Effect (± SEM) of A5CDQ 
(67) on duration of immobility in the 
mouse TST. A5CDQ (67) significantly 
reduced the duration of immobility at a 
dose of 1.0 mg/kg as compared to saline 
according to one-way analysis of 
variance (ANOVA). For A5CDQ (67) 
(F7,63 = 5.529, p = 0.0001), Dunnett’s 
post-hoc test (**** p < 0.0001) and for 
FLX (3) (F5,50 = 3.714, p = 0.0062), 
Dunnett’s post-hoc test (** p < 0.01). 
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Figure 55. The effective dose for the 5-Cl 
analog, A5CDQ (67) was determined to be 
0.57 mg/kg, ~2.5-fold lower than that for 
the lead compound, A6CDQ (65), (ED50 = 
0.23 mg/kg).35 
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  Another important point for consideration is that we are yet to test A8CDQ (68) at 
5-HT3 or hSERT and do not know what, if any, activity it possesses at these targets. A6CDQ 
(65) and A7CDQ (66) behave as 5-HT3 antagonists of differing potencies and binding 
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A8CDQ (68) Figure 56. Effect (± SEM) of A8CDQ 
(68) on duration of immobility in the 
mouse TST. A8CDQ (68) did not 
significantly reduce the duration of 
immobility at any of the doses tested (0.1-
30 mg/kg) compared to saline according to 
one-way analysis of variance (ANOVA). 
For FLX (3) (F5,50 = 3.714, p = 0.0062), 
Dunnett’s post-hoc test (** p < 0.01). 
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ADQ (69) Figure 57. Effect (± SEM) of ADQ (69) 
on duration of immobility in the mouse 
TST. ADQ (69) did not significantly 
reduce the duration of immobility at any 
of the doses tested (0.1-30 mg/kg) 
compared to saline according to one-way 
analysis of variance (ANOVA). For FLX 
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s 
post-hoc test (** p < 0.01). 
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affinities. A5CDQ (67) and A7CDQ (66) behave as reuptake inhibitors whereas A6CDQ 
(65) and ADQ (69) behave as releasers at hSERT. Therefore, the in vivo activity of the 2-
aminodihydroquinazoline analogs (A5CDQ (67), A6CDQ (65) and A7CDQ (66)) might be 
linked to a combination of mechanisms: 5-HT3 antagonism, SERT activity (releaser or 
reuptake inhibitor) and OCT3 inhibition.  
Unlike the chloro-substituted 2-aminodihydroquinazoline analogs (A5CDQ (67), 
A6CDQ (65),35 and A7CDQ (66)),313 both the 6-methyl and the 6-fluoro analogs, A6MDQ 
(74) and A6FDQ (87) showed antidepressant-like effect at a dose of 3.0 mg/kg (Figures 58 
and 59, respectively). For A6MDQ (74) (effect (± SEM) = 28.9 ± 8.3 s) and A6FDQ (87) 
(effect (± SEM) = 25.0 ± 8.9 s) the effect observed was comparable to that produced by FLX 
(3) (effect (± SEM) = 22.4 ± 8.0 s) at a ~6.5-fold lower dose.  
The dose-response curves obtained for the selected 2-aminodihydroquinazoline 
analogs (A5CDQ (67), A6MDQ (74) and A6FDQ (87)) show the U-shaped curve (see 
Figures 54, 58 and 59), which is a feature observed for 5-HT3 agonists348 and is believed to 
arise from desensitization of 5-HT3 receptors. A similar U-shaped curve was also observed 
for compounds A6CDQ (65) and A7CDQ (66) which are 5-HT3 antagonists.35,313 Our 
analogs (A5CDQ (67), A6MDQ (74) and A6FDQ (87)) resulted from structural changes of 
compounds A6CDQ (65) and A7CDQ (66), and might potentially possess activity at 5-HT3 
receptors. Other possible explanations for the U-shaped curve observed include – differences 
in patterns of expressions (presynaptic vs. postsynaptic) as well as densities of 5-HT3 
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receptors and potential sedative effects at higher doses. This was probable since we tested 
only the TST-active doses in the locomotor stimulant activity. Limited solubility of the 
compounds in saline resulting in suspension at higher doses was unlikely since the 
compounds were water-soluble salts and the solutions obtained were clear with no 
precipitate observed. 
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Figure 58. Effect (± SEM) of A6MDQ 
(74) on duration of immobility in the 
mouse TST. A6MDQ (74) significantly 
reduced the duration of immobility at a 
dose of 3.0 mg/kg compared to saline 
according to one-way analysis of variance 
(ANOVA). For A6MDQ (74) (F6,55 = 
3.144, p = 0.0101), Dunnett’s post-hoc test 
(* p < 0.05) and for FLX (3) (F5,50 = 3.714, 
p = 0.0062), Dunnett’s post-hoc test (** p 
< 0.01).  
A6MDQ (74) 
Sa
lin
e
FL
X (
20
)
0.1 0.3 1.0 3.0 10 30
0
50
100
150
Drug doses (mg/kg)
Im
m
ob
ili
ty
 ti
m
e 
(s
)
****
A6FDQ (74)
Figure 59. Effect (± SEM) of A6FDQ 
(87) on duration of immobility in the 
mouse TST. A6FDQ (87) significantly 
reduced the duration of immobility at a 
dose of 3.0 mg/kg compared to saline 
according to one-way analysis of 
variance (ANOVA). For A6FDQ (87) 
(F7,66 = 3.197, p = 0.0056), Dunnett’s 
post-hoc test (** p < 0.01) and for FLX 
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s 
post-hoc test (** p < 0.01).  
6  (87) 
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The ring-opened phenylguanidine analog, 4-CPG (98) was inactive at all doses tested 
(0.1-30 mg/kg) in the mouse TST (Figures 60). On the other hand, while 4-t-BuPG (101) did 
not decrease the immobility time and thus did not exhibit an antidepressant-like effect, it did 
increase immobility at the largest dose tested (30 mg/kg) (Figure 61). This increase in 
immobility time could be a result of a sedative-like effect exerted by 4-t-BuPG (101).  
  
The lack of antidepressant-like effects for 4-CPG (98) and 4-t-BuPG (101), coupled 
with the previous finding that the 3-chloro substituted phenylguanidine analog, 3-CPG (97), 
was inactive (0.1-30 mg/kg) in mouse TST,313 led us to conclude that the methylene bridge 
might be an important structural feature for antidepressant-like activity 
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Figure 60. Effect (± SEM) of 4-CPG (98) 
on duration of immobility in the mouse 
TST. 4-CPG (98) did not significantly 
reduce the duration of immobility at any 
of the doses tested (0.1-30 mg/kg) 
compared to saline according to one-way 
analysis of variance (ANOVA). For FLX 
(3) (F5,50 = 3.714, p = 0.0062), Dunnett’s 
post-hoc test (** p < 0.01). 
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2. Locomotor activity assay: 
 To eliminate the possibility of the antidepressant-like effect observed in the mouse 
TST resulting from a locomotor stimulant effect, we tested the active doses of A5CDQ (67), 
A6MDQ (74) and A6FDQ (87) identified in mouse TST in the locomotor activity assay. The 
mice were injected intraperitoneally with 1.0 mg/kg of A5CDQ (67) or 3.0 mg/kg of 
A6MDQ (74) or A6FDQ (87) or saline and their locomotor activity was measured for a 
period of 45 min. The test duration for the locomotor activity includes the 30 min pre-
treatment time of the mouse TST, the duration of the mouse TST (6 min) and the nine 
minutes after the mice were no longer suspended by their tails.    
 The TruScan control and data acquisition software recorded a number of different 
parameters, out of which the following eleven parameters were analyzed: movement 
episodes, movement time (s), movement distance (cm), ambulatory velocity (cm/s), margin 
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4-tBuPG (81) Figure 61. Effect (± SEM) of 4-t-BuPG 
(101) on duration of immobility in the 
mouse TST. 4-t-BuPG (101) did not 
significantly reduce the duration of 
immobility at any of the doses tested (0.1-
30 mg/kg) compared to saline according to 
one-way analysis of variance (ANOVA). 
For 4-t-BuPG (101) (F7,71 = 7.247, p < 
0.0001), Dunnett’s post-hoc test (**** p < 
0.0001) and for FLX (3) (F5,50 = 3.714, p 
= 0.0062), Dunnett’s post-hoc test (** p < 
0.01). 
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distance (cm), margin time (s), center distance (cm), center time (s), center entries, jumps 
and vertical plane (V-plane) entries. The first four parameters listed, movement episodes, 
movement time (s), movement distance (cm) and ambulatory velocity (cm/s) are altered 
upon administration of stimulants.349,350 The movement time (s), distance (cm) and 
ambulatory velocity (cm/s) are increased, whereas the movement episodes reduce in 
number.349,350 Increases in margin distance (cm) and margin time (s) and a decrease in center 
distance (cm), center time (s) and center entries are indicative of anxiety or anxiogenic 
effects.349,351,352 V-plane entries correspond to rearing behavior of mice and jumps might 
indicate general responsiveness of mice.349,353,354 The unpaired two-tailed t test was used to 
compare the mean values of the parameters evaluated for saline and the compounds tested 
(A5CDQ (67), A6MDQ (74) and A6FDQ (87)) to determine if differences observed were 
statistically significant.  
 Of the three 2-aminodihydroquinazoline analogs tested, A5CDQ (67; 1.0 mg/kg), 
A6MDQ (74; 3.0 mg/kg) and A6FDQ (87; 3.0 mg/kg) at the TST-active doses, no 
statistically significant changes were observed for movement time (s), movement distance 
(cm) and ambulatory velocity (cm/s) when compared to saline (Figure 62). While no change 
in the number of movement episodes were observed for A5CDQ (67; 1.0 mg/kg) and 
A6MDQ (74; 3.0 mg/kg), a statistically significant increase for A6FDQ (87; 3.0 mg/kg) 
compared to saline was observed according to the unpaired two-tailed t test. A single 
movement episode encompasses the period when the movement is initiated by the rodent 
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and ends when the rodent stops moving. Locomotor stimulants decrease the rodent’s 
tendency to stop and hence decreases the number of movement episodes. But, this is 
accompanied by a concomitant increase in the movement distance (cm) and time (s). Since 
we observed an increase in movement episodes without an accompanying increase in 
movement distance (cm) and movement time (s) for A6FDQ (87; 3.0 mg/kg), we might 
conclude that the antidepressant-like effect observed for A5CDQ (67; 1.0 mg/kg), A6MDQ 
(74; 3.0 mg/kg) and A6FDQ (87; 3.0 mg/kg) in the mouse TST were free of stimulant effect.  
  Although the number of center entries and the amount of time spent in the center 
was reduced for mice treated with A6MDQ (74; 3.0 mg/kg), the difference was not 
statistically significant compared to saline (Figure 63). No differences were observed for 
center entries, center distance (cm) and center time (s) for A5CDQ (67; 1.0 mg/kg) and 
A6FDQ (87; 3.0 mg/kg) when compared to saline (Figures 63). Additionally, the parameters 
- margin distance (cm) and margin time (s) – were similar for the drugs tested and saline 
(Figure 64). 
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Figure 62. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0 
mg/kg, respectively for movement episodes, movement time (s), movement distance (cm) and 
ambulatory velocity (cm/s) in the locomotor activity assay. No significant changes were 
observed for the parameters for A5CDQ (67), A6MDQ (74) and A6FDQ (87) compared to 
saline except for movement episodes for A6FDQ (87) according to unpaired two-tailed t test.  
Unpaired two-tailed t test, for movement episodes, A5CDQ (67) t(15) = 0.1749, p = 0.8635, 
A6MDQ (74) t (15) = 0.2331, p = 0.8188, A6FDQ (87) t(13) = 3.416, p = 0.0042 ; for movement 
time (s), A5CDQ (67) t(16) = 0.2698, p = 0.7908, A6MDQ (74) t (16) = 0.3734, p = 0.7137, 
A6FDQ (87) t(15) = 1.027, p = 0.3207; movement distance (cm), A5CDQ (67) t(15) = 0.2677, 
p = 0.7925, A6MDQ (74) t (15) = 0.6018, p = 0.5563, A6FDQ (87) t(15) = 0.2628, p = 0.7963; 
ambulatory velocity (cm/s), A5CDQ (67) t(15) = 0.3027, p = 0.7663, A6MDQ (74) t (15) = 
0.6425, p = 0.5302, A6FDQ (87) t(15) = 0.1642, p = 0.8718. 
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Figure 63. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0 
mg/kg, respectively for center entries, center distance (cm) and center time (s) in the locomotor 
activity assay. No significant changes were observed for the parameters for A5CDQ (67), 
A6MDQ (74) and A6FDQ (87) compared to saline according to unpaired two-tailed t test.  
Unpaired two-tailed t test, for center entries, A5CDQ (67) t(15) = 0.0272, p = 0.9786, A6MDQ 
(74) t (14) = 2.078, p = 0.0566, A6FDQ (87) t(15) = 0.5450, p = 0.5938; for center distance 
(cm), A5CDQ (67) t(16) = 0.8572, p = 0.4040, A6MDQ (74) t (16) = 0.9231, p = 0.3697, 
A6FDQ (87) t(16) = 0.1882, p = 0.8531; center time (s), A5CDQ (67) t(16) = 0.9709, p = 0.3460, 
A6MDQ (74) t (15) = 1.445, p = 0.1690, A6FDQ (87) t(16) = 0.2768, p = 0.7854. 
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Increased anxiety could account for reduced immobility times in mouse TST. 
However, no changes in the amount of time spent in the center vs. the margin eliminated an 
anxiogenic-like effect (Figures 63 and 64).  Decreases in both jumps and V-plane entries 
were observed for all three analogs A5CDQ (67; 1.0 mg/kg), A6MDQ (74; 3.0 mg/kg) and 
A6FDQ (87; 3.0 mg/kg). These decreases however, were not statistically significant 
compared to saline (Figure 65). 
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Figure 64. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 3.0 
mg/kg, respectively for margin distance (cm) and margin time (s). No significant changes were 
observed for the parameters for A5CDQ (67), A6MDQ (74) and A6FDQ (87) compared to 
saline according to unpaired two-tailed t test. Unpaired two-tailed t test, for margin distance 
(cm), A5CDQ (67) t(16) = 0.2085, p = 0.8374, A6MDQ (74) t (16) = 0.7735, p = 0.4505, 
A6FDQ (87) t(16) = 0.7240, p = 0.4795; for margin time (s), A5CDQ (67) t(16) = 0.9709, p = 
0.3460, A6MDQ (74) t (15) = 1.445, p = 0.1690, A6FDQ (87) t(16) = 0.2768, p = 0.7854. 
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The locomotor activity assay indicated an overall lack of locomotor stimulant effect 
for all three 2-aminodihydroquinazoline analogs, A5CDQ (67), A6MDQ (74) and A6FDQ 
(87) at the TST-active doses and gave further credence to the antidepressant-like effect 
observed in mouse TST.   
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Figure 65. Effect (± SEM) of A5CDQ (67), A6MDQ (74) and A6FDQ (87) at 1.0, 3.0 and 
3.0 mg/kg, respectively for jumps and vertical plane (V-plane) entries in the locomotor 
activity assay. No significant changes were observed for the parameters for A5CDQ (67), 
A6MDQ (74) and A6FDQ (87) compared to saline according to unpaired two-tailed t test. 
Unpaired two-tailed t test, for jumps, A5CDQ (67) t(15) = 1.546, p = 0.1429, A6MDQ (74) 
t (16) = 1.730, p = 0.1029, A6FDQ (87) t(16) = 1.498, p = 0.1536; for V-Plane entries, 
A5CDQ (67) t(16) = 0.8320, p = 0.4177, A6MDQ (74) t (16) = 1.607, p = 0.1276, A6FDQ 
(87) t(16) = 0.7756, p = 0.4493.  
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V. Conclusions 
 
 
The overarching goal of the current study was to identify the mechanism of 
antidepressant-like character of the 2-aminodihydrquinazoline analogs, A6CDQ (65) and 
A7CDQ (66). In the course of achieving this goal, we eliminated a solely 5-HT3 receptor 
mediated mechanism of antidepressant-like effect and investigated two other potential 
mechanisms mediated via hSERT and/or OCTs.  
When examined at hSERT we determined that the position of the chloro group 
exerted influence on the activity at hSERT. The positional isomers, A6CDQ (65) and 
A7CDQ (66), exhibited distinct electrophysiological signatures of a releaser and reuptake 
inhibitor, respectively. In trying to determine the reason for this difference in activity, we 
performed molecular modeling studies and identified subtle differences in hydrophobic 
interactions that the 6- and 7-chloro groups were engaged in at hSERT. However, activity at 
hSERT (releaser and reuptake inhibitor) proved incapable of explaining the in vivo activities 
of the two positional isomers. 
Having eliminated both a solely 5-HT3 and hSERT mediated mechanism of 
antidepressant-like effect, we examined OCTs, specifically hOCT3, that has been previously 
implicated as being involved in depression.308,309 We successfully identified 2-
aminodihydroquinazoline analogs as a new class of OCT inhibitors and established an initial 
  124 
SAR at hOCT3 (Figure 66) that was lacking. In delineating the SAR, we concluded the 
following: 
i. The presence and not the position of the chloro group was important for OCT 
inhibitory activity.  
ii. At the 6-position the lipophilic properties of the substituents were more important 
than their electronic properties. Also, there seems to exist a region of bulk 
tolerance capable of accommodating substituents of considerable volume (such 
as iodo, bromo). 
iii. The methylene bridge was not an important structural feature for OCT inhibitory 
activity. 
 
At the present time, we do not know how our compounds, the 2-
aminodihydroquinazolines behave at hOCT3. Are they simply inhibitors or substrates or 
both? There might be considerable differences in SARs for all three categories of 
compounds. This is illustrated by the 6-fluoro analog, A6FDQ (87) which despite having a 
substituent with a lower lipophilic property, possessed ~8-fold greater inhibitory potency at 
hOCT3 as compared to the lead, A6CDQ (65). A lack of selectivity for hOCT3 over hOCT1 
and hOCT2 was a feature common to the chloro-substituted 2-aminodihydroquinazoline 
analogs.  A degree of selectivity was achieved by the 5-methyl analog which bore 10– and 
57–fold selectivity for hOCT3 over hOCT1 and hOCT2, respectively. 
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Figure 66. Summary of SAR of the 2-aminodihydroquinazolines at hOCT3.  
 
 
   
Our efforts to understand how the analogs interacted at a molecular level resulted in 
the first 3-dimensional homology models of both the human and mouse orthologs of OCT3 
(hOCT3 and mOCT3, respectively). Both hOCT3 and mOCT3 share a high degree of 
homology with each other with the amino acid residues comprising the binding regions being 
conserved. Consequently, it was no surprise when analysis of our docking studies at hOCT3 
and mOCT3 indicated a common and key bidendate ionic salt-bridge interaction between 
the guanidinium moiety of our molecules and the oxygen atom of Asp478 and Asp473 in 
Removal of methylene 
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hOCT3 and mOCT3, respectively. Notwithstanding the high degree of homology between 
hOCT3 and mOCT3 there might exist differences in how the proteins fold. This could 
potentially influence the binding region. Hence, despite the fact that all the amino acids of 
the binding region are conserved between the two orthologs (human and mouse) of OCT3, 
the shape of the binding region itself might be considerably different. This might explain the 
very weak inhibitory activity of the ring-opened phenylguanidine analogs at mOCT3 as 
compared to hOCT3. Since we have used the same template, PiPT, for modeling both 
hOCT3 and mOCT3, the orientation of the back bone amino acid residues were highly 
overlapping (RMSD ~2.5 Å between hOCT3 and mOCT3). We have essentially forced 
mOCT3 and by extension its binding region to adopt and mimic the binding region observed 
in hOCT3. Consequently, at this point, our modeling studies are incapable of explaining the 
discrepancies in the inhibitory potencies observed for the ring-opened phenylguandine series 
at the two orthologs - hOCT3 and mOCT3.  Our biological data indicated an importance for 
the lipophilic property of the substituents, a feature mirrored in our modeling studies which 
identified hydrophobic interactions of the substituents with the residues of the binding 
region. Hence, so far, our biological data supports the modeling studies at OCTs.  
Despite sharing the key bidentate ionic salt-bridge interaction with Asp478, the ring-
opened phenylguanidine analogs are oriented differently, i.e., they possess different docking 
modes compared to the 2-aminodihydroquinazolines. We identified two potential docking 
modes for the phenylguanidine analogs and eliminated one of the modes on the basis of 
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unfavorable interactions as indicated by HINT analysis. The SAR of the phenylguanidine 
series parallels that of the 2-aminodihydroquinazoline series with the lipophilic (π) property 
of the substituents at the 4-position being more important than its electronic (σ) property. A 
major feature of the phenylguanidine series, however, was a limitation in the amount of bulk 
that could be tolerated at the 4-poisition (which corresponds to the 6-position of 2-
aminodihydroquinazolines).  
So far, inhibitory potencies at OCT3 have shown promise in providing a potential 
explanation for the in vivo activity observed. Unlike the SAR for 2-
aminodihydroquinazolines at OCTs, both the position and the presence of the chloro group 
might be important for the antidepressant-like effect in the mouse TST. Additionally, 
removal of the methylene bridge, a structural feature unimportant for OCT inhibitory 
activity, resulted in loss of antidepressant-like effect in the mouse TST. A striking feature of 
the antidepressant-like effect observed was the U shaped dose response curves. This feature 
which has been previously observed for 5-HT3 receptor agonists might be a result of multiple 
phenomena such as receptor desensitization, differences in receptor localization (presynaptic 
vs. postsynaptic) and/or densities, sedative effects at higher doses or limited solubility of the 
compounds at higher doses. Since the 2-aminodihydroquinazolines resulted from structural 
modifications of 5-HT3 receptor antagonists and were administered as water-soluble salts, 
desensitization and limited solubility as potential explanations seem unlikely. Therefore, at 
present, the most probable explanation for the U shaped dose response curve appears to be 
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potential sedative effects at higher doses since only the antidepressant-like effects of the 
active doses identified in the mouse TST were shown to be free of a potential locomotor 
stimulant.  
In pursuing our overarching goal, we arrived at the conclusion that it was unlikely 
that the mechanism underlying the antidepressant-like character of the 2-
aminodihydroquinazolines were mediated by a single target but instead might be a result of 
activity at a combination of multiple targets (i.e., 5-HT3 receptors, hSERT and/or OCTs). 
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VI. Experimental 
 
A. Synthesis 
 
Compounds were characterized using a combination of melting point (mp), proton 
nuclear magnetic resonance (1H NMR), infrared (IR), and mass (MS) spectrometry. Purity 
of the compounds was determined based on elemental analysis for C, H and N performed by 
Atlantic Microlab Inc. (Norcross, GA) and compounds were considered pure if the values 
obtained were within 0.4% of theoretical values. The MEL TEMP melting point apparatus 
was utilized to obtain uncorrected melting points (mp) of compounds in glass walled 
capillary tubes. 1H NMR were obtained either using a Bruker ARX 400 MHz or Bruker 
AVANCE III 400 MHz spectrometer. The spectra obtained were reported by indicating the 
position of the peaks in parts per million (ppm) downfield from the tetramethylsilane (TMS), 
used as an internal standard, followed by the splitting pattern of the peak (s = singlet, d = 
doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constant 
(J, Hz) and integration. IR spectra were determined using Thermo Nicolet iS10 FT-IR. MS 
was obtained using a Waters Acquity TQD (tandem quadrapole) spectrometer utilizing 
electrospray ionization in positive ion mode. Reactions were followed using thin-layer 
chromatography (TLC) on silica gel GHLF plates (250 µm, 2.5 x 10 cm; Analtech Inc. 
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Newark, DE). For the purposes of biological studies water-soluble salts of compounds 
(hydrochloride, hydrobromide or nitrate) were prepared except for 2-amino-5-methyl-3,4-
dihydroquinazoline (71) and 2-amino-6-iodo-3,4-dihydroquinazoline (89), for which a 
suitable salt could not be obtained because the salts obtained were hygroscopic.   
 
2-Amino-8-chloro-3,4-dihydroquinazoline Hydrochloride (68). The procedure for a 
similar compound328 was used to synthesize 68. Cyanogen bromide (3 M solution in CH2Cl2, 
3 mL, 8.6 mmol) was added to a stirred solution of 2-amino-3-chlorobenzylamine (73) (0.90 
g, 5.6 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux for 4.5 h, 
allowed to cool to room temperature and stirred overnight. This was followed by removal of 
toluene under reduced pressure to give a yellow solid. The residue was dissolved in H2O (60 
mL) followed by addition of a saturated solution of NaHCO3 to pH = 9 to 10. The H2O layer 
was further basified by addition of NaOH (3 N, to pH 12). The solid was collected by 
filtration and washed with H2O (30 mL) to afford 0.85 g (81%) of the crude free base of 68. 
The solid was dissolved in EtOH (20 mL) and a saturated solution of gaseous HCl in EtOH 
was added (pH 1-2) and the reaction mixture was allowed to stir at room temperature 
overnight. The solid was collected by filtration to afford 0.39 g (65%) which upon 
recrystallization from EtOH gave 0.17 g (28%) of 68 as a white solid: mp 202-204 °C. 1H 
NMR (DMSO-d6) δ 4.52 (s, 2H. CH2), 7.06-7.11 (t, J = 6 Hz, 1H, ArH), 7.15-7.18 (d, J = 12 
Hz, 1H, ArH), 7.38-7.40 (d, J = 8 Hz, 1H, ArH), 8.08 (s, 2H, NH2), 8.82 (s, 1H, NH), 10.07 
  131 
(s, 1H, NH). Anal. Calcd for (C9H11N3·1HCl) C, 44.06; H, 4.16; N, 19.27. Found: C, 44.05; 
H, 4.01; N, 19.15.   
 
2-Amino-3,4-dihydroquinazoline Hydrochloride (69). The procedure for a similar 
compound327 was used to synthesize 69. BH3·THF complex (1 M in THF, 7 mL, 7.2 mmol) 
was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-aminoquinazolin-
4(3H)-one (71) (0.30 g, 1.8 mmol) in anhydrous THF (5 mL) under an N2 atmosphere. The 
stirred reaction mixture was heated at reflux for 2 h to give a pale yellow-colored solution, 
allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH 2). The 
reaction mixture was then heated to evaporate THF until THF could no longer be detected 
by smell. The residue was cooled to 0 °C (ice-bath) and a solution of NaOH (15%, to pH 12) 
was added. Hot CHCl3 (3 x 15 mL) was used to extract the desired compound, which settled 
between H2O and CHCl3 layers. The solid obtained was collected by filtration and washed 
with cold CHCl3 to afford 0.14 g (44%) of the free base of 69 as a white solid: mp 310-314 
°C. NMR (DMSO-d6) δ 4.28 (s, 2H, CH2), 5.41 (s, 2H, NH2 D2O ex), 6.06 (s, 1H, NH D2O 
ex), 6.58-6.60 (d, J = 8 Hz, 1H, ArH), 6.53-6.68 (t, J = 4 Hz, 1H, ArH), 6.81-6.83 (d, J = 8 
Hz, 1H, ArH), 6.94-6.97 (t, J = 4 Hz, 1H, ArH). A saturated solution of gaseous HCl in EtOH 
was added to a solution of the free base of 69 in EtOH (2 mL) and the reaction mixture was 
allowed to stir for 30 min. The EtOH was removed under reduces pressure to obtain a crude 
solid which upon recrystallization from EtOH/Et2O afforded 0.14 g (%) of 69 as cream-
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yellow solid: mp 172-174 °C (EtOH/Et2O) (lit.327,355 mp 158-160 °C); Anal. Calcd for 
(C8H9N3·1HCl) C, 52.32; H, 5.49; N, 22.88. Found: C, 52.40; H, 5.42; N, 22.74.  
 
2-Aminoquinazolin-4(3H)-one (71). A reported procedure for a similar compound327 was 
used to synthesize 73. S-Methylisothiourea sulfate (0.93 g, 6.7 mmol) and Na2CO3 (0.75 g, 
7.1 mmol) were added to a solution of isatoic anhydride (72) (1.00 g, 6.7 mmol) in 80% aq. 
MeCN (20 mL) and the reaction mixture was heated at reflux for 3 h. The reaction mixture 
was then allowed to cool to room temperature. The solid obtained was collected by filtration 
and dried to yield 0.35 g (32%) of 73 as a white solid: mp 320-322 °C (lit.327,356 mp >300 
°C). 
 
2-Amino-3-chlorobenzylamine (73). The procedure for a similar compound329 was used to 
synthesize 71. BH3·THF complex (1 M in THF, 26 mL, 26.2 mmoles) was added in a 
dropwise manner at 0 °C (ice-bath) to 2-amino-3-chlorobenzonitrile (70) (1.00 g, 6.6 
mmoles) under an N2 atmosphere. The stirred reaction mixture was heated at reflux 
overnight, allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH 
2), and refluxed for 30 min. The reaction mixture was allowed to cool to room temperature 
and then to 0 °C (ice-bath) and basified with NaOH (3 N, to pH 12) and extracted with 
CH2Cl2 (2 x 40 mL). The combined organic portion was washed with H2O (100 mL), dried 
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(MgSO4) and evaporated under reduced pressure to afford 0.93 g (90%) of 71 as a sticky 
solid. IR spectroscopy indicated the absence of a characteristic cyano band at 2226.58 cm-1. 
 
2-Amino-6-methyl-3,4-dihydroquinazoline Hydrochloride (74). The procedure for a 
similar compound313 was used to synthesize 74. BH3·THF complex (1 M in THF, 6 mL, 6.0 
mmol) was added in a dropwise manner at 0 °C to 2-amino-6-methylquinazolin-4(3H)-one 
(80) (0.28 g, 1.6 mmol) under an N2 atmosphere. The stirred reaction mixture was heated at 
reflux for 1 h to give a clear solution, allowed to cool to room temperature, quenched by 
addition of HCl (6 N, to pH 3). The reaction mixture was then heated to evaporate THF until 
THF could no longer be detected by smell. The residue was cooled to 0° C (ice-bath) and a 
solution of NaOH (15%, to pH 12) was added. Hot CHCl3 (3 x 10 mL) was used to extract 
the desired compound, which settled between H2O and CHCl3 layers. The solid obtained 
was collected by filtration and washed with cold CHCl3 to afford 0.15 g (44%) of the free 
base of 74 as a white solid: mp >300 °C. A saturated solution of gaseous HCl in EtOH was 
added to a solution of the free base of 74 in EtOH until the solution became acidic (pH = 3). 
The EtOH was removed under reduced pressure to obtain a crude, white solid which upon 
crystallization from EtOH yielded 0.04 g (23%) of 74 as off-white crystals: mp 172-175 °C. 
NMR (DMSO-d6) δ 2.25 (s, 3H, CH3), 4.46 (s, 2H, CH2), 6.86-6.88 (d, J = 8 Hz, 1H, ArH), 
6.99 (s, 1H, ArH), 7.05-7.07 (d, J = 8 Hz, 1H, ArH), 7.54 (s, 1H, NH D2O ex), 8.46 (s, 1H, 
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NH D2O ex), 10.74 (s, 1H, NH D2O ex). Anal. Calcd for (C9H11N3·1.1HCl) C, 54.70; H, 
6.06; N, 20.87. Found: C, 53.95; H, 6.06; N, 20.84.  
 
2-Amino-5-methyl-3,4-dihydroquinazoline (75). The procedure for a similar compound328 
was used to synthesize 75. Cyanogen bromide (3 M solution in CH2Cl2, 2 mL, 6.2 mmol) 
was added to a stirred solution of 2-amino-6-methylbenzylamine (83) (0.56 g, 4.1 mmol) in 
toluene (6 mL). The stirred reaction mixture was heated at reflux overnight to give a dark 
brown suspension, then allowed to cool to room temperature followed by removal of toluene 
under reduced pressure. The residue was dissolved in H2O (20 mL) followed by addition of 
a saturated solution of NaHCO3 resulting in precipitation of a yellow solid. The solid was 
collected by filtration to afford 0.07 g (11%) of 75 as a light-brown solid: mp 180-184 °C. 
1H NMR (DMSO-d6) δ 2.07 (s, 3H, CH3), 4.33 (s, 2H, CH2), 6.52-6.50 (d, J = 8 Hz, 1H, 
ArH), 6.62-6.60 (d, J = 8 Hz, 1H, ArH), 6.93-6.89 (t, J = 8 Hz, 1H, ArH). HMRS (M++H) 
calcd. for C9H12N3 162.1005; found 162.1045. 
 
2-Amino-7-methyl-3,4-dihydroquinazoline Hydrochloride (76). The procedure for a 
similar compound328 was used to synthesize 76. Cyanogen bromide (3 M solution in CH2Cl2, 
3 mL, 9.4 mmol) was added to a stirred solution of 2-amino-4-methylbenzylamine (82) (0.85 
g, 6.2 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight, 
allowed to cool to room temperature followed by removal of toluene under reduced pressure. 
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The residue was dissolved in H2O (80 mL) followed by addition of a saturated solution of 
NaHCO3 to pH = 9 to 10. The aqueous layer was further basified by addition of NaOH (3 N, 
to pH 12). The solid was collected by filtration to afford 0.63 g of crude free base of 76. The 
solid was dissolved in MeOH (10 mL) and a saturated solution of gaseous HCl in EtOH was 
added (pH 1-2) and the reaction mixture was allowed to stir at room temperature overnight. 
The MeOH was removed under reduced pressure to afford 0.60 g (79%) which upon 
recrystallization from EtOH gave 0.20 g (26%) of 76 as a white solid: mp 204-205 °C. 1H 
NMR (DMSO-d6) δ 2.24 (s, 3H, CH3), 4.41 (s, 2H. CH2), 6.75 (s, 1H, ArH), 6.86-6.89 (d, J 
= 12 Hz, 1H, ArH), 7.03-7.05 (d, J = 8 Hz, 1H, ArH), 7.60 (s, 2H, NH2), 8.46 (s, 1H, NH), 
10.77 (s, 1H, NH). Anal. Calcd for (C9H11N3·1.1HCl) C, 53.70; H, 6.06; N, 20.87. Found: 
C, 53.72; H, 5.97; N, 21.19. 
 
2-Amino-8-methyl-3,4-dihydroquinazoline Hydrochloride (77). The procedure for a 
similar compound328 was used to synthesize 77. Cyanogen bromide (3 M solution in CH2Cl2, 
3 mL, 9.9 mmol) was added to a stirred solution of 2-amino-3-methylbenzylamine (81) (0.90 
g, 6.6 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight 
and then allowed to cool to room temperature. This was followed by removal of toluene 
under reduced pressure to give a sticky orange-pink solid. The residue was dissolved in H2O 
(40 mL) followed by addition of a saturated solution of NaHCO3 to pH = 9 to 10. The 
aqueous portion was further basified by addition of NaOH (3 N, to pH 12). The solid was 
  136 
collected by filtration and washed with H2O (30 mL) to afford 0.49 g of crude free base of 
77. The free base was dissolved in EtOH (20 mL) and a saturated solution of gaseous HCl 
in EtOH was added (pH 1-2) and the reaction mixture was allowed to stir at room 
temperature overnight. EtOH was removed under reduced pressure to afford 0.40 g of a 
white solid which upon recrystallization from EtOH gave 0.21 g (16%) of 77 as a white 
solid: mp 168-170 °C. 1H NMR (DMSO-d6) δ 2.28 (s, 3H, CH3), 4.47 (s, 2H. CH2), 6.09-
7.02 (q, J = 6 Hz, 2H, ArH), 7.10-7.12 (q, J = 9 Hz, 1H, ArH), 7.85 (s, 2H, NH2), 8.54 (s, 
1H, NH), 10.01 (s, 1H, NH). Anal. Calcd for (C9H11N3·1HCl) C, 54.69; H, 6.12; N, 21.26. 
Found: C, 54.51; H, 6.06; N, 21.13.    
 
6-Methylisatoic anhydride (79). A reported procedure for a the same compound333 was 
used to synthesize 79. Urea-H2O2 complex (0.78 g, 8.3 mmol) and 3 drops of H2SO4 were 
added to a solution of 5-methylisatin (78) (1.00 g, 6.2 mmol) in 8 mL of HCOOH. The 
reaction mixture was then sonicated for 35 min with occasional stirring. The urea-hydrogen 
peroxide complex was prepared according to a reported procedure332 by adding urea (4.00 
g, 66.6 mmol) portion wise to H2O2 (30% aq., 11.32 mL) heated to 55 °C and keeping the 
temperature below 60 °C. The reaction mixture was poured on to an evaporating dish and 
left overnight. The solid obtained was collected by filtration to afford 4.87 g (78%) of the 
urea-H2O2 complex as a white solid. The precipitate formed during sonication of reaction 
mixture was collected by filtration and washed with Et2O to yield 0.87 g of a bright yellow-
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orange solid which upon recrystallization from HOAc gave 0.62 g (56%) of 79 as bright 
orange crystals: mp 227-230 °C (lit333 mp 233 °C). 
 
2-Amino-6-methylquinazolin-4(3H)-one (80). The procedure for a similar compound313 
was used to synthesize 80. S-Methylisothiouronium sulfate (0.86 g, 3.1 mmol) and Na2CO3 
(0.36 g, 3.4 mmol) were added to a solution of 6-methylisatoic anhydride (79) (0.40 g, 2.2 
mmol) in 80% aq. MeCN (12 mL). The reaction mixture was heated at reflux for 2.5 h. The 
reaction mixture was then allowed to cool to room temperature and the precipitate formed 
was collected by filtration and washed with 80% aq. MeCN to yield 0.18 g (46%) of 80 as a 
pale white solid: mp >300 °C (lit356 mp >250 °C). 
 
2-Amino-3-methylbenzylamine (84). The procedure for a similar compound329 was used to 
synthesize 84. A complex of BH3·THF (1 M in THF, 30 mL, 26.2 mmol) was added in a 
dropwise manner at 0 °C (ice-bath) to 2-amino-3-methylbenzonitrile (81) (1.00 g, 7.6 mmol) 
under an N2 atmosphere. The stirred reaction mixture was heated at reflux overnight, allowed 
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at 
reflux for 30 min. The reaction mixture was allowed to cool to room temperature and then 
to 0 °C (ice bath) and basified with NaOH (3 N, to pH 12) and extracted with CH2Cl2 (2 x 
25 mL). The combined organic portion was washed with H2O (50 mL), dried (MgSO4) and 
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evaporated under reduced pressure to afford 0.92 g (89%) of 84 as a sticky solid. IR 
spectroscopy indicated the absence of a characteristic cyano band at 2219.67 cm-1. 
 
2-Amino-4-methylbenzylamine (85). The procedure for a similar compound329 was used to 
synthesize 85. A complex of BH3·THF (1 M in THF, 30 mL, 30.3 mmol) was added in a 
dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-amino-4-methylbenzonitrile 
(82) (1.00 g, 7.6 mmol) in anhydrous THF (15 mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux overnight, allowed to cool to room temperature, 
quenched by addition of HCl (6 N, to pH 2), and refluxed for 35 min. The reaction mixture 
was allowed to cool to room temperature and then at 0 °C (ice-bath), was basified with NaOH 
(3 N, to pH 12) and extracted with CH2Cl2 (2 x 50 mL). The combined organic portion was 
washed with H2O (50 mL), dried (MgSO4) and evaporated under reduced pressure to afford 
0.89 g (85%) of 85 as a sticky solid: mp 82-86 °C. IR spectroscopy indicated the absence of 
a characteristic cyano band at 2208.91 cm-1. 
 
2-Amino-6-methylbenzylamine (86). The procedure for a similar compound329 was used to 
synthesize 86. A complex of BH3·THF (1 M in THF, 30 mL, 30.3 mmol) was added in a 
dropwise manner at 0 °C (ice-bath) to a stirred solution of 2-amino-6-methylbenzonitrile 
(83) (1.00 g, 7.6 mmol) in anhydrous THF (15 mL) under an N2 atmosphere. The stirred 
reaction mixture was heated at reflux overnight, allowed to cool to room temperature, 
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quenched by addition of HCl (6 N, to pH 2), and heated at reflux for 30 min. The reaction 
mixture was allowed to cool to room temperature and then to 0 °C (ice-bath) and basified 
with NaOH (15% as well as NaOH pellets, to pH 12) and extracted with CH2Cl2 (4 x 20 
mL). The combined organic portion was washed with brine (50 mL), dried (MgSO4) and 
evaporated under reduced pressure to afford 0.69 g (67%) of 86 as a sticky, brown solid. IR 
spectroscopy indicated the absence of a characteristic cyano band at 2222 cm-1. 
 
2-Amino-6-fluoro-3,4-dihydroquinazoline Hydrochloride (87). The procedure for a 
similar compound327,334 was used to synthesize 87. 2-Amino-6-fluoroquinazolin-4(3H)-one 
(91) (0.50 g, 2.8 mmol) was added in a portionwise manner to a stirred solution of BH3•THF 
complex (1 M in THF, 11 mL, 11.0 mmol) at 0 °C (ice-bath) under an N2 atmosphere. To 
this, anhydrous THF (16 mL) was added. The stirred reaction mixture was heated at reflux 
for 1.2 h, allowed to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), 
and then heated at reflux for 35 min. The reaction mixture was allowed to cool to room 
temperature and basified with NaOH (15% as well as NaOH pellets, to pH 12). THF was 
evaporated under reduced pressure to give a white precipitate which was collected by 
filtration and upon recrystallization from EtOH/Et2O afforded 0.09 g (%) of 87 as a cream-
colored solid: mp 228-230 °C 1H NMR (DMSO-d6) δ 4.49 (s, 2H, ArCH2), 6.99-7.02 (m, 
1H, ArH), 7.09-7.13 (m, 2H, ArH), 7.68 (s, 2H, NH2), 8.55 (s, 1H, NH), 10.96 (s, 1H, NH). 
HRMS (ESI-TOF) calcd for C8H9N3F [M + H] 166.0775, found 166.0761. 
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2-Amino-6-bromo-3,4-dihydroquinazoline Hydrobromide (88). The procedure for a 
similar compound328 was used to synthesize 88. Cyanogen bromide (3 M solution in CH2Cl2, 
2 mL, 6.0 mmol) was added to a stirred solution of 2-amino-5-bromobenzylamine (95) (0.80 
g, 4.0 mmol) in toluene (6 mL). The stirred reaction mixture was heated at reflux overnight 
and allowed to cool to room temperature. This was followed by removal of toluene under 
reduced pressure to give a sticky, yellow solid. The residue was washed with H2O (50 mL) 
and the solid was collected by filtration and washed with H2O (30 mL) to afford 0.40 g (32%) 
of 85 as a beige solid: mp 196-198 °C. 1H NMR 400 MHz (DMSO-d6) δ 4.49 (s, 2H. CH2), 
6.95-6.97 (d, J = 8 Hz, 1H, ArH), 7.44-7.46 (t, J = 4 Hz, 2H, ArH), 7.57 (s, 2H, NH2), 8.30 
(s, 1H, NH), 10.52 (s, 1H, NH). Anal. Calcd for (C8H8N3Br·0.75HBr) C, 33.51; H, 3.08; N, 
14.65. Found: C, 33.23; H, 3.00; N, 14.35.    
 
2-Amino-6-iodo-3,4-dihydroquinazoline (89). The procedure for a similar compound328 
was used to synthesize 89. Cyanogen bromide (3 M solution in CH2Cl2, 0.4 mL, 1.2 mmol) 
was added to a stirred solution of 2-amino-5-iodobenzylamine (96) (0.20 g, 0.8 mmol) in 
EtOH (6 mL). The stirred reaction mixture was heated at reflux for 3.5 h and allowed to cool 
to room temperature. This was followed by removal of EtOH under reduced pressure to give 
a sticky, yellow solid. The residue was washed with H2O (10 mL) and the aqueous portion 
was basified with NaOH (1 N, to pH ~10-11) and extracted with CH2Cl2 (4 x 25 mL). The 
combined organic portion was washed with H2O (30 mL), dried (MgSO4) and evaporated 
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under reduced pressure to afford 0.04 g (18%) of 89 as a yellow-colored oil. A saturated 
solution of gaseous HCl in anhydrous EtOH was added in a dropwise manner at 0 °C (ice-
bath) to a stirred solution of the oil (0.04 g, 4.9 mmol) in EtOH (5 mL). Both the 
hydrochloride and nitrate salt were hygroscopic and the compound was converted back to 
the free base to afford 0.01 g (5%) of 89 as a yellow solid: mp 196-198 °C. 1H NMR 400 
MHz (DMSO-d6) δ 4.45 (s, 2H. CH2), 6.79-6.81 (d, J = 8 Hz, 1H, ArH), 7.56-7.60 (m, 3H, 
ArH), 8.29 (s, 1H, NH), 10.49 (s, 1H, NH). HRMS (ESI-TOF) calcd for C8H8N3I [M + H] 
272.9763, found 272.9902. 
 
6-Fluoroisatoic anhydride (91). A reported procedure for the same compound333 was used 
to synthesize 91. Urea-hydrogen peroxide complex (0.74 g, 7.9 mmol) and 3 drops of H2SO4 
were added to a solution of 5-fluorolisatin (90) (1.00 g, 6.1 mmol) in 8 mL of HCOOH. The 
reaction mixture was then sonicated for 45 min with occasional stirring.  The urea-H2O2 
complex was prepared according to a reported procedure332 by adding urea (4.00 g, 66.6 
mmol) portion wise to H2O2 (30% aq., 11 mL) heated to 55 °C taking care to not let the 
temperature increase beyond 60 °C. The reaction mixture was poured on to an evaporating 
dish and left overnight. The solid obtained was collected by filtration to afford 4.87 g (78%) 
of the urea-H2O2 complex as a white solid. The solid precipitated as a result of sonication 
was collected by filtration to afford 1.03 g (94%) of 91 as an orange solid: mp 256-258 °C 
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(lit.333 mp: 238-240 °C (HOAc)). IR (solid, cm-1) 671, 687, 734, 785, 846, 893, 932, 1002, 
1038, 1121, 1145, 1224, 1257, 1268, 1336, 1424, 1515, 1633, 1693, 1749, 3185. 
 
2-Amino-6-fluoroquinazolin-4(3H)-one (92). The procedure for a similar compound327,334 
was used to synthesize 92. S-methylisothiourea sulfate (0.92 g, 3.3 mmol) and Na2CO3 (0.37 
g, 3.5 mmol) were added to a stirred solution of 6-fluoroisatoic anhydride (91) (0.60 g, 3.3 
mmol) in MeCN (80% aq., 10 mL). The stirred reaction mixture was heated at reflux for 1.5 
h to give a green solution, then allowed to cool to room temperature. The solid obtained was 
collected by filtration and washed with 80% aq. MeCN (30 mL) to afford 0.53 g (89%) of 
92 as a cream-colored solid: mp 370 °C. 1H NMR (DMSO-d6) δ 6.39 (s, 1H, NH), 7.22-7.26 
(q, J = 4 Hz, 1H, ArH), 7.42-7.47 (m, 1H, ArH) 7.53-7.56 (dd, 1H, ArH). IR (solid, cm-1) 
668, 693, 734, 791, 823, 886, 937, 1074, 1127, 1152, 1214, 1251, 1347, 1387, 1479, 1515, 
1569, 1659, 2769, 3039, 3334. 
 
2-Amino-5-bromobenzylamine (95). The procedure for a similar compound329 was used to 
synthesize 95. A complex of BH3·THF (1 M in THF, 20 mL, 20.3 mmol) was added in a 
dropwise manner at 0 °C (ice-bath) to 2-amino-5-bromobenzonitrile (93) (1.00 g, 5.1 mmol) 
under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 2.5 h, allowed 
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at 
reflux for 30 min. The reaction mixture was allowed to cool to room temperature and then 
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to 0 °C (ice bath) and basified with NaOH (3 N, to pH 12) and extracted with CH2Cl2 (3 x 
25 mL). The combined organic portion was washed with H2O (2 x 100 mL), dried (MgSO4) 
and evaporated under reduced pressure to afford 0.81 g (79%) of 95 as a white waxy solid: 
mp 110-112 °C. IR spectroscopy indicated the absence of a characteristic cyano band at 
2218.22 cm-1. 
 
2-Amino-5-iodobenzylamine (96). The procedure for a similar compound329 was used to 
synthesize 96. A complex of BH3·THF (1 M in THF, 7 mL, 6.6 mmol) was added in a 
dropwise manner at 0 °C (ice-bath) to 2-amino-5-bromobenzonitrile (94) (0.40 g, 1.6 mmol) 
under an N2 atmosphere. The stirred reaction mixture was heated at reflux overnight, allowed 
to cool to room temperature, quenched by addition of HCl (6 N, to pH 2), and heated at 
reflux for 40 min. The reaction mixture was allowed to cool to room temperature and then 
to 0 °C (ice bath) and basified with NaOH (3 N, to pH ~10-12) and extracted with CH2Cl2 
(2 x 25 mL). The combined organic portion was washed with H2O (30 mL), dried (MgSO4) 
and evaporated under reduced pressure to afford 0.39 g (95%) of 96 as a yellowish brown 
solid: mp 122-126 °C. IR spectroscopy indicated the absence of a characteristic cyano band 
at 2227 cm-1. 
 
4-tert-Butylphenylguanidine Nitrate (101). A reported procedure for the same 
compound336 was used to synthesize 101. Cyanamide (0.20 g, 4.9 mmol) was added to a 
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stirred solution of 4-tert-butylaniline hydrochloride (110) (0.43 g, 2.3 mmol) in EtOH (2 
mL). The stirred reaction mixture was heated at reflux overnight, then allowed to cool to 
room temperature followed by removal of EtOH under reduced pressure. The residue was 
dissolved in H2O (5 mL) followed by addition of an excess of NH4NO3 resulting in 
precipitation of a white solid. The solvent was removed under reduced pressure to afford 
0.90 g of white solid, which upon two recrystallizations from EtOH, yielded 0.20 g (34%) 
of 101 as a white crystalline powder: mp 181-183 °C (lit.34 mp 183-185 °C). 1H NMR 
(DMSO-d6) δ 1.36 (s, 9H, C(CH3)3), 7.22-7.25 (d, J = 12 Hz, 4H, NH), 7.52-7.54 (d, J = 8 
Hz, 4H, ArH).  
 
4-Fluorophenylguanidine Nitrate (103). The procedure for a similar compound336 was 
used to synthesize 103. Cyanamide (0.81 g, 19.2 mmol) was added to a stirred solution of 4-
fluoroaniline hydrochloride (107) (1.40 g, 9.5 mmol) in EtOH (8 mL). The stirred reaction 
mixture was heated at reflux overnight, then allowed to cool to room temperature followed 
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL) 
followed by addition of excess NH4NO3 (2.19 g, 27.4 mmol) resulting in precipitation of a 
pale violet solid. The solid was collected by filtration to afford 1.54 g of a pale violet solid 
which upon two recrystallizations from i-PrOH/MeOH, yielded 1.00 g (37%) of 103 as a 
pale violet crystalline powder: mp 182-185 °C 1H NMR (DMSO-d6) δ 7.28-7.29 (d, J = 4 
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Hz, 2H, ArH), 7.30 (s, 4H, NH2), 9.50 (s, 1H, NH). Anal. Calcd for (C7H8N3F·1HNO3) C, 
38.89; H, 4.20; N, 25.92. Found: C, 39.14; H, 4.12; N, 25.90.    
 
4-Bromophenylguanidine Nitrate (104). The procedure for a similar compound336 was 
used to synthesize 104. Cyanamide (0.63 g, 15.1 mmol) was added to a stirred solution of 4-
bromoaniline hydrochloride (112) (1.50 g, 7.2 mmol) in EtOH (6 mL). The stirred reaction 
mixture was heated at reflux overnight, then allowed to cool to room temperature followed 
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL) 
followed by addition of excess NH4NO3 (1.30 g, 16.2 mmol) resulting in precipitation of a 
pale brown solid. The solid was collected by filtration to afford 1.23 g of a pale violet solid, 
which upon recrystallization from i-PrOH/MeOH, yielded 0.77 g (37%) of 104 as a cream-
colored powder: mp 188-190 °C 1H NMR (DMSO-d6) δ 7.20-7.22 (d, J = 8 Hz, 2H, ArH), 
7.43 (s, 4H, NH2), 7.62-7.64 (d, J = 8 Hz, 2H, ArH), 9.62 (s, 1H, NH). Anal. Calcd for 
(C7H8N3Br·1HNO3) C, 30.34; H, 3.27; N, 20.22. Found: C, 30.63; H, 3.16; N, 20.17.    
 
4-Iodophenylguanidine Nitrate (105). The procedure for a similar compound336 was used 
to synthesize 105. Cyanamide (0.35 g, 8.2 mmol) was added to a stirred solution of 4-
iodoaniline hydrochloride (113) (1.00 g, 3.9 mmol) in EtOH (6 mL). The stirred reaction 
mixture was heated at reflux overnight, then allowed to cool to room temperature followed 
by removal of EtOH under reduced pressure. The residue was dissolved in EtOH (2 mL) 
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followed by addition of excess of NH4NO3 (0.81 g, 10.2 mmol) resulting in precipitation of 
a pale violet solid. The solid was collected by filtration to afford 1.16 g of a pale violet solid, 
which upon two recrystallizations from i-PrOH/MeOH, yielded 0.49 g (45%) of 105 as a 
pale violet crystalline powder: mp 182-184 °C. 1H NMR (DMSO-d6) δ 7.05-7.07 (d, J = 8 
Hz, 2H, ArH), 7.43 (s, 4H, NH2), 7.77-7.80 (d, J = 12 Hz, 2H, ArH), 9.64 (s, 1H, NH). Anal. 
Calcd for (C7H8N3I·1HNO3) C, 25.94; H, 2.80; N, 17.29. Found: C, 26.20; H, 2.80; N, 17.31.    
 
4-tert-Butylaniline Hydrochloride (110). A saturated solution of gaseous HCl in anhydrous 
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-tert-
butylaniline (106) (0.74 g, 4.9 mmol) in Et2O (2 mL). The precipitate was collected by 
filtration to yield 0.89 g (97%) of 110 as a white-colored solid: mp 188-192 °C (lit. mp 
358268-270 °C, 359270-274 °C). The crude 110 was used without purification in the next step. 
 
4-Fluoroaniline Hydrochloride (111). A saturated solution of gaseous HCl in anhydrous 
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-
fluoroaniline (107) (1.00 g, 9.0 mmol) in Et2O (6 mL). The precipitate was collected by 
filtration to yield 1.40 g of 111 as a white-colored solid: mp 198-200 °C (lit. mp 360235-237 
°C, 361246-248 °C, 362253 °C). The crude 111 was used without purification in the next step. 
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4-Bromoaniline Hydrochloride (112). A saturated solution of gaseous HCl in anhydrous 
Et2O was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-
bromoaniline (108) (1.00 g, 5.8 mmol) in Et2O (6 mL). The precipitate was collected by 
filtration to yield 1.66 g of a crude white solid 112 that was used in the next step without 
further purification: mp 216-218 °C (lit.363 mp 190 °C).  
 
4-Iodoaniline Hydrochloride (113). A saturated solution of gaseous HCl in anhydrous Et2O 
was added in a dropwise manner at 0 °C (ice-bath) to a stirred solution of 4-iodoaniline (109) 
(4.10 g, 18.7 mmol) in Et2O (6 mL). The precipitate was collected by filtration to yield 1.46 
g (30%) of 113 as a pale violet-colored solid: mp 200-210 °C. The crude 113 was used 
without purification in the next step.  
 
B. Molecular modeling studies and HINT analysis: 
1. Homology modeling:  
i. hSERT: 
Sequences of the template drosophila melanogaster dopamine transporter (dDAT, 
PDB ID: 4M48)317 were retrieved as FASTA files from the Protein Databank (PDB) at 
hhtp://www.rcsb.org. The sequences were prepared prior to alignment by removal of water 
molecules, ligands and/or other molecules used to facilitate crystallization (such as 
surfactants). The sequence of the human serotonin transporter (hSERT; UniProt accession 
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codes: P31645) was retrieved as a FASTA files from the Universal Protein Resource 
(UniPort) Database. The alignment published by Sakloth et al.320 was used to generate the 
models. Three dimensional homology models of hSERT were built using Modeller v9.14364 
(University of California San Francisco, San Francisco, CA) using dDAT as the template 
and were supported by docking the known substrate 5-HT (1) and known reuptake inhibitor 
FLX (3). 
 
ii. OCT3: 
Sequences of the templates, lactose permease (LacY, PDB ID: 1PV6)292 and 
inorganic phosphate transporter (PiPT, PDB ID: 4J05)343 were retrieved as FASTA files 
from the Protein Databank (PDB) at http://www.rcsb.org. The sequences were prepared by 
removal of water molecules, ligands and/or other molecules used to facilitate crystallization 
(such as surfactants). The sequences retrieved consisted of a dimer and this was considered 
a by-product of crystallization. Hence, only residues from one monomer was retained. The 
sequences of the proteins of interest, human and mouse OCT3 (UniProt accession codes: 
O75751 and Q9WTW5, respectively), were retrieved as FASTA files from the Universal 
Protein Resource (UniPort) Database. The sequences (template and protein of interest) were 
aligned using Clustal W 2.0.344 Three dimensional homology models of human and mouse 
OCT3 were built using Modeller v9.14364 (University of California San Francisco, San 
Francisco, CA) using PiPT as the template. The homology models built were supported by 
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docking the known model substrate MPP+ (53). Ramachandran plots346 were generated to 
examine the models and indicated the percentage of amino acid residues in each of the 
following region - most favored (red), additional allowed region (yellow), generously 
allowed region (light yellow) and disallowed region (white). No amino acids from the 
substrate binding region of hOCT3 or mOCT3 were found in the disallowed region.  
 
2. Docking studies:  
i. hSERT: 
The ligands (A6CDQ (65), A7CDQ (66), 5-HT (1) and FLX (3)) were sketched in 
and energy minimized using Gasteiger-Hückel charges (dielectric constant = 4.0) in SYBYL 
X-2.1 (Tripos International). Docking studies at hSERT were conducted using GOLD suite 
5.2345 (Cambridge Crystallographic Data Centre, Cambridge, UK), an automated genetic 
algorithm docking program with GOLD score as the chosen scoring function. The binding 
site was defined as a spherical region of radius 5 Å using Asp98 and Ile172 in the central 
substrate (S1) site of hSERT. The docking poses were clustered using a script on the basis 
of similarity of poses within a RMSD of 2 Å. The clusters were visually inspected and on 
the basis of orientation of the ligands in the binding region, the solution with the best fit was 
merged into the transporter. The ligand-transporter complexes were energy minimized using 
the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric constant = 
4.0) in SYBYL X-2.1 (Tripos International).      
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ii. OCT3: 
The ligands (all 2-aminodihydroquinazoline and ring-opened phenylguanidine 
analogs) were sketched in and energy minimized using Gasteiger-Hückel charges (dielectric 
constant = 4.0) in SYBYL X-2.1 (Tripos International). Docking studies at both human and 
mouse OCT3 were conducted using GOLD suite 5.2345 (Cambridge Crystallographic Data 
Centre, Cambridge, UK), an automated genetic algorithm docking program with GOLD 
score as the chosen scoring function. The binding site was defined as a spherical region of 
radius 12 Å with the delta-carbon atom of Asp478 and Asp473 in hOCT3 and mOCT3, 
respectively as the center. The docking poses were clustered using a script on the basis of 
similarity of poses within a RMSD of 2 Å. The clusters were visually inspected and on the 
basis of orientation of the ligands in the binding region, the solution with the best fit was 
merged into the transporter. The ligand-transporter complexes were energy minimized using 
the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric constant = 
4.0) in SYBYL X-2.1 (Tripos International) and the models analyzed using PROCHECK.      
 
iii. HINT analysis:  
The chosen ligand-transporter complexes were scored using the HINT (Hydropathic 
INTeraction) program326 in SYBYL 8.1, to quantify the interactions observed in molecular 
modeling studies. The protein was partitioned using the dictionary option while the ligand 
was partitioned using the calculate option using the default settings. The atom-based 
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breakdown of HINT score was analyzed to determine the contributions of the individual 
atoms to the interactions with amino acid residues at the binding region of hSERT and 
hOCT3. 
 
C. Radioligand binding studies 
The Ki values for A6CDQ (65) and A7CDQ (66) at hSERT were generously provided 
by the National Institute of Mental Health's Psychoactive Drug Screening Program, # 
HHSN-271-2013-00017-C (NIMH PDSP). 
 
D. Electrophysiological studies  
1. 5-HT3 receptors:  
Electrophysiological studies at 5-HT3 receptors were conducted in the Schulte laboratory at 
University of Sciences (Philadelphia, PA) by Shailesh Khatri (graduate student).  
 
i. Expression:  
Stage IV oocytes were harvested from the ovarian lobes of Xenopus laevis frogs 
following established protocols.35 The selected oocytes were injected with cRNA (50 nL per 
oocyte) for the m5-HT3A receptors. The cRNA was prepared using the mMACHINETM High 
Yield Capped RNA Transcription Kit (Ambion, TX). After injection, the oocytes were 
incubated for a period of 2-4 days at 19 °C.  
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ii. Two-electrode voltage-clamp:  
The experiments were conducted following previously established protocols.35 The 
oocytes expressing m5-HT3A receptors were voltage-clamped (–60 mV). Electrodes 
employed possessed a resistance of 1–2 MΩ and were filled with 3 M KCl. The buffer used in 
the experiments was the ND-96 recording buffer. This buffer consists of the following 
components: 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4. 
The ND-96 buffer was used to make solutions of the test compound, A7CDQ (66). A7CDQ 
(66) displayed an inability to induce currents at m5-HT3A receptors, but had an effect on 5-
HT-induced responses at m5-HT3A receptors. Prior to perfusion with a mixture of 5-HT and 
test compound, A7CDQ (66) at concentrations ranging from 0.1-30 µM, the oocytes were 
perfused with 5-HT (2.2 µM).  
 
iii. Analysis:  
The uninhibited 5-HT (2.2 µM) response was used to normalize all other peak current 
amplitudes. The data obtained from the electrical recordings were used to generate 
concentration-response curves in GraphPad Prism (GraphPad Software Inc. La Jolla, CA). 
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2. hSERT:  
Electrophysiological studies at hSERT were conducted in the De Felice laboratory at 
Virginia Commonwealth University (Richmond, VA) by Dr. Ernesto Solis Jr. (postdoctoral 
fellow).  
 
i. Expression:  
Adult Xenopus laevis females were used to harvest oocytes based on established 
protocols.365 After isolation, oocytes belonging to Stage V-VI were selected for cRNA 
injection within 24 h. The mMessage Machine T7 kit (Ambion Inc., Austin, TX) was used 
to transcribe cRNA from the pOTV vector. This was followed by injection of oocytes with 
hSERT cRNA (32.2 ng) (Nanoject AutoOocyteInjector, Drummond Scientific Co., 
Broomall, PA) and incubation at 18 °C for 4-12 days. The incubation was carried out in the 
presence of Ringers solution that was supplemented with sodium pyruvate (550 µg/mL), 
streptomycin (100 µg/mL), tetracycline (50 µg/mL) and 5% dialyzed horse serum. 
 
ii. Two-electrode voltage-clamp:  
The methodology for the two-electrode voltage-clamp (TEVC) experiments were 
followed from previously established procedures.366 Electrodes employed in electrical 
recordings possessed resistances from 1-5 MΩ and were filled with 3 M KCl. Oocytes 
expressing hSERT were voltage-clamped (–60 mV) with a GeneClamp 500 (Axon 
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Instruments). The experiment was conducted at room temperature (23-25 °C). Test 
compounds, A6CDQ (65) and A7CDQ (66), were perfused following perfusion of buffer 
which was composed of 120 mM NaCl, 7.5 mM HEPES, 5.4 mM KGluconate, 1.2 mM 
CaGluconate, pH 7.4.   
 
iii. Analysis:  
5-HT-induced current measured at a concentration of 5 µM was used to normalize 
peak current amplitudes of test compounds, A6CDQ (65) and A7CDQ (66). The data 
obtained were fitted to the Hill 1 equation, y = Vmax + (Vmin - Vmax) * xn / (kn + xn) and used 
to generate concentration-response curves in Origin 8.0 (OriginLab Corporation, 
Northampton, MA). The equation gave the Km and Vmax values for the test compounds, 
A6CDQ (65) and A7CDQ (66). GraphPad Prism (GraphPad Software Inc. La Jolla, CA) was 
utilized to determine the statistical significance of differences in Km observed in the presence 
and absence of A7CDQ (66) using one-way analysis of variance (ANOVA). 
 
E. Functional studies at OCTs:  
Functional studies were conducted in the Sweet laboratory at Virginia Commonwealth 
University (Richmond, VA) by Dr. Xiaolei Pan (graduate student).  
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1. Expression: 
The human and mouse orthologs of OCT1-3 were stably expressed in human 
embryonic kidney 293 (HEK293) cells. Empty vector transferred HEK293 cells were used 
as background. Following previously established procedures,256,265 the cells were incubated 
at 37 °C in Dulbecco’s modified eagle medium (DMEM), high glucose and additionally 
supplemented with 10% serum and 1% Penicillin/Streptomycin. 
 
2. Drugs: 
[3H]MPP+ (53) bought from PerkinElmer Life And Analytical Science (Waltham, 
MA) was used as a substrate to test the activities of the compounds. Unlabeled MPP+ (53) 
was bought from Sigma-Aldrich (Saint Louis, MO). Compounds A5CDQ (67), A6CDQ 
(65), A7CDQ (66), 3-CPG (97), 4-CPG (98), PG (99), 4-MePG (100) and 4-BnPG (102) 
were available from previous studies for testing. Compounds A8CDQ (68), ADQ (69), 
A5MDQ (75), A6MDQ (74), A7MDQ (76), A8MDQ (77), A6FDQ (87), A6BrDQ (88), 4-
t-BuPG (101), 4-FPG (103), 4-BrPG (104) and 4-IPG (105) were synthesized for the current 
study.   
 
3. Cell accumulation assay: 
HEK293 cells seeded into 24-well tissue culture plates for a period of 48 hours were 
used to conduct the experiments. The cells were treated with unlabeled MPP+ (53) (1 µM) 
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after a 10 min pre-treatment with transport buffer (500 µL). To the unlabeled MPP+ (53) 
[3H]MPP+ (0.25 µCi/mL) was added. The compounds were tested at various concentrations 
(0.01 to 200 µM) by being applied simultaneously as spiked MPP+ (53). The cells were lysed 
and the amount of [3H]MPP+ (53) taken up by the cells were determined by measuring 
radioactivity using liquid scintillation counting of the cell lysates. The experiments were 
conducted in triplicate.  
 
4. Analysis: 
The data obtained were used to generate concentration-response curves in GraphPad 
Prism (GraphPad Software Inc. La Jolla, CA) utilizing the log(inhibitor) vs. response model. 
Based on the concentration-response curves the inhibitory potency (IC50) was calculated for 
each compound and reported as the average of three values (IC50 ± SEM) in µM.      
 
F. Behavioral studies: 
 
1. Animals:  
Male ICR mice (20-24 g) from Harlan Laboratories Inc. (Indianapolis, IN) were used 
for the mouse TST. The animals were housed and maintained in solid-bottom plastic cages 
in a temperature (~22 °C)- and humidity (~50 %)-controlled environment with a standard 
12:12 h dark:light cycle. No restrictions were placed on food and water, which were 
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available ad lib. After an acclimatization period of 2 days the experiments were conducted 
in accordance to IACUC protocol AM10399 with the standards set by the Institutional 
Animal Care and Use Committee (IACUC) of Virginia Commonwealth University (VCU) 
and the National Institute of Health’s (NIH) Guide for Care and Use of Laboratory Animals.  
 
2. Drugs:  
Fluoxetine hydrochloride (Prozac®, Batch 4A/80352; Eli Lily) was purchased from 
Tocris. A5CDQ (67), A6MDQ (74), A6FDQ (84) and A8CDQ (68) were used as 
hydrochloride salts. 4-t-BuPG (101) was used as a nitrate salt. A5CDQ (67) was available 
from previous studies for testing. A6MDQ (74), A6FDQ (84), A8CDQ (68) and 4-t-BuPG 
(101) were synthesized for the current study. Solutions of all compounds were prepared by 
dissolving in 0.9% saline and were administered via intraperitoneal (ip) injections in a total 
volume of 10 mL/kg body weight. The solutions were stored overnight in the refrigerator 
and were used over a three-day period.     
 
3. Mouse tail suspension test (TST):  
The experiment was conducted by following protocols previously established by the 
Dukat laboratory.35 Mice were brought to the room where the experiment was conducted at 
least 2 h prior to start of the experiment. Mice were marked and weighed 1 h prior to the 
experiment which was conducted between 1200 to 1700 h. Mice were suspended ~1.5 cm 
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from the tips of their tails from a bar at a distance of 60 cm from the bench using industrial 
grade Duct Tape (2 x ½ inch) after the pretreatment time. The experiments were conducted 
in a blind manner as the experimentor was unaware of the identity of the drug as well as 
dose being injected. The mice were injected with saline (10 mL/kg; 30 min pre-treatment 
time), fluoxetine hydrochloride (1.0, 3.0, 10, 15 or 20 mg/kg; 30 min pre-treatment time), 
A5CDQ (67) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time), ADQ (69) (0.1, 
0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time), A6MDQ (74) (0.1, 0.3, 1.0, 3.0 or 
10 mg/kg; 30 min pre-treatment time), A6FDQ (87) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 
min pre-treatment time), A8CDQ (68) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-
treatment time), 4-CPG (98) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time) 
and 4-t-BuPG (101) (0.1, 0.3, 1.0, 3.0, 10 or 30 mg/kg; 30 min pre-treatment time) using a 
random number table.367 The mice were administered the compounds via intraperitoneal (ip) 
injections and tested only once, and each compound was tested in 8-11 mice (n = 8-11 
mice/treatment). The experiment (duration of 6 mins) was video recorded using a Canon 
Rebel T3i camera. The immobility times for each compound were determined by viewing 
each mouse’s 6 min video recording and using a stopwatch to record the immobility times. 
Each mouse was scored in triplicate and a mean of these scores was utilized. Immobility was 
defined as lack of movement or passive swaying. Mobility was defined as running motions, 
body jerks, movement of only hind or fore legs, or attempts to catch its own tail. The mice 
were sacrificed using a CO2 chamber at the end of the experiment. 
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4. Locomotor activity assay:  
The experiment was conducted by following protocols previously established by the 
Dukat laboratory.35 Mice were brought to the room where the experiment was conducted at 
least 2 h prior to start of the experiment. Mice were marked and weighed 30 min prior to the 
experiment, which was conducted between 1000 to 1500 h. Mice were placed in TruScan 
locomotor activity chambers immediately after injections (0 min pre-treatment time). The 
mice were injected with saline (10 mL/kg; 0 min pre-injection time), A5CDQ (67) (1.0 
mg/kg; 0 min pre-injection time), A6MDQ (74) (3.0 mg/kg; 0 min pre-injection time) or 
A6FDQ (87) (3.0 mg/kg; 0 min pre-injection time) using a random number table.367 The 
mice were administered the compounds via intraperitoneal (ip) injections and tested only 
once, and each compound was tested in 9 mice (n = 9 mice/treatment). The experiment 
(duration of 45 mins) was conducted by placing injected mice in TruScan activity system 
(Coulbourn Instruments, Allentown, PA) photocell arena chambers (model E63-10; 26 cm 
x 26 cm x 39 cm). Since the walls of the chamber were transparent black screens were placed 
between the individual chambers to prevent the mice from being influenced by each other. 
The movement of the mice were tracked by two infrared photodetectors and the information 
was collated using the accompanying software. After each run, the TruScan activity 
chambers were wiped down with a detergent solution and the plates washed and dried prior 
to the next run. The following parameters were analyzed: movement episodes, movement 
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time (s), movement distance (cm), ambulatory velocity (cm/s), margin distance (cm), margin 
time (s), center distance (cm), center time (s), center entries, jumps and vertical plane (V-
plane) enteries. The mice were sacrificed using a CO2 chamber at the end of the experiment.  
 
5. Analysis:  
The data collected were analyzed using one-way analysis of variance (ANOVA) 
followed by Dunnett’s post-hoc test for the mouse TST and unpaired two-tailed t test for the 
locomotor activity assay in GraphPad Prism6 (GraphPad Software Inc. La Jolla, CA). 
Outliers were identified using GraphPad QuickCalcs which utilized Grubb’s test.    
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APPENDIX A 
 
Note added in proof: After the dissertation was submitted to the committee, additional 
biological data became available. This allowed QSAR studies to be conducted. This 
appendix material was presented to the committee and was available for my oral defense. 
New biological data are presented in bold red font, and a QSAR discussion is provided. 
 
 
Table A1. Inhibitory potencies of methyl-substituted 2-aminodihydroquinazoline analogs at 
hOCT1-3 determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R hOCT1 hOCT2 hOCT3 
 
ADQ      (69) H 14.5 ± 3.5  46.5 ± 1.1 12.2 ± 3.4 
A5MDQ (75) 5-CH3   4.6 ± 0.6     26.4 ± 0.7   0.5 ± 0.0   
A6MDQ (74) 6-CH3   8.2 ± 2.2  12.1 ± 0.3   2.0 ± 0.4 
A7MDQ (76) 7-CH3   6.3 ± 1.3    12.1 ± 3.2    8.4 ± 4.3 
A8MDQ (77) 8-CH3   4.5 ± 1.6      35.1 ± 11.6   3.7 ± 0.3 
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Table A2. Comparison of inhibitory potencies of chloro- and methyl-substituted 2-
aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of 
[3H]MPP+ (53). 
   IC50 ± SEM (µM)   
 Ligand R hOCT3 Ligand R hOCT3 
 
ADQ      (69) H 12.2 ± 3.4 ADQ     (69) H 12.2 ± 3.4 
A5MDQ (75) 5-CH3   0.5 ± 0.0   A5CDQ (67) 5-Cl   0.9 ± 0.2  
A6MDQ (74)  6-CH3   2.0 ± 0.4 A6CDQ (65) 6-Cl   3.9 ± 2.4 
A7MDQ (76) 7-CH3   8.4 ± 4.3   A7CDQ (66) 7-Cl   5.9 ± 3.9 
A8MDQ (77) 8-CH3   3.7 ± 0.3 A8CDQ (68) 8-Cl   4.9 ± 0.2 
 
 
 
Table A3. Inhibitory potencies of unsubstituted and 6-halo-substituted 2-
aminodihydroquinazoline analogs at hOCT1-3 determined by measuring uptake of 
[3H]MPP+ (53). 
   IC50 ± SEM (µM) 
Ligand R hOCT1 hOCT2 hOCT3 
ADQ       (69)     H 14.5 ± 3.5 46.5 ± 1.1  12.2 ± 3.4 
A6CDQ  (65) 6-Cl   3.0 ± 0.8 16.4 ± 4.7 3.9 ± 2.4 
A6FDQ   (87) 6-F   1.3 ± 0.1 11.9± 0.2    0.5 ± 0.0 
A6BrDQ (88) 6-Br     2.7 ± 0.8      9.3 ± 1.1    1.9 ± 0.2 
A6IDQ    (89) 6-I ND 
 
 
 
 
NHN
NH2
R
7
6
5
8
NHN
NH2
R
7
6
5
8
  201 
Table A4. Inhibitory potencies of ring opened 2-aminodihydroquinazolines, the 
phenylguanidine analogs at hOCT1-3 determined by measuring uptake of [3H]MPP+ (53). 
   IC50 ± SEM (µM) 
 Ligand R hOCT1 hOCT2 hOCT3 
 PG          (99) H     41.1 ± 14.4     89.0 ± 12.2     99.8 ± 2.8 
3-CPG    (97) 3-Cl     13.7 ± 0.8     60.5 ± 4.1       7.6 ± 0.7 
4-CPG    (98) 4-Cl     10.0 ± 0.6     18.9 ± 0.1       2.8 ± 0.7 
4-MePG  (100) 4-CH3     10.0 ± 0.2       9.3 ± 4.8       4.6 ± 1.1 
4-t-BuPG (101) 4-C(CH3)3       0.9 ± 0.2       6.3 ± 3.4       2.2 ± 0.2 
4-BnPG  (102) 4-CH2C6H5   761.4 ± 254.7     96.2 ± 8.0   452.5 ± 87.9 
4-FPG     (103) 4-F     22.6 ± 0.8    48.3 ± 18.9 27.8 ± 11.0 
4-BrPG   (104) 4-Br 6.3 ± 1.0  11.3 ± 3.2 4.8 ± 0.7 
4-IPG      (105) 4-I       2.4 ± 0.3    4.4 ± 1.5 1.5 ± 0.3 
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Quantitative structure-activity relationship (QSAR) studies: 
  
Hansch analysis, a type of QSAR, relates activities of a congeneric series of 
compounds to the physicochemical properties of the substituents. A number of 
physicochemical properties such as lipophilic (π) and electronic properties, Verloop’s steric 
parameters368 as well as volume and polarizability of substituent could be considered for the 
analysis. A detailed list of the parameters used in the current study is shown in Table A5 and 
their values for the phenylguanidine series (98-105) are shown in Table A6. 
To determine the role of the substituent at the 4-position of the phenylguanidine 
analogs, a Hansch analysis was performed on the following sets of compounds:  
Set I: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105)  
Set II: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100)  
Set III: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-t-BuPG (101)  
Set IV: PG (99), 4-FPG (103), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-t-BuPG (101), 
4-BnPG (102)  
Set V: 2-aminodihydroquinazolines substituted at the 6-position and their corresponding 4-
substituted phenylguanidine analogs  
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Table A5. Description of parameters used for the QSAR study 
Parameter Description 
π Hydrophobic constant of the substituent331 
σ Hammett electronic constant (for para substituents)331 
L Verloop length of the substituent368 
B1 Verloop minimum width of the substituent368 
B5 Verloop maximum width of the substituent368 
Volume Solvent accessible volume of the compounda 
Polarizability Polarizability of the compoundb 
aCalculated for the entire molecule using SYBYL X-2.1 
bCalculated for the entire molecule using ChemSketch 2016.1.1 (Advanced Chemistry 
Development Inc.) 
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Table A6. Values for the different parameters used for the Hansch analysis type of QSAR 
studied conducted on the phenylfuanidine analogs (98-105).  
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Set I: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105)  
 
Table A7. Summary of the linear regression analysis conducted for the 4-halo-substituted 
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105)) 
(n = 5). 
Figure 
No. 
Equation 
No. 
QSAR Equation r F P 
A1 1 0.6093 (± 0.1021) x π – 2.511 (± 0.5203) 0.960    35.61 0.0094 
A2 2 0.1260 (± 0.03355) x σ – 0.4963 (± 0.1709) 0.908    14.10 0.0330 
A3 3 32.88 (± 5.282) x Volume + 342.2 (± 26.92) 0.963    38.74 0.0084 
A4 4 1.142 (± 0.1617) x L – 2.509 (± 0.8241) 0.971    49.85 0.0058 
A5 5 0.6042 (± 0.08055) x B1 – 1.402 (± 0.4105) 0.974    56.26 0.0049 
A6 6 0.6042 (± 0.08055) x B5 – 1.402 (± 0.4105) 0.974    56.26 0.0049 
A7 7 2.479 (± 0.7999) x Polarizability + 4.949 (± 4.076) 0.873     9.60 0.0533 
 
 
 
 
 
 
 
 
 
Figure A1. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
the hydrophobic constant (π) of the substituents (r = 0.960, n = 5, p = 0.0094). 
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Figure A2. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
Hammett constant (σ) of the substituents (r = 0.908, n = 5, p = 0.0330). 
 
 
 
 
 
Figure A3. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
volume of the compounds (r = 0.963, n = 5, p = 0.0084). 
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Figure A4. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
Verloop length (L) of the substituents (r = 0.971, n = 5, p = 0.0058). 
 
Figure A5. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
Verloop minimum width (B1) of the substituents (r = 0.974, n = 5, p = 0.0049). 
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Figure A6. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
Verloop maximum width (B5) of the substituents (r = 0.974, n = 5, p = 0.0049). 
 
Figure A7. Plot of pIC50 values of the 4-halo-substituted phenylguandine analogs versus 
polarizability of the compounds (r = 0.873, n = 5, p = 0.0533). 
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Set II: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100)  
 
Table A8. Summary of the linear regression analysis conducted for the 4-substituted 
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 
4-MePG (100)) (n = 6). 
Figure 
No. 
Equation 
No. 
QSAR Equation r F P 
A8 8 0.5909 (± 0.1020) x π – 2.448 (± 0.5238) 0.945 33.58 0.0044 
A9 9 0.09076 (± 0.1056) x σ – 0.3744 (± 0.5425) 0.393  0.739 0.4386 
A10 10 33.83 (± 5.278) x Volume + 338.9 (± 27.11) 0.955 41.08 0.0030 
A11 11 1.082 (± 0.2204) x L – 2.303 (± 1.132) 0.926 24.12 0.0080 
A12 12 0.5734 (± 0.1125) x B1 – 1.295 (± 0.5776) 0.931 26.00 0.0070 
A13 13 0.6263 (± 0.09375) x B5 – 1.478 (± 0.4816) 0.958 44.62 0.0026 
A14 14 2.385 (± 0.7338) x Polarizability + 5.272 (± 3.770) 0.852 10.56 0.0314 
 
 
 
Figure A8. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
hydrophobicity constant (π) of the substituents (r = 0.945, n = 6, p = 0.0044). 
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Figure A9. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus Hammett 
constant (σ) of the substituents (r = 0.393, n = 6, p = 0.4386). 
 
 
Figure A10. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus volume 
of the compounds (r = 0.955, n = 6, p = 0.0030). 
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Figure A11. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop length (L) of the substituents (r = 0.926, n = 6, p = 0.0080). 
 
  
 
Figure A12. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop minimum width (B1) of the substituents (r = 0.931, n = 6, p = 0.0070). 
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Figure A13. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop maximum width (B5) of the substituents (r = 0.958, n = 6, p = 0.0026).  
 
Figure A14. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
polarizability of the compounds (r = 0.852, n = 6, p = 0.0314).  
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Set III: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-
t-BuPG (101)  
 
Table A9. Summary of the linear regression analysis conducted for the 4-substituted 
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 
4-MePG (100), 4-t-BuPG (101)) (n = 7). 
Figure  
No. 
Equation 
No. 
QSAR Equation r F P 
A15 15 0.7899 (± 0.2771) x π – 3.323 (± 1.445) 0.787 8.126 0.0358 
A16 16 0.02857 (± 0.1216) x σ – 0.1008 (± 0.6340) 0.104 0.052 0.8235 
A17 17 61.81 (± 37.29) x Volume + 215.8 (± 194.4) 0.595 2.747 0.1583 
A18 18 1.136 (± 0.1996) x L – 2.538 (± 1.041) 0.931 32.38 0.0023 
A19 19 0.6910 (± 0.1825) x B1 – 1.813 (± 0.9516) 0.861 14.34 0.0128 
A20 20 0.7923 (± 0.2336) x B5 – 2.209 (± 1.218) 0.835 11.51 0.0194 
A21 21 3.127 (± 1.162) x Polarizability + 2.009 (± 6.058) 0.769 7.243 0.0432 
 
 
Figure A15. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
hydrophobicity constant (π) of the substituents (r = 0.787, n = 7, p = 0.0358). 
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Figure A16. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
Hammett constant (σ) of the substituents (r = 0.104, n = 7, p = 0.8235). 
 
 
 
 
 
Figure A17. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus volume 
of the compounds (r = 0.595, n = 7, p = 0.1583). 
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Figure A18. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop length (L) of the substituents (r = 0.931, n = 7, p = 0.0023) 
 
 
Figure A19. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop minimum width (B1) of the substituents (r = 0.861, n = 7, p = 0.0128). 
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Figure A20. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop maximum width (B5) of the substituents (r = 0.835, n = 7, p = 0.0194). 
 
 
Figure A21. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
polarizability of the compounds (r = 0.769, n = 7, p = 0.0432). 
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Set IV: PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 4-MePG (100), 4-
t-BuPG (101), 4-BnPG (102) 
 
Table A10. Summary of the linear regression analysis conducted for the 4-substituted 
phenylguanidine analogs (PG (99), 4-FPG (103), 4-CPG (98), 4-BrPG (104), 4-IPG (105), 
4-MePG (100), 4-t-BuPG (101), 4-BnPG (102)) (n = 8).  
 
Figure  
No. 
Equation 
No. 
QSAR Equation r F P 
A22 22 0.01229 (± 0.3457) x π + 0.8617 (± 1.735) 0.014 0.001 0.9728 
A23 23 0.05305 (± 0.07668) x σ – 0.2326 (± 0.3848) 0.272 0.479 0.5149 
A24 24 -28.19 (± 41.74) x Volume + 700.1 (± 209.5) 0.266 0.456 0.5247 
A25 25 0.4509 (± 0.2914) x L + 1.147 (± 1.463) 0.534 2.394 0.1728 
A26 26 0.3958 (± 0.1610) x B1 – 0.2241 (± 0.8082) 0.708 6.043 0.0492 
A27 27 -0.8194 (± 0.6368) x B5 + 6.466 (± 3.196) 0.465 1.656 0.2456 
A28 28 -1.156 (± 1.800) x Polarizability + 25.06 (± 9.035) 0.254 0.412 0.5446 
 
 
Figure A22. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
hydrophobicity constant (π) of the substituents (r = 0.014, n = 8, p = 0.9278). 
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Figure A23. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
Hammett constant (σ) of the substituents (r = 0.272, n = 8, p = 0.5149). 
 
 
 
 
Figure A24. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
volume of the compounds (r = 0.266, n = 8, p = 0.5247). 
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Figure A25. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop length (L) of the substituents (r = 0.534, n = 8, p = 0.1728). 
 
 
 
Figure A26. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop minimum width (B1) of the substituents (r = 0.708, n = 8, p = 0.0492). 
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Figure A27. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus 
Verloop maximum width (B5) of the substituents (r = 0.465, n = 8, p = 0.2456). 
 
 
Figure A28. Plot of pIC50 values of the 4-substituted phenylguandine analogs versus the 
polarizability of the compounds (r = 0.254, n = 8, p = 0.5446). 
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Table A11. Internal correlations between the various parameters (highlighted in bold blue 
font) for the phenylguandine series (98-105) as indicated by Pearson’s r.  
 π σ Volume L B1 B5 Polarizability 
π  -0.351 0.946 0.776 0.678 0.831 0.949 
σ -0.351  -0.537 0.154 0.001 -0.382 -0.349 
Volume 0.946 -0.537  0.539 0.439 0.919 0.958 
L 0.776 0.154 0.539  0.901 0.432 0.634 
B1 0.678 0.001 0.439 0.901  0.179 0.438 
B5 0.831 -0.382 0.919 0.432 0.179  0.946 
Polarizability 0.949 -0.349 0.958 0.634 0.438 0.946  
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Set V: 2-Aminodihydroquinazolines substituted at the 6-position and their corresponding 4-
substituted phenylguanidine analogs  
 
Table A12. Comparison of inhibitory potencies of 4-substitued phenylguanidines (98-100, 
103, and 104) and their corresponding 6-substituted 2-aminodihydroquinazolines (65, 69, 
and 87-89) at hOCT3. 
 
 
 
Ligand R   IC50 (µM) 
    hOCT3 
  IC50 (µM) 
    hOCT3 
R Ligand 
PG       (99) H  99.8 ± 2.8 12.2 ± 3.4 H     ADQ     (69) 
4-FPG  (103) 4-F  27.8 ± 11.0   0.5 ± 0.0 6-F     A6FDQ (87) 
4-CPG  (98) 4-Cl    2.8 ± 0.7   3.9 ± 2.4 6-Cl     A6CDQ (65) 
4-BrPG (104) 4-Br    4.8 ± 0.7   1.9 ± 0.2 6-Br     A6BrDQ (88) 
4-MePG (100) 4-CH3    4.6 ± 1.1   2.0 ± 0.4 6-CH3     A6MDQ (89) 
 
 
  
NHN
NH2
6
R
NH2N
NH2
4
R
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Table A13. Values for the different parameters use in the Hansch analysis type of QSAR 
studied conducted on the 6-substituted 2-aminodihydroquinazolines (65, 69, 74, 87 and 88).  
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Table A14. Summary of the linear regression analysis conducted for the 6-substituted 2-
aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine 
analogs (n = 11).  
 
Figure  
No. 
Equation 
No. 
QSAR Equation r F P 
A29 29 0.3203 (± 0.1698) x π – 1.194 (± 0.9115) 0.532 3.560 0.0918 
A30 30 0.04676 (± 0.07857) x σ – 0.1694 (± 0.4218) 0.195 0.3542 0.5664 
A31 31 21.98 (± 9.058) x Volume + 394.6 (± 48.63) 0.629 5.887 0.0382 
A32 32 0.6398 (± 0.3106) x L – 0.2898 (± 1.667) 0.566 4.245 0.0695 
A33 33 0.3460 (± 0.1629) x B1 – 0.2642 (± 0.8746) 0.578 4.510 0.0627 
A34 34 0.3924 (± 0.1767) x B5 – 0.4176 (± 0.9485) 0.587 4.943 0.0535 
A35 35 1.590 (± 0.6545) x Polarizability + 9.249 (± 3.514) 0.629 5.901 0.0380 
 
 
Figure A29. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus hydrophobicity constant (π) of the 
substituents (r = 0.532, n = 11, p = 0.0918). 
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Figure A30. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Hammett constant (σ) of the 
substituents (r = 0.195, n = 11, p = 0.5664). 
 
 
Figure A31. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus volume of the compounds (r = 0.629, 
n = 11, p = 0.0382). 
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Figure A32. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop length (L) of the substituents 
(r = 0.566, n = 11, p = 0.0695). 
 
Figure A33. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the 
substituents (r = 0.578, n = 11, p = 0.067). 
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Figure A34. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop maximum width (B5) of the 
substituents (r = 0.587, n = 11, p = 0.0535). 
 
 
 
Figure A35. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus polarizability of the compounds (r = 
0.629, n = 11, p = 0.0380). 
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Table A15. Cook’s distances (Cook’s D) for the 6-substituted 2-aminodihydroquinazoline 
analogs (65, 69, 74, 87 and 88) and their corresponding 4-substituted phenylguanidine 
analogs (99-100, 103-105) for all of the parameters used in the Hansch analysis (n = 11). 
  
 
aThe Statistical Package for the Social Sciences (SPSS Science, Chicago, IL).  
  Cook’s Da 
Ligand pIC50 π σ Volume L B1 B5 Polariz 
-ability 
PG         (99) 4.00 0.5847 0.2752 0.7142 0.6477 0.6691 0.7082 0.5832 
4-FPG    (103) 4.56 0.0839 0.0737 0.0749 0.0830 0.0836 0.0817 0.0455 
4-CPG    (98) 5.55 0.0005 0.0030 0.0068 0.0001 0.0000 0.0024 0.0218 
4-BrPG   (104) 5.32 0.0396 0.0062 0.0130 0.0623 0.0628 0.0211 0.0119 
4-IPG      (105) 5.83 0.0018 0.0345 0.0000 0.0038 0.0030 0.0028 0.0762 
4-MePG  (100) 5.34 0.0002 0.0406 0.0238 0.0008 0.0007 0.0421 0.0032 
ADQ       (69) 4.92 0.0010 0.0214 0.0228 0.0131 0.0227 0.0494 0.0098 
A6FDQ   (87) 6.33 0.7424 0.1300 0.5668 0.4310 0.4033 0.5801 0.4724 
A6CDQ   (65) 5.41 0.0022 0.0007 0.0267 0.0039 0.0049 0.0003 0.0057 
A6BrDQ  (88) 5.73 0.0028 0.0232 0.0026 0.0007 0.0006 0.0062 0.0108 
A6MDQ  (74) 5.69 0.0180 0.3077 0.0032 0.0334 0.0335 0.0005 0.0073 
Cut-off  
(3 x mean) 
 0.4020 0.2490 0.3960 0.3480 0.3510 0.4080 0.3390 
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Table A16. Summary of the linear regression analysis conducted for the 6-substituted 2-
aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine 
analogs without A6FDQ (87) (n = 10).  
 
Figure 
No. 
Equation 
No. 
QSAR Equation r F P 
A36 36 0.5694 (± 0.1207) x π – 2.428 (± 0.6351) 0.858 22.26 0.0015 
A37 37 0.07067 (± 0.09569) x σ – 0.2879 (± 0.5036) 0.253 0.5454 0.4813 
A38 38 35.56 (± 6.138) x Volume + 327.3 (± 32.31) 0.899 33.57 0.0004 
A39 39 1.038 (± 0.2681) x L – 2.265 (± 1.411) 0.808 15.00 0.0047 
A40 40 0.5526 (± 0.1423) x B1 – 1.288 (± 0.7490) 0.808 15.08 0.0047 
A41 41 0.6497 (± 0.1275) x B5 – 1.692 (± 0.6711) 0.874 25.96 0.0009 
A42 42 2.517 (± 0.4961) x Polarizability + 4.655 (± 2.611) 0.873 25.73 0.0010 
 
 
 
 
Figure A36. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus hydrophobicity constant (π) of the 
substituents (r = 0.858, n = 10, p = 0.0015). 
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Figure A37. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Hammett constant (σ) of the 
substituents (r = 0.253, n = 10, p = 0.4813). 
 
 
 
 
Figure A38. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus volume of the compounds (r = 0.899, 
n = 10, p = 0.0004). 
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Figure A39. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop length (L) of the substituents 
(r = 0.808, n = 10, p = 0.0047). 
 
 
 
Figure A40. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the 
substituents (r = 0.808, n = 10, p = 0.0047).  
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Figure A41. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus Verloop minimum width (B1) of the 
substituents (r = 0.874, n = 10, p = 0.0009). 
 
 
 
 
Figure A42. Plot of pIC50 values of the 6-substituted 2-aminodihydroquinazolines and their 
corresponding 4-substituted phenylguandines versus polarizability of the compounds (r = 
0.873, n = 10, p = 0.0010). 
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Table A17. Internal correlations between the various parameters (highlighted in bold blue 
font) for the combined phenylguanidine and 2-aminodihydroquinazoline series as indicated 
by Pearson’s r (n = 10). 
 π σ Volume L B1 B5 Polarizability 
π  0.481 0.925 0.979 0.976 0.904 0.856 
σ 0.481  0.187 0.611 0.605 0.088 0.351 
Volume 0.925 0.187  0.865 0.867 0.969 0.846 
L 0.979 0.611 0.865  1.000 0.840 0.801 
B1 0.976 0.605 0.867 1.000  0.844 0.790 
B5 0.904 0.088 0.969 0.840 0.844  0.759 
Polarizability 0.856 0.351 0.846 0.801 0.790 0.759  
 
Table A18. Summary of the linear regression analysis conducted for the 6-substituted 2-
aminodihydroquinazoline analogs and their corresponding 4-substituted phenylguanidine 
analogs without PG (99) (n = 10).  
 
Equation 
No. 
QSAR Equation r F P 
43 0.2613 (± 0.2461) x π – 0.8626 (± 1.351) 0.351 1.127 0.3194 
44 0.03486 (± 0.1146) x σ – 0.1026 (± 0.6288) 0.107 0.093 0.7690 
45 16.76 (± 12.96) x Volume + 423.9 (± 71.09) 0.416 1.673 0.2320 
46 0.4985 (± 0.4478) x L + 0.5041 (± 2.457) 0.366 1.239 0.2980 
47 0.2653 (± 0.2343) x B1 + 0.1889 (± 1.286) 0.372 1.282 0.2904 
48 0.2898 (± 0.2526) x B5 + 0.1587 (± 1.386) 0.376 1.316 0.2845 
49 1.523 (± 0.9554) x Polarizability + 9.625 (± 5.242) 0.491 2.541 0.1496 
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Discussion of QSAR studies: 
 
We have identified two properties, volume and lipophilicity (π) of the substituents as 
potentially playing a role in the inhibitory activity of phenylguanidines at hOCT3. We 
considered four different sets of compounds adding one new compound to the set at a time. 
In the first set of compounds, we used only the 4-halo-substituted phenylguanidine analogs. 
The biological data suggested that progressively increasing the volume of the substituent at 
the 4-position of the phenylguanidines from the unsubstituted PG (99) to the 4-iodo 
substituted analog (4-IPG; 105) improved the inhibitory potency at hOCT3 (Table A6). This 
lends credence to the positive correlation observed between the pIC50 of the 4-halo-
substituted phenylguanidines and the solvent accessible volume (r = 0.963, n = 5, p = 0.0084) 
(Table A7, Figure A3). Since the substituents under consideration possessed similar 
electronic (σ) properties, we observed a positive correlation with the Hammett constant (σ) 
(r = 0.908, n = 5, p = 0.0330) (Table A7, Figure A2).  
Our modeling studies had indicated the lipophilic (π) properties of the substituent at 
the 4-position to be more important than its electronic (σ) properties. Addition of 4-MePG 
(100) bearing the methyl group with opposite electronic properties (σ) compared to halogens 
led to loss of correlation with the Hammett constant (σ) (r = 0.393, n = 6, p = 0.4386) (Table 
A8, Figure A9). This, coupled with retention of positive correlation with the lipophilic (π) 
properties (r = 0.945, n = 6, p = 0.0044) (Table A8, Figure A8) of the substituent at the 4-
position, further supported the results of our molecular modeling. With the addition of 4-t-
BuPG (101) in the third set of compounds, a loss of positive correlation with volume (r = 
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0.595, n = 7, p = 0.1538) (Table A9, Figure A17) was observed while a positive correlation 
was retained with lipophilic (π) properties, Verloop length (L), minimum width (B1) and 
maximum width (B5) as well as polarizability (Table A9).  Finally, addition of 4-BnPG (102) 
resulted in poor positive correlation between pIC50, and only the Verloop minimum width 
(B1) of the substituents (r = 0.708, n = 8, p = 0.0492) (Table A10, Figure A26) was 
significant.   
Overall, out of the seven parameters considered for the Hansch analysis, two 
parameters, i.e., the volume and the lipophilic (π) properties of the substituents were 
identified as potentially important for inhibitory activity at hOCT3. For the Hansch analyses 
performed, two potential caveats exist. The first being, out of the eight substituents examined 
at the 4-position of phenylguanidines (Table A6), the benzyl group was the only substituent 
that was aromatic in nature. This could be a contributing factor to the ~205-fold lower 
inhibitory potency at hOCT3 of 4-BnPG (102) compared to 4-t-BuPG (101). The 4-
cyclohexylmethyl group has comparable volume as the 4-Bn group but lacks the aromatic 
nature and could help us answer if there was truly a limitation in bulk tolerance. The second 
was there exists significant high internal correlations between a number of parameters 
evaluated including π and volume, π and B5, and π and polarizability among others as shown 
by the positive Pearson’s r value (Table A11). The Pearson’s r value can range from -1 to 
+1. A value of r = 0 indicates a lack of correlation while a value of -1 or +1 is indicative of 
a negative or positive correlation, respectively. The following parameters were positively 
correlated to each other: π and volume, π and B5, π and polarizability, volume and B5, volume 
and polarizability, length and B1, B5 and polarizability, and polarizability and volume (Table 
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A11). For each parameter considered in the Hansch analysis, a minimum of 6 compounds 
are required for a statistically valid correlation. As such, we currently lack the requisite 
number of compounds to accurately identify the parameters (π, volume, B5 and 
polarizability) important for inhibitory activity at hOCT3.  
For the final set of compounds, we combined the two series of compounds, 2-
aminodihydroquinazolines and phenylguanidines. The reasoning behind doing this was 
while these two series differed in their orientations (docking poses) in the binding region, 
both utilized the key Asp478 residue in a bidentate ionic salt-bridge interaction. Our 
modeling studies indicated that the lipophilic (π) properties of the substituent at the 6-
position of 2-aminodihydroquinazolines might be more important than their electronic (σ) 
properties. In accordance with our findings from the molecular modeling studies, no 
significant correlation was observed between pIC50 and Hammett constant (σ) of the 
substituents (r = 0.195, n = 11, p = 0.5664) (Figure A30) (Table A14).  A statistically 
significant but modest correlation was observed between pIC50 of the analogs and volume (r 
= 0.629, n = 11, p = 0.0382) (Figure A31) as well as with polarizability (r = 0.629, n = 11, 
p = 0.0380) (Figure A35) (Table A14). Additionally, no significant correlation was observed 
between pIC50 of the analogs and the other parameters evaluated (Table A14). In all of the 
correlations obtained, A6FDQ (87) appeared to be a potential outlier and removal of A6FDQ 
(87) from the sample set might lead to improved correlations with the parameters under 
consideration. Of note, the 4-fluoro group of A6FDQ (87) despite possessing lower 
lipophilic (π) property than the 4-chloro group of A6CDQ (65) (π = 0.06 and 0.71 for fluoro 
and chloro group, respectively) exhibited ~8-fold higher potency than A6CDQ (65) at 
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hOCT3. This was in contrast to our results from the modeling studies. However, at present, 
we do not know if the 2-aminodihydroquinazoline analogs are only inhibitors or only 
substrates or both. Hence, there might be differences in the SARs of these categories of 
compounds, i.e., substrates and inhibitors. To determine if A6FDQ (87) was indeed a 
potential outlier we determined the Cook’s distances (Cook’s D) for all the compounds for 
the seven parameters under consideration (Table A15). The Cook’s distance identifies data 
points as outliers if the distance is greater than the cut off which can be defined in several 
ways such as three times the mean Cook’s distance or greater than 4/n (where n is the sample 
size) or greater than 1.0. The Cook’s D was greater than the cut offs for A6FDQ for all of 
the parameters (Table A15) for two of the three methods of cut offs (i.e. 4/n and 3 times the 
mean Cook’s distance). Though removal of A6FDQ (87) led to improved correlations (Table 
A16), the parameters themselves had high positive internal correlation (Table A17). This 
made identification of parameters important for inhibitory activity extremely difficult. The 
unsubstituted phenylguanidine, PG (99), was also identified as an outlier according to the 
Cook’s D test (Table A15). However, PG (99) does not appear to be a true outlier since 
removal did not result in improved correlations with any of the seven parameters considered 
(Table A18). Moreover, PG (99) followed the trend of being less active than the substituted 
analogs in both the ring opened phenylguanidine as well as 2-aminodihydroquinazoline 
series. Additionally, the 6-methyl analog, A6MDQ (74) was identified as an outlier by the 
Cook’s D test for Hammett constant (σ) if the cut off considered was three times the mean 
Cook’s distance (Table A15). If on the other hand, the cut off was considered to be 4/n 
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(where n is the sample size), which in the current scenario was 4/11 = 0.393, then A6MDQ 
(74) was not an outlier (Table A15).   
So far, volume and lipophilic properties of the substituents appear to be important 
for the inhibitory potencies of the 2-aminodihydroquinazoline and their ring opened 
phenylguanidine analogs at hOCT3. A lack of sufficient number of compounds and high 
internal correlation between parameters prevented a more accurate identification of 
properties important for activity at hOCT3.  
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